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Cardiovascular disease, type 2 diabetes, and related cardiometabolic traits are responsible for substantial 
mortality and economic costs globally. Cardiometabolic traits are common complex phenotypes with both genetic 
and environmental components and are influenced by several tissues, including adipose, liver, skeletal muscle, and 
pancreas. Genome-wide association studies (GWAS) have identified thousands of loci associated with 
cardiometabolic traits, but most of these loci are in noncoding regions of the genome and their molecular functions 
are not well annotated. Variants at GWAS loci are often found within transcriptional regulatory elements and/or are 
associated with gene expression in trait-relevant tissues, suggesting that GWAS variants frequently alter gene 
regulation. Transcriptional regulatory elements vary by genotype, tissue, and cellular state, but regulatory element 
annotation in many of these disease-relevant contexts is lacking. A more complete annotation of regulatory elements 
may uncover mechanisms for GWAS loci for cardiometabolic traits. To this end, I profiled chromatin accessibility, a 
marker of regulatory elements, in adipose tissue, liver tissue, and multiple stages of adipocyte differentiation. The 
accessible chromatin landscape in adipose tissue was underannotated and our profiles helped identify GWAS 
variants that may alter adipose gene regulation. I identified accessible chromatin regions that vary by genotype in 
liver tissue, providing suggestive evidence that these variants alter regulatory element activity. The accessible 
chromatin regions that differ between stages of adipocyte differentiation suggest specific cellular states in which 
GWAS variants may alter gene regulation. I integrated accessible chromatin regions with multiple genomic data 
types to predict functional variants, disrupted TF binding motifs, and target genes at cardiometabolic GWAS loci. 
Variants at several loci showed allelic differences in transcriptional reporter and protein binding assays, providing 
further evidence of regulatory function. My findings contribute to the understanding of which variants, regulatory 
elements, and genes influence cardiometabolic traits. These predicted functional variants, regulatory elements, and 
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CHAPTER 1: INTRODUCTION 
 
Overview of cardiometabolic traits 
Cardiovascular disease (CVD), type 2 diabetes (T2D), and related risk factors, termed cardiometabolic 
traits, account for substantial health and economic costs worldwide. CVD is the leading cause of death in the United 
States and worldwide, and was responsible for 17.8 million deaths globally in 20171,2. An estimated 485.6 million 
people have CVD globally and the direct and indirect annual economic costs of CVD in the United States were 
estimated to be $351.3 billion from 2014-20151. T2D was the seventh leading cause of death in the United States as 
of 20161 and was responsible for 1.5 million deaths worldwide in 20122. In the United States, an estimated 26 
million adults have T2D and 91.8 million have prediabetes1. Several cardiometabolic traits are risk factors for CVD 
and T2D, including obesity, insulin resistance, hypertension, high triglycerides, and high LDL cholesterol1,3,4, and 
T2D itself is a risk factor for CVD5.   
Several tissues influence cardiometabolic traits, including adipose, liver, skeletal muscle, and pancreas. 
Adipose tissue influences cardiometabolic traits through its roles in lipid storage and hormone secretion6,7. 
Decreased lipid storage capacity in subcutaneous adipose tissue leads to increased lipid storage and increased insulin 
resistance in skeletal muscle, visceral adipose, and liver6. Adipose tissue secretes numerous hormones including 
leptin, which regulates energy intake and several other metabolic processes, and adiponectin, which is negatively 
associated with T2D and may protect against insulin resistance7. The liver regulates glucose, lipid, and cholesterol 
availability through multiple mechanisms8. The liver stores excess glucose as glycogen in response to increased 
insulin levels and secretes glucose through gluconeogenesis to provide energy to other tissues when insulin levels 
decrease8. Insulin resistance in the liver leads to increased hepatic glucose secretion and increased hepatic lipid 
accumulation, which is associated with the development of CVD, T2D, and nonalcoholic fatty liver disease8. Insulin 
resistance in skeletal muscle, resulting in reduced glucose uptake and metabolism, is associated with T2D, obesity, 
hypertension, and other conditions9. Impaired insulin secretion by pancreatic beta cells contributes to the 





Genetics of cardiometabolic traits 
Cardiometabolic traits are complex and have both genetic and environmental components. Risk for 
developing CVD, T2D, hypertension, and other cardiometabolic conditions is associated with environmental factors 
such as nutrition, physical activity, smoking, and stress1,3. Both rare and common genetic variation contributes to 
risk for CVD, T2D, and related risk factors1,11,12. A twin study estimated the heritability of death from coronary heart 
disease to be 38% in women and 57% in men13, and individuals with a sibling with CVD are at an increased risk of 
CVD even after correcting for other risk factors14. Single gene mutations have been identified that drive familial 
hypercholesterolemia, a rare condition resulting in increased LDL cholesterol and CVD risk15–17. The heritability of 
T2D varies with the age of onset and is estimated to be 31-72%18,19. Genome-wide association studies (GWAS) have 
been instrumental in identifying genetic variation influencing common traits20. GWAS have identified thousands of 
genetic associations with cardiometabolic traits, including 161 loci for coronary artery disease21, 403 distinct genetic 
signals at 243 loci for T2D22, 901 loci for blood pressure traits23, 941 distinct signals at 536 loci for body mass index 
(a measure of obesity)24, and 826 distinct signals at 386 loci for blood lipid traits25. Identified GWAS signals explain 
18% of T2D risk22, 5.7% of variation in systolic blood pressure23, and 6.0% of variation in body mass index24. While 
GWAS are instrumental in identifying the genetic basis of common complex traits, they do not identify which 
genetic variants at a signal are functional and how these variants impact the trait20,26. Additional approaches are 
needed to identify the functional variant/s at a signal, the gene/s influenced by the variants, the tissue in which the 
variant acts, and the mechanism of action20,26. 
Identifying target genes and tissues at GWAS loci 
There are multiple approaches to linking GWAS variants to genes, including coding variants, gene 
expression quantitative trait locus (eQTL) mapping, and chromatin conformation capture (3C) techniques26. Rare 
variants at some GWAS loci are found within coding regions and are predicted to alter protein function, but most 
GWAS loci do not have coding variants26. eQTL are identified by associating genetic variants with gene expression 
levels across individuals in a given tissue27. Target genes at GWAS loci can be predicted by identifying shared, or 
colocalized, eQTL and GWAS signals27–29. Multiple methods exist for identifying colocalized GWAS and eQTL 
signals, including linkage disequilibrium (LD) between GWAS and eQTL lead variants, examining the eQTL 
association after conditioning on the GWAS lead (termed conditional analysis), and methods that compare GWAS 




has been used to predict target genes at cardiometabolic trait GWAS loci in trait-relevant tissues, including genes at 
body fat distribution and lipid GWAS loci in adipose tissue28, lipids in liver29,32,  and glucose and T2D in skeletal 
muscle33. 
Chromosomes form loops that form contacts between different genomic regions, including those far apart 
based on linear DNA sequence34. The 3C technique identifies a pair of genomic regions that physically interact with 
one another, and the high-throughput version, Hi-C, identifies pairs of interacting regions genome-wide34. Promoter 
capture Hi-C involves specifically selecting interactions with gene promoters, which is particularly use for linking 
distal regulatory elements to genes34,35. Chromatin interactions vary by cell and tissue type and have been used to 
link GWAS variants to gene promoters35. 
Many methods that predict target genes at GWAS loci, such as eQTL and 3C, only provide suggestive 
evidence that a variant alters a gene and additional experiments are needed to prove a causal relationship. Variant-
gene links predicted by multiple methods are more likely functional and are strong candidates for downstream 
experiments. While eQTL suggest that a variant may alter gene expression, additional experiments are needed to 
determine the mechanisms by which genetic variants alter gene expression. 
Predicting functional variants and mechanisms using transcriptional regulatory elements 
Individual studies and large-scale efforts, such as ENCODE36 and the NIH Roadmap Epigenomics 
Project37, have made great progress in mapping transcriptional regulatory elements of genes, such as promoters, 
enhancers, silencers, and insulators, but many cell and tissue types remain under-annotated. ENCODE has 
performed thousands of experiments to map multiple aspects of regulatory element activity in hundreds of cell and 
tissue types, including accessible chromatin regions, binding sites for transcription factors (TFs) and other proteins, 
DNA methylation, and histone modifications36. The Roadmap Epigenomics Project mapped chromatin accessibility, 
histone modifications, and DNA methylation in 111 cell and tissue types and integrated these data types to identify 
regulatory chromatin states, such as promoter, enhancer, transcribed, and repressed states37. Chromatin accessibility 
is a canonical feature of active and poised regulatory elements36, and is thus broadly useful in mapping regulatory 
elements. However, the accessible chromatin landscapes of many human cardiometabolic-relevant tissues, such as 
adipose and liver, remain under-annotated. At the time of analysis of the data presented in CHAPTER 2, only three 
chromatin accessibility profiles existed from primary human adipose tissue: one in whole subcutaneous adipose 




accessible chromatin profiles have been mapped in adipocytes differentiated from cell models, including human 
multipotent adipose-derived stem cells39 and the Simpson Golabi-Behmel Syndrome (SGBS) cell strain40,41. Liver 
chromatin accessibility has mainly been profiled in the HepG2 hepatoblastoma cell line, which is immortalized and 
aneuploid36,42–44. A limited number of primary tissue samples have been generated by ENCODE36. Mapping 
chromatin accessibility in liver, adipose, and other cardiometabolic-relevant tissues is needed to characterize 
transcriptional regulation in these tissues. 
Several lines of evidence suggest that genetic variants, including those at GWAS loci, can alter regulatory 
element activity. First, activity of many regulatory elements is heritable45. Second, GWAS loci are over-represented 
in regulatory elements of tissues relevant to the GWAS trait37, including body fat distribution loci in adipose tissue 
regulatory elements46 and T2D loci in skeletal muscle33. Third, genetic variants associated with levels of chromatin 
accessibility, termed chromatin accessibility QTL (caQTL), have been identified in multiple tissues, a subset of 
which are colocalized with GWAS loci and eQTL47–52, suggesting that genetic variants may mediate effects on gene 
expression and GWAS traits by altering chromatin accessibility. Consequently, mapping chromatin accessibility in 
cardiometabolic-relevant tissues in multiple individuals may uncover functional variants that alter chromatin 
accessibility and ultimately impact GWAS traits. 
Regulatory element activity also differs between environmental contexts. Chromatin accessibility levels 
and regulatory element chromatin states vary between different tissue and cell types36,37, including across cellular 
differentiation53–55 and across different cell types of the same tissue56,57. Various stimuli can alter chromatin 
accessibility, including inflammation58,59, dietary lipids53, and hypoxia60. Context-dependent genetic effects on 
chromatin accessibility have also been identified across immune cell activation49,58. Consequently, mapping 
chromatin accessibility in a variety of disease-relevant cellular contexts may identify GWAS variants with context-
specific effects on chromatin and GWAS traits. 
Aims and overview 
In this dissertation, I contribute to our understanding of how genetic variation impacts chromatin 
accessibility and disease. In CHAPTER 2 I describe chromatin accessibility profiles in three adipose tissue samples 
and in replicates from SGBS preadipocytes and adipocytes using ATAC-seq. I show that GWAS variants for body 
fat distribution, cholesterol, and other cardiometabolic traits are overrepresented in adipose chromatin accessibility. I 




CHAPTER 3 I present caQTL in liver tissue using genotypes and chromatin accessibility data from 20 individuals. I 
integrate caQTL with multiple genomic data types, such as eQTL and TF motifs, to predict functional variants, 
target genes, and mechanisms at GWAS loci. In CHAPTER 4 I describe differences in chromatin accessibility and 
gene expression between states of adipocyte differentiation. I use these data to predict GWAS variants that may act 
in different cellular states in adipose tissue. In CHAPTER 5 I summarize my findings, reflect on what I have 
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CHAPTER 2: OPEN CHROMATIN PROFILING IN ADIPOSE TISSUE MARKS GENOMIC REGIONS 
WITH FUNCTIONAL ROLES IN CARDIOMETABOLIC TRAITS1 
 
Introduction 
Dysregulation of genes expressed in adipose tissue influences cardiometabolic traits and diseases. 
Subcutaneous adipose tissue serves as a buffering system for lipid energy balance, particularly fatty acids,1-3 and 
may play a protective role in cardiometabolic risk.4 Subcutaneous adipose expression quantitative trait loci (eQTL) 
studies have identified genes involved in central obesity and metabolic traits,5-9 and specific cardiometabolic 
genome-wide association study (GWAS) loci have been shown to colocalize with subcutaneous adipose eQTLs.9-13 
In addition, a recent GWAS study of waist-hip ratio, a measure of central obesity, identified loci that were enriched 
both for putative regulatory elements in adipose nuclei and for genes expressed in subcutaneous adipose tissue,12 
many of which have been linked to adipose function.14 Identification and characterization of adipose tissue 
regulatory regions and variants would improve understanding of biological processes and the mechanisms 
underlying cardiometabolic loci.  
Adipose tissue is composed of many cell types, including adipocytes, preadipocytes, vascular cells, 
immune cells, and nerve cells.15 Characterization of heterogeneous whole adipose tissue and its component cell 
types are both needed to fully delineate the role of adipose tissue in cardiometabolic disease. Human adipose tissue 
samples can be used to identify differences in chromatin accessibility due to genotype and link variants to 
cardiometabolic traits; however, samples may also differ due to site of tissue extraction, sample handling and 
storage conditions, and environmental contributions. Although cell models do not fully replicate cells within a 
complex tissue, their growth, storage, and environmental conditions can be controlled. Cells from the Simpson 
Golabi-Behmel Syndrome (SGBS) human preadipocyte cell strain are diploid, easy to grow in culture, can be
 
1 The work in this chapter has been previously published. The citation is: 
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Laakso, M., et al. (2019). Open chromatin profiling in adipose tissue marks genomic regions with functional roles in 





differentiated to mature adipocytes16 and are exposed to less experimental variation than primary human 
preadipocytes due to genotype or sample collection differences. 
Adipose tissue and adipocytes are poorly represented in chromatin accessibility datasets because the high 
lipid content makes experimental assays challenging. To date, for human adipose tissue or adipocytes, only three 
DNase-seq datasets17,18 and three ATAC-seq datasets19,20 are available. In addition to chromatin accessibility, 
chromatin immunoprecipitation (ChIP)-seq for histone marks have been characterized in adipose nuclei from 
subcutaneous adipose tissue and in differentiated adipocytes from mesenchymal stem cells (Roadmap Epigenomics 
Project), and these data were integrated to annotate genomic regions into chromatin states characteristic of 
regulatory functions such as promoters, enhancers, or insulators.21 Regions of chromatin accessibility in many cell 
types are located preferentially in regulatory regions,21,22 suggesting that chromatin accessibility maps can improve 
accuracy of predicting regulatory chromatin states in adipose cell types. 
Chromatin accessibility data can be used to characterize candidate variants at noncoding GWAS loci. 
Allelic differences have been found in levels of accessible chromatin, transcription factor binding, and histone marks 
of chromatin state,23-28 and these differences have provided a functional context for interpreting GWAS loci.29-31 
Identifying transcription factor motifs and footprints in accessible chromatin regions can be used to predict 
transcription factor binding sites.32 Improved annotation of candidate regulatory variants and candidate transcription 
factors in adipose tissue could aid identification of molecular mechanisms at GWAS loci. 
In this study, we performed ATAC-seq on frozen clinical subcutaneous adipose tissue needle biopsy 
samples and SGBS preadipocytes and adipocytes to identify regions of accessible chromatin for each sample type. 
We identified cardiometabolic GWAS loci and transcription factor binding motifs in ATAC-seq open chromatin 
regions and used the ATAC-seq annotations to characterize candidate variants at cardiometabolic GWAS loci with 
colocalized adipose tissue eQTL associations. Finally, through experimental analysis of allelic differences in 
regulatory functions, we report functional non-coding variants at two cardiometabolic GWAS loci. 
Materials and Methods 
METSIM study participants 
Subcutaneous adipose tissue needle biopsies were obtained from METabolic Syndrome in Men (METSIM) 
participants as previously described.9 We used three adipose tissue needle biopsy samples for ATAC-seq. The 




and examined in 2005 – 2010.33,34 The Ethics Committee of the University of Eastern Finland in Kuopio and the 
Kuopio University Hospital approved the METSIM study and it was carried out in accordance with the Helsinki 
Declaration. DNA samples were genotyped on the Illumina OmniExpress and HumanCoreExome arrays and 
imputed using the Haplotype Reference Consortium35 as previously described.9 
Sample processing and ATAC-seq library preparation 
Human adipose tissue was flash frozen and stored at -80º until use. For adipose tissue samples 1 and 3, we 
generated libraries using nuclei isolation buffers that contained detergent (1% NP-40) or did not contain detergent. 
For tissue sample 2, we generated libraries using ~12 mg or ~36 mg of tissue and contained detergent. Replicates 
including detergent and less tissue in library preparation resulted in a greater number of peaks and higher peak 
similarity between individuals compared to no detergent. From these observations, we performed all subsequent 
analyses with the three detergent-treated replicates. Tissue was pulverized in liquid nitrogen using a Cell Crusher 
homogenizer (cellcrusher.com). The tissue powder was resuspended in nuclei isolation buffer (20 mM Tris-HCl, 50 
mM EDTA, 60 mM KCl, 40% glycerol, 5 mM spermidine, 0.15 mM spermine, 0.1% mercaptoethanol, 1% NP-40). 
Tubes were rotated at 4º for 5 minutes. The solution was homogenized using a tight homogenizer (Wheaton) for 10 
strokes and was centrifuged at 1500 x g for 10 minutes at 4º. Following removal of the lipid layer and supernatant, 
the pellet was resuspended in buffer (10 mM Tris-HCl, 10 mM NaCl, 3 mM MgCl2) and centrifuged at 1200 x g for 
10 minutes at 4º. The supernatant was removed and the pellet was used for the transposase reaction as previously 
described.36 We used 2.5 ul Tn5 for adipose tissue libraries. Following library PCR amplification for adipose tissue, 
we removed primer dimers using Ampure Beads (Agencourt) with a 1:1.2 ratio of library to beads. Libraries were 
visualized and quantified using a TapeStation or Bioanalyzer and sequenced with 50-bp reads on an Illumina Hi-Seq 
2500 at the Duke University Genome Sequencing shared resource facility (single-end sequencing). 
SGBS cells37 were generously provided by Dr. Martin Wabitsch (University of Ulm) and cultured as 
previously described.38 To differentiate SGBS cells, SGBS preadipocytes were cultured in serum-containing 
medium until confluent, then rinsed in PBS and differentiated for four days in basal medium (DMEM:F12 + 3.3mM 
biotin + 1.7mM panthotenate) supplemented with 0.01 mg/mL transferrin, 20 nM insulin, 200 nM cortisol, 0.4 nM 
triiodothyronine, 50 nM dexamethasone, 500 uM IBMX, and 2 uM rosiglitazone. After four days, differentiated 
SGBS cells were maintained in basal medium supplemented with 0.01 mg/mL transferrin, 20 nM insulin, 200 nM 




We removed primer dimers using Zymo DNA Clean and Concentrator, visualized and quantified libraries using a 
TapeStation or Bioanalyzer, and sequenced with 50-bp reads on an Illumina Hi-Seq 4000 at the University of North 
Carolina High-Throughput Sequencing Facility (paired-end sequencing).  
ATAC-seq alignment and peak calling 
We obtained previously published adipose ATAC-seq datasets from subcutaneous adipose tissue 
(ENCODE ENCSR540BML),20 tissue-derived adipocytes,19 and GM12878 lymphoblasts.36 The tissue-derived 
adipocyte ATAC-seq data was shared by the McGill Epigenomics Mapping Centre and is available from the 
European Genome-phenome Archive of the European Bioinformatics Institute (dataset EGAD00001001300).  
To minimize mapping differences between read length and single-end vs. paired-end samples, we merged 
the mate pair fastq files and trimmed reads to 50 nucleotides for each paired-end ATAC-seq sample and aligned 
reads from all samples as single-end. We removed sequencing adapters from raw ATAC-seq sequence reads using 
Tagdust40 with a false discovery rate of 0.1% and selected high quality reads with a Phred score of at least 20 for at 
least 90% of bases using the FASTX toolkit (http://hannonlab.cshl.edu/fastx_toolkit). We aligned filtered reads to 
the hg19 human genome using bowtie241, penalizing ambiguous bases as mismatches. We removed any alignments 
with mapping quality less than 20, mitochondrial reads, or blacklisted regions42,43 and shifted the resulting 
alignments by +4 on the + strand and -5 on the – strand so that the 5’ base of each alignment corresponded to the 
center of the binding site of the Tn5 transposase36,44. For the METSIM adipose tissue samples, we verified sample 
identity using verifyBamID45 using genotyped variants with at least 10 ATAC-seq reads in the sample with the 
lowest read depth (Tissue 2; 8,683 variants), minimum minor allele frequency of 0.01, and call rate of at least 0.5; 
we used the best-matched genotypes for each sample. For all samples, we called peaks using MACS246 with no 
background dataset, smoothing ATAC-seq signal over a 200 bp window centered on the Tn5 integration site, 
allowing no duplicates, and a false discovery rate (FDR)<5%; we refer to peaks called on reads from technical 
replicate samples (SGBS adipocytes, SGBS preadipocytes, tissue-derived adipocytes, and GM12878 lymphoblasts) 
as ‘replicate peaks’.  
Representative ATAC-seq peaks 
For samples with technical replicates, we pooled reads across replicates and called peaks (MACS2, 
FDR<5%), and then defined the portion of these peaks that shared at least one base with a replicate peak in two or 




are not technical replicates. Due to a low number of samples, we used the union of peaks across individuals as 
representative peaks. Unless otherwise noted, we selected the top 50,000 representative peaks in each group for 
downstream analyses. For the groups with technical replicates and the single ENCODE adipose tissue sample, we 
selected the top 50,000 representative peaks with the most significant peak p-values. For METSIM adipose tissue, 
we ranked the peak p-values in each individual (with 1 being the strongest) and used the average of these ranks to 
select the top 50,000 representative peaks. This approach reduced the chance that outlier p-values from a single 
individual would bias peak rank. 
ATAC-seq principal component analysis 
We generated a total set of accessible chromatin regions by taking the top 50,000 peaks in each group of 
ATAC-seq samples. For each ATAC-seq sample, we counted the number of non-duplicated nuclear reads 
overlapping the total set of accessible chromatin regions using featureCounts.47 We performed library size 
normalization and variance stabilization using the regularized log (rlog) function in DESeq2.48 We performed 
principal component analysis (PCA) using a modified version of the DESeq2 plotPCA function. 
Peak genomic distribution and overlap with Roadmap chromatin states 
We determined the location of ATAC-seq peaks relative to genes from the GENCODE 24lift37 Basic Set. 
Using BEDTools,42 we divided peaks into the following categories: TSS-proximal (5 kb upstream to 1 kb 
downstream of a GENCODE transcription start site), intragenic (within a gene body but not within TSS-proximal 
regions), downstream (within 5 kb downstream of a transcription termination site but not within any gene body), and 
distal (>5 kb from either end of any gene). We obtained chromatin states for an 18-state model based on ChIP-seq 
data for 98 cell and tissue types using 6 histone marks (H3K4me1, H3K4me3, H3K36me3, H3K27me3, H3K9me3, 
and H3K27ac) from the Roadmap Epigenomics Consortium.21 We generated the following combined states by 
merging states of similar genomic context: promoter (1_TssA, 2_TssFlnk, 3_TssFlnkU, 4_TssFlnkD, 14_TssBiv), 
transcribed (5_Tx, 6_TxWk), enhancer (7_EnhG1, 8_EnhG2, 9_EnhA1, 10_EnhA2, 11_EnhWk, 15_EnhBiv), and 
polycomb repressed (16_ReprPC, 17_ReprPCWk). Using BEDTools42 we calculated the number of representative 
ATAC-seq peak bases that overlapped each chromatin state. We ranked the ATAC-seq peak overlap of each 
chromatin state in adipose nuclei (Roadmap epigenome ID E063) relative to all other cell types, where a rank of 1 





Enrichment of transcription factor motifs within ATAC-seq peaks 
We tested for enrichment of 519 transcription factor binding motifs from the JASPAR core 2016 
vertebrates database49 within the top 50,000 representative peaks for adipose tissue and GM12878 lymphoblasts 
using Analysis of Motif Enrichment (AME)50. We used shuffled peak sequences with preserved dinucleotide content 
as background for the enrichment and the Fisher Exact Test to calculate enrichment significance. We classified 
motifs with an Expect value (E) less than 1x10-100 as significantly enriched.  
Transcription factor motif scanning and footprinting within ATAC-seq peaks 
To identify transcription factor motifs both disrupted and generated by GWAS variants, we constructed 
personalized reference genomes (hg19) with the –create_reference option in the AA-ALIGNER pipeline51 using 
genotypes in the adipose tissue samples. We scanned the resulting haplotypes for 519 transcription factor binding 
motifs from the JASPAR core 2016 vertebrates database using FIMO.49,52 If two motifs for the same factor existed 
at the exact same genomic coordinates and on the same strand on each haplotype, we used the motif with the highest 
motif score.  
We performed transcription factor footprinting for 35 transcription factor motifs corresponding to 34 
unique adipose-related transcription factors. The 34 transcription factors included 21 described as adipose core 
transcription factors53, six dimer motifs that contained a core transcription factor, plus CEBPA, CEBPB, CEBPD, 
ZEB1, SPI1, SPIB, and CTCF. For the resulting motifs, we generated windows containing the genomic coordinates 
of the motif and 100 bp flanking both motif edges. We removed motif windows where fewer than 90% of bases 
could be uniquely mapped or that overlapped blacklisted regions.42,43,54 We constructed matrices of the number of 
Tn5 transpositions across the remaining motif windows and predicted which motifs were likely bound using 
CENTIPEDE.55 We used motif scores calculated by FIMO for CENTIPEDE priors and classified a motif with a 
CENTIPEDE posterior binding probability greater than 0.99 as bound and less than 0.5 as unbound.  
Next, we determined which transcription factors exhibited an average decrease in ATAC-seq signal across 
their motifs relative to flanking regions, termed an aggregate footprint profile; we considered these footprints to be 
the most robust and consistent footprints across all motif sites. We calculated the average transposition probability at 
each window position separately for bound and the top 10,000 unbound sites to obtain aggregate bound and 
unbound profiles, calculated the transposition probability ratio (TPR) by dividing each position in the bound profiles 




(mTPR) and the 100 bp flanking regions (fTPR). We considered transcription factor motifs to display an aggregate 
footprint profile if mTPR was less than fTPR.  
Enrichment of GWAS variants in ATAC-seq peaks 
We tested for enrichment of genetic variants in ATAC-seq peaks using GREGOR, which compares overlap 
of GWAS variants relative to control variants matched for number of LD proxies, allele frequency, and gene 
proximity.56 We selected lead variants with a p-value less than 5x10-8 from 11 trait categories from the GWAS 
catalog (December 2016): type 2 diabetes, insulin, glucose, cardiovascular outcomes, blood pressure traits, low-
density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), triglycerides, total 
cholesterol, body mass index (BMI), and waist-hip ratio adjusted for BMI (WHR). Loci that were associated with 
multiple traits were assigned to each trait. To remove multiple lead variants for the same association signal, we 
performed LD clumping using swiss (https://github.com/welchr/swiss) with the 1000G_2014-11_EUR LD 
reference; variants in moderate LD (r2>0.2) and within 1 Mb of a variant with a more significant p-value were 
removed. We used GREGOR to test for enrichment of the resulting GWAS lead variants or their LD proxies (r2 
threshold of 0.8 within 1 Mb of the GWAS lead, 1000 Genomes Phase I) in ATAC-seq peaks relative to control 
variants. We tested for enrichment in the top 50,000 representative peaks for adipose tissue, SGBS adipocytes, 
SGBS preadipocytes, and GM12878 lymphoblasts. Enrichment was considered significant if the enrichment p-value 
was less than the Bonferroni-corrected threshold of 5x10-3 (0.05/11 trait groups). To compare enrichment 
magnitudes between regions and traits, we calculated an enrichment z-score: 
 
The expected overlaps and standard deviation were estimated using GREGOR.56 We visualized the enrichment 
results using the heatmap.2 function in the gplots R package.57,58  
Overlap of GWAS-eQTL colocalized loci with ATAC-seq peaks 
eQTL mapping in 770 subcutaneous adipose tissue samples and determination of GWAS-coincident eQTLs 
was described previously.9,38 We identified overlap of ATAC-seq peaks with any variant in LD (r2>0.8) with the 
GWAS lead variant at 110 loci (6,692 variants) using BEDTools.42 LD was calculated using the 770 METSIM 







Transcriptional reporter luciferase assays 
SGBS preadipocyte, 3T3-L1 preadipocyte, SW872 liposarcoma, and THP-1 monocyte cells were 
maintained and transcriptional reporter luciferase assays were performed as previously described.38,59 3T3-L1 
preadipocytes (ATCC, CL-173) were differentiated as described in the ATCC protocol. Amplified regions were 
inserted in pGL4.23 firefly luciferase reporter vectors (Promega) upstream of the minimal promoter and luciferase 
gene. We cloned two sizes of constructs for rs7187776 due to a restriction enzyme site in the middle of the larger 
construct; we tested both in luciferase assays. The long construct includes part of the 3’ UTR of TUFM and part of 
the 5’ UTR of SH2B1. Fragments containing potential enhancers are designated as ‘forward’ or ‘reverse’ based on 
their orientation with respect to the genome. Regions were designed to include the entire ATAC-seq peak 
overlapping the variant of interest. Three to five independent clones were cotransfected with Renilla luciferase 
vector in triplicate (SGBS, 3T3-L1 adipocytes) or duplicate (SW872, THP1, 3T3-L1 preadipocytes) wells using 
Lipofectamine 3000 (SGBS, THP-1, Life Technologies), Lipofectamine 2000 (3T3-L1 preadipocytes and 
adipocytes) or FUGENE 6 (SW872, Promega). Firefly luciferase activity of the clones containing the PCR 
fragments was normalized to Renilla luciferase readings to control for differences in transfection efficiency. We 
repeated all luciferase transcriptional reporter experiments on independent days and obtained consistent results. Data 
are reported as fold change in activity relative to an empty pGL4.23 vector. We used two-sided Student’s t-tests to 
compare luciferase activity. 
Electrophoretic mobility shift assays (EMSA) 
For EMSA, we prepared nuclear cell extracts from SGBS preadipocyte and SW872 cells using the NE-PER 
nuclear and cytoplasmic extraction kit (Thermo Scientific) as previously described.60 Double-stranded oligos were 
incubated with SGBS preadipocyte or SW872 nuclear extract or 100 ng purified PU.1 protein (Creative Biomart 
SPI1-172H) and DNA-protein complex visualization was carried out as previously described.60 A positive control 
oligo contained the PU.1 motif from JASPAR and a negative control did not contain the motif. We repeated all 
EMSA experiments on independent days and obtained consistent results. 
Allelic imbalance 
We aligned reads for the adipose tissue samples to personalized genomes using the allele-aware aligner 
GSNAP allowing two mismatches, no indels, and treating ambiguous bases (encoded as N’s) as mismatches.61 We 




WASP,62 we removed alignments that did not uniquely map to each allele at heterozygous sites. Allele count pileup 
files were generated at heterozygous sites with a minimum base quality Phred score of 30 to minimize the impact of 
sequencing errors using samtools. We removed heterozygous loci with aligned bases other than the two genotyped 
alleles and selected heterozygous sites with at least 10 total counts and at least 1 count per allele. To account for 
residual biases, we fit allele counts to a beta-binomial distribution with the probability of success (reference allele 
ratio) and dispersion estimated using maximum likelihood separately for each sample using the VGAM R 
package.57,63 We performed two-tailed beta-binomial tests of allelic imbalance using VGAM.  
To confirm allelic imbalance in PU.1 binding and chromatin accessibility at rs7187776 (genomic position 
chr16:28857645), we analyzed public genotype, SPI1 ChIP-seq, and DNase-seq data for the GM12891 cell line. We 
obtained genotypes for individual NA12891 from ftp://ftp-trace.ncbi.nih.gov/1000genomes/. We downloaded 
GM12891 SPI1 ChIP-seq alignments (ENCFF450BQJ, ENCFF152ZGE) and DNase-seq alignments 
(ENCFF070BAN) from ENCODE. Allele count pileup files were generated at heterozygous sites with a minimum 
base quality Phred score of 30 to minimize the impact of sequencing errors using samtools.  
Results 
Chromatin accessibility in frozen adipose tissue and SGBS preadipocytes and adipocytes 
We generated ATAC-seq open chromatin profiles from three frozen subcutaneous adipose tissue needle 
biopsy samples, two replicates of SGBS preadipocytes, and three replicates of SGBS adipocytes. In the adipose 
tissue samples, we generated ~56-70 million non-duplicated nuclear reads and ~36-58 thousand peaks (FDR<5%, 
Table 2.1, Methods). We identified 68,571 representative adipose tissue peaks by taking the union of peaks across 
the three samples. We generated a comparable number of non-duplicated nuclear reads in the SGBS samples (~30-
90 million), but identified many more peaks (122,924 and 164,252 representative peaks for SGBS preadipocytes and 
adipocytes respectively) (Table 2.1, Methods). The lower signal-to-noise of adipose tissue profiles compared to 
cultured, largely homogeneous SGBS cells is expected due to the heterogeneity of whole adipose tissue and stress 
resulting from sample freezing.  
Using principal component analysis of ATAC-seq read counts within representative peaks, we identified 
that adipose tissue, SGBS preadipocyte, and SGBS adipocyte samples cluster into three distinct groups with strong 




than to SGBS preadipocyte profiles (Figure 2.1A), suggesting the adipose tissue samples contain more adipocytes 
than preadipocytes. 
We tested for enrichment of 519 transcription factor binding motifs from the JASPAR database in the top 
50,000 representative adipose tissue ATAC-seq peaks using AME.49,50 We identified 162 significantly enriched 
motifs (E < 1x10-100), including 41 motifs enriched in adipose tissue but not lymphoblasts. The set of 41 contains 
motifs for transcription factors known to promote adipogenesis, such as CEBP family members, STAT family 
members, and PPARG.64 
To evaluate the distribution of ATAC-seq peaks across samples, we examined the accessible chromatin 
landscape at ADIPOQ, which encodes adiponectin, a hormone secreted by adipocytes that is not expressed in 
preadipocytes.65,66 Adipose tissue and SGBS adipocyte ATAC-seq peaks overlapped the transcription start site 
(TSS) and parts of previously described regulatory elements upstream and in intron 1 of ADIPOQ that showed 
increased transcriptional activity in reporter assays67,68 (Figure 2.1B). Additionally, a strong ATAC-seq peak 
downstream of ADIPOQ was present in SGBS preadipocytes, suggesting this region may harbor preadipocyte-
specific regulatory elements. These data demonstrate that reproducible ATAC-seq open chromatin profiles can be 
obtained from small amounts (12-36 mg, one-third to two-thirds of a needle biopsy) of frozen clinical subcutaneous 
adipose tissue samples and SGBS preadipocytes and adipocytes. 
Comparison of adipose tissue, adipocyte, and preadipocyte open chromatin 
We compared our adipose tissue and SGBS representative ATAC-seq peaks to existing ATAC-seq datasets 
from tissue-derived adipocytes,19 ENCODE subcutaneous adipose tissue, and GM12878 lymphoblasts (outgroup) 
using three methods. First, principal component analysis of read counts within representative peaks shows that our 
adipose tissue profiles were most similar to ENCODE adipose tissue and tissue-derived adipocyte profiles (Figure 
2.1A). These tissue-derived adipocyte and ENCODE adipose tissue profiles were also more similar to SGBS 
adipocytes than SGBS preadipocytes. Our adipose tissue and SGBS profiles were more similar to existing adipocyte 
profiles than to GM12878 profiles. 
Second, we compared the distribution of ATAC-seq peaks to Roadmap Epigenomics Consortium 
chromatin states in adipose nuclei isolated from subcutaneous adipose tissue.21 We used the top 50,000 
representative peaks in each group of samples. For all ATAC-seq profiles, the majority of peaks were located in 




(heterochromatin, polycomb states). Our adipose tissue peaks showed the strongest overlap (40% enhancer, 49% 
promoter, 89% combined) with adipose nuclei promoters and enhancers compared to all other ATAC-seq profiles 
(Figure 2.1C). With the exception of ENCODE adipose tissue, enhancer coverage was consistently higher for 
adipose tissue and adipocyte profiles compared to preadipocyte and GM12878 lymphoblast profiles, whereas 
promoter coverage was similar between all samples (Figure 2.1C). The ENCODE adipose tissue profile had more 
peak bases in regions near transcription start sites and fewer peak bases in distal regions compared to all other 
profiles which may reflect technical differences in sample processing.  
Third, to characterize the epigenome distribution of ATAC-seq peaks across cell types, we determined the 
overlap of representative peaks from each ATAC-seq group with enhancer chromatin states from 98 Roadmap 
tissues and cell types including adipose nuclei.21 Adipose tissue and tissue-derived adipocyte peaks showed the most 
overlap with adipose nuclei enhancers, and SGBS adipocytes showed the 4th most overlap with adipose nuclei 
enhancers compared to enhancers in other tissue and cell types. SGBS preadipocytes showed the most overlap with 
enhancers in fibroblast cell types, and adipose nuclei ranked 24th among all cell types. As expected, GM12878 
lymphoblast peaks showed much less overlap with adipose nuclei enhancers, consistent with the cell type-specific 
nature of enhancers.21 Across the three methods, our adipose tissue and SGBS ATAC-seq profiles showed strong 
similarity with existing adipocyte ATAC-seq profiles and with active regulatory element chromatin states in adipose 
nuclei. 
Cardiometabolic GWAS loci in ATAC-seq peaks  
To identify cardiometabolic traits that may be strongly affected by adipocyte regulatory elements, we tested 
for enrichment of GWAS variants for 11 cardiometabolic trait groups in the top 50,000 representative ATAC-seq 
peaks in adipose tissue, SGBS adipocytes, SGBS preadipocytes, and GM12878 lymphoblasts. Variants at loci for 
four trait groups (WHR, HDL-C, cardiovascular outcomes, and blood pressure traits) showed significant enrichment 
(P<5x10-3) in adipose tissue, SGBS adipocyte, and SGBS preadipocyte peaks (Figure 2.2). WHR was the most 
strongly enriched trait in adipose tissue (z-score=8.66) and SGBS adipocyte (z-score=4.53) peaks, whereas blood 
pressure traits were most strongly enriched in SGBS preadipocyte peaks (z-score=4.29). Loci for insulin traits and 
WHR showed stronger enrichment in adipose tissue peaks compared to SGBS adipocyte or preadipocyte peaks, 
suggesting in vivo conditions and/or non-adipocyte cell types in adipose tissue may contribute to these traits. Loci 




with the roles of adipocytes in lipid storage. In contrast, loci for none of the tested traits were enriched in GM12878 
lymphoblast peaks. Our results suggest that genetic variation in adipose tissue and adipocyte accessible chromatin 
regions is frequently associated with several cardiometabolic traits and that the stronger enrichment of WHR and 
insulin trait loci in adipose tissue relative to adipocyte or preadipocyte peaks demonstrates the importance of 
profiling chromatin accessibility in tissue.  
Functional evaluation of cardiometabolic GWAS variants overlapping ATAC-seq peaks  
We next identified cardiometabolic GWAS variants that overlapped candidate regulatory elements defined 
by ATAC-seq peaks. We focused on ATAC-seq peaks at a subset of 110 cardiometabolic GWAS loci that were 
colocalized with gene expression quantitative trait loci (eQTLs) in subcutaneous adipose tissue;9,38 these loci 
consisted of 6,692 variants (LD r2>0.8 with lead GWAS variants). To strengthen annotation at these loci, we 
overlapped variants at these loci with all representative ATAC-seq peaks rather than the top 50,000 peaks. 147 
variants at 59 loci overlapped an adipose tissue peak. The loci that had only one variant overlapping an adipose 
tissue ATAC-seq peak are shown in Table 2.2; these variants are strong candidates for functional activity at these 
loci. Of these 147 variants, 136 (93%) also overlapped an SGBS adipocyte peak and 116 (79%) overlapped both an 
SGBS adipocyte and preadipocyte peak. Variants that overlap peaks in adipose tissue and adipocytes or 
preadipocytes may be more likely to act through regulatory elements present in adipocytes rather than blood, 
immune, or other adipose tissue cell type regulatory elements. Of the 147 variants, 97 (66%) overlapped a 
transcription factor (TF) motif from JASPAR.49 Using a stringent definition for transcription factor footprints 
(Methods), we identified aggregate footprint profiles for 12 of 35 tested TF motifs in adipose tissue and found that 
four variants overlapped a TF footprint. These candidate functional variants, target regulatory elements, and TFs 
provide a resource to investigate the mechanisms underlying cardiometabolic GWAS loci. 
We tested variants at two loci for allelic differences in functional regulatory assays. The first, rs1534696, 
was identified as a candidate regulatory variant based on overlap with an ATAC-seq peak in adipose tissue and 
tissue-derived adipocytes, but was not a candidate based on SGBS adipocyte or preadipocyte ATAC-seq peaks or 
adipose promoter or enhancer Roadmap chromatin state (Figure 2.3A). rs1534696 is located in the second intron of 
SNX10 (encoding sorting nexin 10), was associated with WHR (P=2x10-8, ß=0.027, in women)12 and exhibited a 
colocalized eQTL for SNX10 (P=3.4x10-150, ß=1.12) and CBX3 (P=1.1x10-13, ß=0.39) in adipose tissue.9 We tested 




luciferase reporter assays using four cell types (Figure 2.3B). In 3T3-L1 preadipocytes and adipocytes, the construct 
containing rs1534696-A showed higher transcriptional activity than rs1534696-C (P=0.01) in both orientations 
(Figure 2.3B). Similar trends were also observed in SW872 liposarcoma and SGBS preadipocyte cells; this 
direction of effect is consistent with the eQTL association of rs1534696-A with higher levels of SNX10 and CBX3. 
In addition, rs1534696-A showed increased protein binding in EMSAs using nuclear extract from SGBS 
preadipocytes (Figure 2.3C). These data suggest that a transcriptional activator binds more strongly to rs1534696-A 
and increases transcriptional activity of SNX10 and/or CBX3, contributing to the molecular mechanism at this 
GWAS locus (Figure 2.3D). 
The second variant we tested overlapped an ATAC-seq peak in adipose tissue, SGBS preadipocytes, SGBS 
adipocytes, and tissue-derived adipocytes and a SPI1 (PU.1) ChIP-seq peak, motif and footprint (Figure 2.4A). In 
adipose tissue sample 1, we further observed an allelic imbalance in ATAC-seq reads (P=2.90x10-3): 25 reads 
contained rs7187776-A and 3 reads contained rs7187776-G. rs7187776 is located near a long isoform of SH2B1 
(encoding SH2B adaptor protein 1) and is in strong LD (r2 > 0.8) with the lead variant associated with BMI 
(rs3888190, P=3.14x10-23, ß=0.031).13 This GWAS signal exhibited a colocalized eQTL for SH2B1 (P=4.7x10-15, 
ß=-0.39) and ATXN2L (P=2.5x10-11, ß=-0.34) in adipose tissue.9 rs7187776 is one of 124 candidate variants based 
on LD (r2>0.8) with the lead GWAS and eQTL variants, and one of five variants that overlapped ATAC-seq peaks 
at this locus. Using EMSA, we observed allele-specific binding of rs7187776-G to purified PU.1 protein and similar 
binding using nuclear extract from SW872 cells, consistent with the predicted motif (Figure 2.4B). We also tested 
alleles of rs7187776 in a 477-bp region encompassing the ATAC-seq peak and a smaller 186-bp region in 
transcriptional reporter assays (Figure 2.4). In THP-1 monocytes, the constructs containing rs7187776-A showed 
increased transcriptional activity compared to rs7187776-G (Figure 2.4C). In SGBS preadipocyte, SW872 
liposarcoma, 3T3-L1 preadipocyte, and 3T3L-1 adipocyte cells, we observed extremely strong transcriptional 
activity (>200-fold compared to background) but no allelic differences; differences may have been masked by the 
massive >200-fold transcription-enhancing effect of this region. rs7187776-G is associated with decreased 
expression levels of SH2B1 and ATXN2L, suggesting that PU.1 or another ETS family member may act as a 
transcriptional repressor at this locus. We observed fewer ATAC-seq reads corresponding to more PU.1 binding, a 
direction that has been observed less often than increased ATAC-seq reads corresponding to increased transcription 




ChIP-seq reads contained rs7187776-A and 11 reads contained rs7187776-G, whereas 11 DNase-seq reads 
contained rs7187776-A and 1 read contained rs7187776-G. Multiple ETS family members, including PU.1, can act 
as transcriptional repressors, including by recruiting histone deacetylases and DNA methyltransferases, resulting in 
closed chromatin,69-72 consistent with rs7187776-G showing fewer ATAC-seq reads. These data suggest that 
rs7187776-G increases binding of an ETS family member, and may contribute to the molecular mechanism at the 
ATP2A1-SH2B1 BMI GWAS locus (Figure 2.4D).  
Allelic imbalance in ATAC-seq reads 
We looked for other examples of allelic imbalance in ATAC-seq reads at heterozygous positions that may 
indicate altered chromatin accessibility. Only 387 sites showed nominal allelic imbalance (beta-binomial P<0.05) in 
at least one sample, 6 of which overlapped variants at GWAS-eQTL loci. However, only 40 of 6,692 total GWAS-
eQTL variants were heterozygous in at least one adipose tissue sample and were covered by enough ATAC-seq 
reads for allelic imbalance analysis, suggesting that higher read depth and larger sample sizes that increase the 
chance of heterozygosity at more eQTL and GWAS loci may enable identification of more disease-associated loci 
that could mediate their effects on disease through chromatin accessibility. 
Discussion 
In this study, we generated ATAC-seq open chromatin profiles from three frozen clinical adipose samples 
and replicate preparations of SGBS preadipocytes and adipocytes. We identified differences between adipose tissue, 
preadipocyte, and mature adipocyte open chromatin profiles, including cell-type-specific peaks at selectively 
expressed promoters. Adipose tissue, SGBS adipocyte, and SGBS preadipocyte open chromatin profiles largely 
overlapped Roadmap adipose nuclei chromatin states. Transcription factor motifs and footprints in ATAC-seq peaks 
overlapped GWAS variants, and GWAS variants for several traits were enriched in ATAC-seq peaks. Finally, we 
used the ATAC-seq profiles to annotate potential regulatory variants at GWAS-eQTL colocalized loci and provided 
experimental evidence of allelic differences in regulatory activity for variants at the SNX10 and ATP2A1-SH2B1 
GWAS loci. Taken together, these data are among the deepest characterization of chromatin accessibility in adipose 
tissue, adipocytes, and preadipocytes to date. 
Important differences exist between adipose tissue, preadipocyte, and mature adipocyte ATAC-seq profiles. 
Explanations for these differences include cell-type composition/heterogeneity, the differentiation state of 




At the TSS for ADIPOQ, we observed adipose tissue and SGBS adipocyte ATAC-seq peaks, and downstream of 
ADIPOQ, we observed ATAC-seq peaks specific to SGBS preadipocytes. The accessibility pattern of ADIPOQ is 
consistent with its role in adipocyte differentiation 73-75 and a previous finding that the ADIPOQ promoter is 
inaccessible until differentiation76. Among 98 Roadmap tissue and cell types, SGBS preadipocyte ATAC-seq 
profiles were more similar to fibroblast-like cells and cell lines than to adipose nuclei, and SGBS adipocytes were 
more similar to adipose nuclei, reflecting differences likely due to the fibroblast-like nature of preadipocytes. 
Differences between our adipose tissue ATAC-seq profiles and the ENCODE adipose tissue data may be due to 
differences in biopsy location, freezing method, storage conditions, or library preparation.  
Adipose ATAC-seq profiles provide insight into the mechanisms of cardiometabolic GWAS loci. For 
example, we found that GWAS variants for WHR— but not BMI—are enriched in adipose ATAC-seq peaks. This 
enrichment is consistent with recent findings that WHR loci are enriched in adipose transcriptional regulatory 
elements12 and that BMI GWAS loci are enriched in pathways involved in central nervous system biology.13 We 
also identified enrichment of other cardiometabolic traits, including insulin traits, lipids, and cardiovascular 
outcomes, highlighting the relevance of adipose regulatory elements for these traits. Identifying the transcription 
factor(s) bound to a regulatory variant is a challenging part of defining the molecular mechanisms underlying 
cardiometabolic GWAS loci. While transcription factor footprints better predict that a transcription factor is bound 
at a locus compared to motif occurrence alone,55 neither footprints nor motifs identify the bound transcription factor 
with 100% accuracy, particularly when multiple transcription factors share similar binding motifs. We successfully 
generated transcription factor footprints for 12 transcription factor motifs, which can be used to identify GWAS 
variants that may alter transcription factor binding. However, additional experiments are needed to confirm the 
identity of transcription factors bound at loci containing these footprints.  
We described two GWAS loci for which ATAC-seq peaks helped prioritize candidate variants. At the 
SNX10 WHR locus, we identified a potentially functional variant, rs1534696, which is not located in a predicted 
regulatory region based on existing chromatin state data. rs1534696 overlaps an ATAC-seq peak in adipose tissue 
and showed allelic differences in transcriptional reporter and protein-binding assays. Interestingly, we observed 
allelic differences in protein binding in SGBS preadipocytes, yet low transcriptional activity, similar to empty 
vector, in SGBS preadipocytes and 3T3L1 cells. One possibility is that a repressor binds in preadipocytes to prevent 




determine the apparent differences between preadipocytes and adipocytes at this locus. At the ATP2A1-SH2B1 BMI 
locus, we identified a PU.1 binding motif and footprint at rs7187776, as well as allelic imbalance in ATAC-seq 
reads, and confirmed the allelic differences in PU.1 binding in vitro. PU.1 is part of the ETS family of transcription 
factors, all of which have very similar DNA binding motifs,77 so PU.1 may not be the specific TF binding at this 
locus, especially because PU.1 is expressed at very low levels in SGBS preadipocytes, SGBS adipocytes, and 
isolated mature adipocytes.18,19 Interestingly, we observed significant allelic differences in transcriptional activity in 
THP-1 monocyte cells but not in preadipocyte or adipocyte cell types (Figure 2.4), suggesting that this variant 
might be important in non-adipocyte cells within adipose tissue. These data provide excellent examples of how to 
integrate GWAS, eQTL, and ATAC-seq data to identify functional variants at GWAS loci. Further experiments are 
needed to determine if these variants are the only functional variants at each locus, as we also observed allelic 
differences in protein binding for a second variant overlapping an ATAC-seq peak at the SH2B1 locus and others 
have suggested different functional variants at this locus,78,79 and which gene(s) are contributing to obesity risk.  
In summary, we presented ATAC-seq open chromatin profiles for frozen adipose tissue and cultured 
preadipocytes and adipocytes. We showed the utility of open chromatin profiles in multiple tissue samples and 
across cell types within heterogeneous tissue. Together, these data add to the growing understanding of gene 
regulation in adipose and the complex genetic mechanisms of cardiometabolic traits and diseases.  
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Figure 2.1. Comparison of ATAC-seq read profiles and peaks between samples and with Roadmap adipose 
nuclei chromatin states. (A) Principal components analysis (PCA) of ATAC-seq read counts within representative 




from the Roadmap Epigenomics project adipose nuclei are shown at the top in green and blue. ATAC-seq signal 
tracks are shown in different colors by source: SGBS preadipocytes in light blue, SGBS adipocytes in red, adipose 
tissue in purple, ENCODE adipose tissue in light purple, and tissue-derived adipocytes in orange. DNase 
hypersensitivity signal tracks for SGBS adipocytes are also shown in orange. Asterisks represent ATAC-seq data 
generated in this manuscript. Peak regions are indicated by gray bars. The bottom track shows chromatin states from 
the Roadmap Epigenomics Project for adipose nuclei (yellow = enhancer; green = transcribed; orange/red = 
promoter; light green = genic enhancer; gray = repressed/polycomb; light red = bivalent/poised TSS; turquoise = 
heterochromatin). (C) Overlap of the top 50,000 ATAC-seq peaks with promoter and enhancer chromatin states 





Figure 2.2. Cardiometabolic GWAS loci are enriched in ATAC-seq peaks. The heatmap shows enrichment of 
cardiometabolic GWAS loci (z-score) for the top 50,000 representative ATAC-seq peaks in adipose tissue, SGBS 
adipocytes, SGBS preadipocytes, and GM12878 lymphoblasts. Cells with a significant p-value (p<0.005) contain an 





Figure 2.3. A variant at the SNX10 WHR GWAS locus alters transcriptional activity and protein binding. (A) 
rs1534696 overlaps an ATAC-seq peak (adipose tissue 3 is shown in the figure; adipose tissue 1 shows stronger 
signal and peak) and is located in intron 2 of SNX10, transcribed left-to-right in the image, but is not located in a 
predicted regulatory region based on Roadmap chromatin states. TCF4 ENCODE ChIP-seq binding was observed in 
HepG2 cells. (B) The genomic region containing rs1534696-A shows increased transcriptional activity and allelic 
differences in transcriptional reporter luciferase assays in 3T3-L1 adipocytes and preadipocytes. The genomic region 
was cloned upstream of a minimal promoter and the luciferase gene. Dots represent the average of 2-3 technical 




in the image. P-values determined by Student’s t-test. EV, empty vector. (C) rs1534696-A shows increased protein 
binding in EMSA using SGBS preadipocyte nuclear extract. The black arrow shows allelic differences in protein 
binding. The gray arrow denotes non-specific binding observed for both rs1534696-A and rs1534696-G. (D) 






Figure 2.4. A variant at the ATP2A1-SH2B1 BMI GWAS locus alters chromatin accessibility and PU.1 
binding. (A) rs7187776 is located in the promoter of a long SH2B1 isoform, transcribed left-to-right in the image; 
the 5’-UTR of TUFM, transcribed right-to-left in the image; and a region containing ATAC-seq peaks from multiple 
sources. ETS1 and PU.1 ENCODE ChIP-seq binding was observed in K562 and GM12891, respectively. Many 
additional transcription factor ChIP-seq peaks overlap this region in the ENCODE datasets. (B) A 19-nt probe 
containing rs7187776-G shows increased protein binding to purified PU.1 in EMSA, similar to a positive control 
probe containing the consensus PU.1 motif (+). A negative control probe (-) and a probe containing rs7187776-A 
showed no binding to PU.1. Black arrows indicate allele-specific protein binding, gray arrow indicates the well of 
the gel. Similar protein binding patterns and equal amounts of free DNA probe were observed using SW872 nuclear 
extract. PU.1 consensus motif from JASPAR 49. (C) The genomic region containing rs7187776-A shows increased 




UTR of TUFM and part of the 5’ UTR of SH2B1 was cloned upstream of a minimal promoter and the luciferase 
gene. Dots represent the average of two technical replicates. Forward and reverse designated with respect to the 
genome, so forward corresponds to left-to-right in the image. P-values determined by Student’s t-test. EV, empty 





















Tissue 1 129.5 87.4 8.5 80.0 70.6 58,550 
Tissue 2 131.5 83.6 12.8 72.9 60.6 36,785 
Tissue 3 119.3 70.5 11.9 62.2 57.1 49,962 
Adipocytes 1a 382.6 275.9 2.1 268.6 90.4 184,455 
Adipocytes 2a 245.1 172.9 1.9 168.7 84.1 172,247 
Adipocytes 3a 253.7 181.0 1.5 177.2 87.5 191,141 
Preadipocytes 1a 97.3 71.8 1.0 70.8 34.6 171,279 
Preadipocytes 2a 75.1 54.1 1.1 53.3 30.5 139,911 
Table 2.1. ATAC-seq alignment metrics of human adipose tissue and SGBS preadipocytes and adipocytes. 
Reads are reported in millions of reads. aSamples were sequenced using paired-end reads, but processed as single-
end reads. bWe identified 68,571 representative peaks across adipose tissue, 122,924 across SGBS preadipocytes, 




















(r2>.8) at locus 
ATAC  samples 








LIPA rs1412444 LIPA rs1412445 rs1332328 8 
3, Adipocytes, 
Preadipocytes 
HDL cholesterol GSK3B rs6805251 GSK3B rs334533 rs334558 61 








1, 2, 3, Adipocytes, 
Preadipocytes 
Serum metabolites NAT8 rs13391552 ALMS1 rs6740766 rs4547554 180 1, 2, 3, Adipocytes 









rs2131925 DOCK7 rs631106 rs631106 237 
1, Adipocytes, 
Preadipocytes 
Triglycerides FADS1 rs174548 FADS1 rs174555 rs174561 48 
1, 2, 3, Adipocytes, 
Preadipocytes 










WHRadjBMI SNX10 rs1534696 CBX3, SNX10 rs1534696 rs1534696 1 1 
Table 2.2. Selected variants at GWAS-eQTL colocalized loci that overlap ATAC-seq peaks. A subset of loci in which only one variant overlapped an 
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Genome-wide association studies (GWAS) have identified thousands of loci associated with complex traits, 
but the causal variants, molecular mechanisms, target genes, and tissues of action for most loci have not been 
characterized. Gene expression quantitative trait loci (eQTL) studies have been instrumental in identifying plausible 
target genes and tissues for GWAS loci1. Chromatin conformation capture techniques, such as Hi-C, have identified 
variants at GWAS loci that physically interact with gene promoters2. However, additional approaches are needed to 
further pinpoint functional variants and to identify how these variants alter gene expression.  
Variants at GWAS loci are enriched in transcriptional regulatory elements, which are typically marked by 
chromatin accessibility, in trait-relevant tissues3. Recent studies have identified chromatin accessibility QTL 
(caQTL), many of which overlap transcription factor (TF) binding sites and motifs4–9. A subset of caQTL are 
colocalized with eQTL and GWAS loci, suggesting that variants at these loci impact gene expression and GWAS 
traits by altering chromatin accessibility4–9. However, caQTL have been mapped in a limited set of human tissues. 
Mapping caQTL in additional tissues and cell types is valuable to characterize the transcriptional regulatory 
mechanisms for a larger set of GWAS loci. 
Liver is involved in numerous processes, including lipid metabolism, glucose storage, drug metabolism, 
and immune response10. Several studies have mapped eQTL in liver tissue, and liver eQTL are colocalized with 
GWAS loci for lipid, drug response, and other traits11–13. Lipid GWAS loci are enriched in regulatory chromatin 
states, including enhancers and promoters, in HepG2 hepatocyte cells14. QTL for the active regulatory element 
histone marks H3K27ac and H3K4me3 have been identified in liver tissue, including a subset colocalized with liver 
eQTL and GWAS loci12. Chromatin accessibility marks active regions containing H3K4me3 and H3K27ac, as well 
as poised promoters and enhancers that often do not display these histone marks15,16. Consequently, mapping caQTL 
in liver tissue can help functionally characterize GWAS loci that act by altering gene expression in liver. 
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In this study, we jointly mapped genotypes, gene expression, and chromatin accessibility in liver tissue 
from 20 organ donors and identified caQTL in liver tissue. We predicted the impact of caQTL variants on TF 
binding and predicted caQTL target genes using four approaches. Finally, we used caQTL, TF binding motifs, and 
target gene links to predict mechanisms at GWAS loci for multiple traits. 
Material and Methods 
Liver tissue samples  
Healthy human liver tissue was collected from deceased organ donors at St. Jude (Memphis, TN) as part of 
the National Institutes of Health Liver Tissue Cell Distribution System. Tissue was collected with the approval of 
institutional review boards (IRBs) and the University of North Carolina (Chapel Hill, NC) approved their use for 
this study as non-human subjects research. 
Genotyping and imputation 
We genotyped over 2.5 million variants using the Infinium Omni2.5Exome-8 BeadChip array v1.3 
(Illumina, San Diego, CA, USA) at the NHGRI Genomics Core facility. Overall genotyping call rates ranged from 
99.0-99.6%. We mapped the Illumina array probe sequences to the hg19 genome assembly17 using novoalign (see 
web resources), excluding variants with ambiguous probe alignments and variants with 1000 Genomes (1000G) 
phase 3 minor allele frequency (MAF) >.01 within 7 bp of the 3’ end of probes. No individuals were related at a 3rd-
degree relationship threshold using KING v1.418. Prior to testing for population stratification, we removed variants 
with minor allele count < 5 and that were found within regions of unusually high linkage disequilibrium (LD, see 
web resources) using VCFtools v0.1.1419,  and selected distinct (r2<0.2) variants using PLINK v1.920. We did not 
observe evidence of population stratification using principal component analysis (PCA) of 65,113 genotypes using 
PLINK v1.920. 
Prior to genotype imputation, we combined the genotypes of the samples in this study with genotypes from 
173 samples from a separate study genotyped on similar chips and removed variants that met the following criteria: 
allele frequency difference >20% with 1000G phase 3 Europeans, palindromic variants with MAF>.2, genotype 
missingness > 2.5%, and extreme deviation from Hardy-Weinberg Equilibrium (p<1x10-4). Using the Michigan 
Imputation Server21, we phased 1,825,454 variants using Eagle v2.322 and imputed missing genotypes using 
minimac321 with the Haplotype Reference Consortium (hrc.r1.1.2016) panel23. We retained variants with imputation 
r2>.3 for downstream analyses.  
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RNA-seq library preparation, read alignment, and selection of expressed genes 
We extracted and purified total RNA from frozen liver tissue using Trizol as previously described24. Paired-
end, strand-specific, poly-A RNA sequencing (RNA-seq) was performed on an Illumina NovaSeq 6000 with 2x151 
bp cycles. RNA-seq reads were trimmed using Trimmomatic25 and aligned to the hg19 genome assembly17 using 
STAR v2.5326 with default parameters. Using verifyBamID v1.1.127, we found no evidence of library contamination 
or sample swaps. Expression levels of GENCODE v1928 genes were quantified using QoRTs v1.2.4229. We 
classified genes as expressed if the median transcripts per million (TPM) across the 20 individuals was at least 1. 
We performed principal component analysis on gene counts normalized by library size and variance-stabilized using 
DESeq230. 
ATAC-seq library preparation 
Nuclei were isolated as previously described31 with the following modifications. We pulverized 50-mg 
pieces of frozen human liver tissue in liquid nitrogen using a Cell Crusher (CellCrusher, Cork Island), homogenized 
the tissue powder in ice cold nuclei isolation buffer (NIB: 20 mM Tris-HCl, 50 mM EDTA, 5 mM spermidine, 0.15 
mM spermine, 0.1% mercaptoethanol, 40% glycerol, pH 7.5) using a 1-mL dounce for 40 strokes, and rotated for 5 
minutes at 4oC. We filtered the solution through a Miracloth (Calbiochem, San Diego, Ca USA), centrifuged at 
1100g for 10 minutes at 4oC, washed the pellet with 250-uL NIB containing 0.5% Triton-X, centrifuged at 500g for 
5 minutes at 4oC, and resuspended the pellet in 250-uL of resuspension buffer (10 mM Tris-HCl, 10 mM NaCl, 3 
mM MgCl2, pH 7.4). After counting isolated nuclei, we pelleted 50,000 nuclei at 500g for 5 minutes at 4oC for each 
of three replicate ATAC-seq libraries per sample. Libraries were prepared using Nextera kits (Illumina) as 
previously described32. 
ATAC-seq read alignment and identification of consensus peaks 
We trimmed ATAC-seq reads to a uniform length of 126 bp using cutadapt33 and aligned reads as 
previously described34. Briefly, we trimmed sequencing adapters using CTA (see web resources) and aligned reads 
to the hg19 human genome17 using BWA-MEM (see Web Resources). We selected properly paired autosomal 
alignments with high mapping quality (mapq>30) with samtools35 and removed duplicate alignments using Picard 
(see web resources). We used ataqv36 to generate ATAC-seq quality metrics and confirmed ATAC-seq libraries 
corresponded to the correct genotypes using verifyBamID27. 
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To assess reproducibility of libraries from the same individual, we called narrow peaks separately for each 
library using MACS237 with parameters –nomodel -100 –extsize 200, then merged peaks across all individuals and 
replicates using BEDTools merge38, and selected peaks present in at least 3 libraries. We counted the number of 
reads overlapping each peak using featureCounts39 and performed library size normalization and variance-
stabilization using DESeq230. We computed pairwise Pearson correlations of normalized counts for all peaks and for 
the 10,000 most variable peaks between libraries and visualized the results using the heatmap.2 function in the 
gplots R package40 (see Web Resources). Libraries from the same individual were highly correlated, so we merged 
the alignment .bam files across libraries for each individual using SAMtools35. 
To identify consensus peaks, we converted the merged .bam files for each individual to .bed files using 
BEDTools38, called narrow peaks for each individual using MACS237 with parameters –nomodel –shift -100 –
extsize 200 –keep-dup all, and removed peaks overlapping blacklisted regions38,41. We then merged peaks across 
individuals using BEDTools38 and defined consensus peaks as merged peaks that shared at least 1 base with a peak 
present in samples from at least 3 individuals. 
Overlap of consensus peaks with roadmap chromatin states 
We computed overlap of ATAC-seq consensus peaks with chromatin states in adult liver tissue from the 
Roadmap Epigenomics Consortium3. We defined the following states: promoter (1_TssA, 2_TssFlnk, 3_TssFlnkU, 
4_TssFlnkD, 14_TssBiv), transcribed (5_Tx, 6_TxWk), enhancer (7_EnhG1, 8_EnhG2, 9_EnhA1, 10_EnhA2, 
11_EnhWk, 15_EnhBiv), polycomb (16_ReprPC, 17_ReprPCWk), heterochromatin (13_Het), ZNF repeats 
(12_ZNF/Rpts), and quiescent (18_Quies). For each consensus ATAC peak, we computed the fraction of bases that 
overlapped each chromatin state in liver tissue (Roadmap epigenome ID E066) using BEDTools coverage38. We 
assigned each peak to the chromatin state with which it shared the most bases, except for the quiescent state; we 
only assigned a peak to a quiescent state if all bases of a peak were found within a quiescent state. If a peak shared 
most, but not all, of its bases with a quiescent state, we assigned the peak to the state with the second highest 
coverage. 
Selection of transcription factor motifs 
We obtained transcription factor (TF) binding motifs from Cis-BP v1.0242, selected all directly determined 
motifs per TF or the best inferred motif when a TF did not have a directly determined motif (TF_Information.txt 
dataset from Cis-BP), and restricted to motifs for TFs expressed in liver tissue from GTEx v8 (median transcripts 
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per million 1). We performed clustering to remove redundant motifs using RSAT matrix-clustering43 with 
parameters -hclust_method average -calc sum -metric_build_tree Ncor -lth w 5 -lth cor 0.8 -lth Ncor 0.8 -quick, 
resulting in 516 motif clusters. For each motif cluster, we defined the representative TF as the TF with the highest 
expression in liver tissue from GTEx v8 (measured in median TPM) and the representative motif as the motif 
assigned to the representative TF. If multiple motifs existed for the representative TF in a given cluster, we selected 
the motif with the highest information content. Although we often use the representative TF name to refer to motif 
clusters for convenience, any TF in the cluster may bind at a given locus. Therefore, we listed all expressed TFs in 
the cluster in supplemental tables. Some TFs were assigned as the representative TF for multiple clusters, potentially 
representing distinct binding profiles for the same TF. We retained all of these clusters unless otherwise noted. 
Enrichment of TF motifs and ChIP-seq binding sites in ATAC peaks 
We tested for enrichment of 286 non-redundant transcription factor (TF) motifs in consensus ATAC peaks 
using Analysis of Motif Enrichment (AME)44 with parameters –control –shuffle-- –kmer 2 –scoring max –hit-lo-
fraction 0.75. We classified motifs with E-value < 1x10-100 as significantly enriched. We derived the 286 motifs 
from the set of 516 non-redundant motifs (see “Selection of transcription factor motifs”) by selecting the motif with 
the highest information content per TF. 
We downloaded liver tissue ChIP-seq peaks for 17 TFs45 from the ENCODE portal46 (sample accession 
ENCDO882MMZ) and defined binding sites as the summit of the ChIP-seq peaks. We computed the number of 
binding sites overlapping consensus ATAC-seq peaks for each TF using BEDTools intersect38. To determine if the 
number of binding sites overlapping ATAC peaks was more than expected given their genomic frequency, we 
permuted binding sites across the genome 1,000 times excluding blacklisted regions41 using BEDTools shuffle38 and 
computed the number of overlaps for each permutation. We calculated an enrichment p-value by determining the 
fraction of permuted overlaps that were equal to or greater than the observed number of overlaps. 
Chromatin accessibility QTL identification 
We identified chromatin accessibility quantitative trait loci (caQTL) using RASQUAL5, which jointly tests 
for association of genotype with peak accessibility across individuals and allelic imbalance in read counts at 
heterozygous variants within the same individual. We selected ~4 million genetic variants with MAF > .1 in the 20 
individuals and within 100 kb of consensus peak centers and restricted to variants present in 1000 genomes phase 3 
Europeans. To quantify peak accessibility across samples, we extended alignments 100 bp from either end of the 5’-
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most base using BEDTools38 and counted the number of alignments overlapping each peak using featureCounts39. 
We used DESeq2 size factors30 to adjust for library size and the gcCor.R script provided with RASQUAL5 to adjust 
for GC bias. To identify global variation between samples that may confound caQTL detection, we performed PCA 
on peak counts adjusted for library size and variance-stabilized by DESeq230,40. We ran RASQUAL using differing 
numbers of PCs as covariates ranging from 0 to 10 in increments of 1 and selected 2 PCs to maximize the number of 
peaks with a caQTL at false discovery rate (FDR) of 5%. We performed multiple testing correction using the two-
step eigenMT-BH procedure47. First, we used eigenMT48 with the 1000 genomes phase 3 European reference panel 
to adjust for the differing variant density around each peak, taking into account the LD between variants. Second, we 
selected the most significant eigenMT-adjusted p-value for each peak and calculated FDR using the Benjamini-
Hochberg (BH) procedure49. We selected significant caQTL with FDR<5% and correlation r2 between prior and 
posterior genotypes >0.8. We refer to peaks with a significant caQTL as caPeaks. We repeated the caQTL analysis 
using ~0.6 million variants within 1 kb of peak centers. Unless otherwise noted, all downstream analyses were 
performed using caQTL identified using variants within 1 kb of peak centers.  
ATAC-seq allelic imbalance and comparison to caQTL effect sizes 
To assess the robustness of the caQTL, we used an alternative method for calculating allelic imbalance 
(AI). We removed ATAC-seq reads exhibiting allelic mapping bias using the WASP mapping pipeline50 and 
counted the number of ATAC-seq reads mapping to each allele at heterozygous variants using ASEReadCounter51 
with the option –min-base-quality 30. We removed variants that had aligned bases other than the two genotyped 
alleles and selected variants with >=10 total reads, >=3 reads per allele, and that were heterozygous in >=3 
individuals. After pooling reads across individuals, each variant had a minimum of 30 total reads and 9 reads per 
allele. We fit allele counts to a beta-binomial distribution using the VGAM R package40,52, tested for AI using a two-
tailed beta-binomial test, and adjusted for multiple testing using the BH procedure. 
To compare effect sizes of AI variants and caQTL signals, we selected caQTL that had at least one AI 
variant in strong LD (r2>0.8, 1000G phase 3 Europeans) with the caQTL lead variant and that resided within the 
caPeak; LD was calculated using PLINK v1.920. For each caQTL with a linked AI variant, we selected the AI 
variant with the strongest evidence of AI (smallest beta-binomial p-value). For both methods, we calculated an 
effect size by subtracting 0.5 from the estimated fraction of reads containing the alternate allele, which is the 
RASQUAL PI value for caQTL. An alternate allele fraction of 0.5 corresponds to an equal number of reads on each 
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allele, which is an effect size of 0. We then computed the Pearson correlation between the absolute value of effect 
sizes between the caQTL and AI variants. 
caQTL enrichment in chromatin states 
To identify which regulatory elements preferentially contain caPeaks, we compared the number of caPeaks 
(FDR<5%) and non-caPeaks (eigenMT-adjusted p>0.5) assigned to various liver tissue chromatin states from 
Roadmap3. We tested if caQTL variants were enriched in liver tissue chromatin states relative to variants matched 
for MAF, number of LD proxies, and distance to nearest gene using the logistic regression model implemented in 
GARFIELD53. We defined caQTL variants as significantly enriched in a chromatin state if the p-value for the 
logistic regression beta was less than the Bonferroni-corrected threshold (for 7 chromatin states) of 7.1x10-3 and the 
odds ratio was greater than 1. We defined caQTL variants as significantly depleted in a chromatin state if p<7.1x10-3 
and odds ratio<1. 
Transcription factor motif disruption by caQTL variants 
We selected 5,378 caQTL variants that resided within the caPeak using BEDTools intersect38 and that were 
in strong LD (r2>0.8, calculated with PLINK20) with the caQTL lead variant. To ensure that each motif occurrence 
was disrupted by only one variant, we removed 793 variants within 30 bp of another caQTL variant, resulting in 
4,585 variants. For both alleles of each caQTL variant, we extracted the nucleotide sequence for the region 
containing the variant and the 30 nucleotides on either side of the variant using the BEDTools slop and getfasta 
tools38. We scanned these sequences for occurrences of 516 non-redundant TF motifs using Find Individual Motif 
Occurrences (FIMO)54 with parameters --thresh 0.01 --max-stored-scores 1000000 --no-qvalue --skip-matched-
sequence –text and only retained motif occurrences that overlapped caQTL variant positions. For each motif-variant 
pair, we selected the strongest motif match (smallest p-value) per allele and only retained motif occurrences that 
matched strongly to at least one allele (p<1x10-4). If different motifs for the same representative TF overlapped the 
same variant, we selected the motif with the strongest match. 
Similar to a recent study55, we quantified the difference in motif match between alleles of a variant using 
the log ratio of FIMO p-values. The FIMO p-value for a given motif occurrence is the probability of observing a 
motif occurrence with the same or greater score, which inherently accounts for differences in score distributions 
between different motifs. For a given variant-motif pair, we define motif disruption as log10(paw) – log10(pas), where 
paw and pas are the FIMO p-values for the alleles with the weaker and stronger motif match, respectively. As motif 
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disruption is always positive, we classified a motif as disrupted if motif disruption was >1, corresponding to a 10-
fold difference in the FIMO p-values between alleles. 
We identified motifs whose disruption was associated with caQTL status using logistic regression. To 
generate a set of non-caQTL variants, we first selected peaks with no evidence of genetic regulation (caQTL 
eigenMT-adjusted p>0.5), that overlapped at least one variant tested in the caQTL analysis, and that were similar to 
caPeaks in GC content (±5%), peak width (±20%), and distance to nearest transcription start site (TSS) of a protein-
coding gene in GENCODE28 (±20%). We identified 10 non-caPeaks for >99% of the caPeaks used in the motif 
disruption analysis and defined non-caQTL variants as the 50,054 variants that were within non-caPeaks and were 
located more than 30 bp from the nearest variant. We tested these non-caQTL variants for TF motif disruption using 
the same procedure as for caQTL variants and restricted analysis to the 109 motifs with at least 20 disruptions by 
caQTL variants. For each representative TF, we selected the motif with the most disruptions by caQTL variants to 
ensure that we used only one motif per representative TF. We then regressed caQTL status (1=caQTL, 0=non-
caQTL) against motif disruption status (1=disrupted, 0=not disrupted) for each motif-variant pair using logistic 
regression. We classified motif disruption as associated with caQTL status if the p-value for the logistic regression 
beta was less than the Bonferroni-corrected threshold (for 109 motifs) of 4.6x10-4. Because residual differences may 
exist in peak GC content, width, and distance to nearest protein coding TSS, we performed logistic regression with 
and without these features as covariates and obtained the same set of significantly enriched motifs. 
caPeak target gene identification 
We used four methods to identify target genes for caPeaks: proximity to a gene’s TSS, overlap of caPeaks 
with promoter-centered chromatin contacts, correlation of caPeaks with peaks at gene promoters or with gene 
expression, and colocalization of caQTL and eQTL. We excluded genes from the analysis if their Entrez ID did not 
map to exactly one Ensembl ID (eQTL data only) or if their symbol (common name) didn’t map to exactly one 
Ensembl ID. When combining results across the four methods, we matched genes based on Ensembl ID. 
TSS proximity: We classified a caPeak as TSS proximal if it was located within 2 kb upstream and 1 kb 
downstream of the TSS of any of the 13,782 expressed genes (median TPM>1) in our 20 liver samples using 
BEDTools closest38. 
Promoter-centered chromatin contacts: We obtained promoter-distal and promoter-promoter contacts 
mapped in liver tissue using promoter capture Hi-C from a recent study2 (see web resources). Using described 
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filtering criteria2, we selected contacts with p-value<0.01 and interaction frequency >=5. We identified caPeaks 
overlapping distal ends of promoter-distal contacts or either end of promoter-promoter contacts using BEDTools 
intersect38.  
Correlation of caPeaks with promoter peaks and gene expression: We classified an ATAC-seq peak as the 
promoter peak for an expressed gene if it was the closest peak to the TSS of the gene and it was within 2 kb 
upstream and 1 kb downstream of the TSS56. A promoter peak may or may not be a caPeak. We identified promoter 
peaks for 10,074 of 13,782 expressed genes. For each gene with a promoter peak, we identified caPeaks for 
correlation that were within 1 Mb of the gene’s TSS but that were not TSS proximal. For peak and gene counts, we 
performed library size normalization and variance-stabilization using DESeq230 and GC bias-correction using 
RASQUAL5. We additionally adjusted peak counts by the fraction of reads in peaks, which was strongly correlated 
with the first ATAC-seq PC, and gene counts by the percent of reads mapping to the most expressed gene and the 
percent of reads mapping to the top 10 most expressed genes (geneDiversityProfile_top1pct and 
geneDiversityProfile_top10pct metrics from QoRTs29), which were strongly correlated with RNA-seq PCs 1 and 2 
respectively, using the limma removeBatchEffects function57. We then computed the Spearman correlation between 
(1) gene expression and caPeaks and (2) promoter peaks and caPeaks using the cor.test function in R40. We adjusted 
for multiple testing using the BH procedure49 and classified correlations with FDR<5% as significant. 
Colocalization of caQTL and eQTL: We obtained liver tissue expression quantitative trait loci (eQTL) for 
15,668 genes (FDR<5%) from a meta-analysis of 1,183 individuals11 and restricted to the 15,418 eQTL on 
autosomes. We calculated LD and haplotype phase between eQTL and caQTL lead variants using PLINK20 v1.9 and 
classified signals as colocalized if these lead variants exhibited strong pairwise LD (r2>0.8, 1000G phase 3 
Europeans). To compare the direction of effect for colocalized caQTL and eQTL, we compared the sign of the 
caQTL effect size (RASQUAL pi statistic - 0.5) and the eQTL effect size (meta T statistic).  
Colocalization of caQTL and GWAS signals 
We downloaded the NHGRI-EBI GWAS catalog58 on October 28, 2019, extracted only single variant 
associations, and converted variant genomic coordinates from GRCh3817 to GRCh37 (hg19) using liftOver59. We 
extracted variants associated with 19 trait groups (p<5x10-8) relevant to liver function and cardiometabolic diseases: 
liver enzymes, high-density lipoprotein cholesterol (HDL), low-density lipoprotein cholesterol (LDL), total 
cholesterol (TC), triglycerides (TG), cardiovascular disease (CVD), hypertension/blood pressure (HTBP), type 2 
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diabetes (T2D), insulin, glucose, glycated albumin, serum albumin, glycated hemoglobin (HbA1c), C-reactive 
protein (CRP), bilirubin, body mass index (BMI), waist-hip ratio adjusted for BMI (WHRadjBMI), liver injury, and 
non-alcoholic fatty liver disease (NAFLD). We extracted alleles for each variant from the dbSNP60 build 151 
common variant set (see web resources), restricting to biallelic variants. To select one variant per association signal, 
we performed LD clumping separately for each trait using swiss (see web resources); variants in strong LD (r2>0.8, 
1000G phase 3 Europeans) and within 1 Mb of a variant with a more significant p-value were removed. We 
calculated LD between lead caQTL and GWAS variants using PLINK20 v1.9 and classified signals in high LD 
(r2>0.8) as colocalized.  
Transcriptional activity reporter assays 
HepG2 hepatocyte cells were cultured in MEM-alpha supplemented with 10% FBS and 1 mM sodium 
pyruvate, THP-1 monocyte cells were cultured in RPMI-1640 supplemented with 10% FBS, and both cell types 
were maintained at 37oC with 5% CO2. To test haplotypic differences in transcriptional activity, we designed PCR 
primers (5’-TATGTTGCACAGGCTGGTCT and 5’- GGCAATAACGCCCACCTC) to amplify a 666-bp DNA 
element (chr16:11,644,551 – 11,645,216) spanning the ATAC-seq peak and containing variants rs3784924, 
rs11644920, and rs57792815, and we generated PCR products using DNA from individuals homozygous for both 
haplotypes. We cloned the derived PCR products into luciferase reporter vector pGL4.23 (Promega) as described 
previously61. The day before transfection, we plated 120,000 HepG2 cells, and on the day of transfection, we plated 
300,000 THP-1 cells. We co-transfected four to five sequence-verified constructs with phRL-TK Renilla reporter 
vector using lipofectamine 3000 (Life Technologies) following the manufacturer’s protocol. To induce 
differentiation into macrophages, we added 100 nM 1α,25-Dihydroxyvitamin D3 (Sigma) to the THP-1 cells at the 
time of transfection. To obtain activated macrophages, we added 100 ng/ml lipopolysaccharides (Sigma) to vitamin 
D3-treated cells 24 hours after transfection and incubated cells for an additional 24 hours. Firefly luciferase activity 
was measured 48 hours post-transfection and normalized to Renilla activity to adjust for differences in transfection 
efficiency. Fold-changes in luciferase activity were calculated relative to an empty pGL4.23 vector, and statistical 
differences in activity were determined using two-tailed Student’s t-tests. 
Electrophoretic mobility shift assays (EMSA) 
We designed and annealed 3 biotin-labeled and unlabeled 17-bp complementary oligonucleotide probes 
centered on each of variants rs3784924, rs11644920, and rs57792815. We conducted EMSAs using the LightShift 
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Chemiluminescent EMSA kit (Thermo Scientific) following the manufacturer’s protocol. The binding reactions 
consisted of 6 μg HepG2 nuclear extract (NE-PER Kit, Thermo Fisher Scientific), 1 μg poly(dI-dC), 1x binding 
buffer, and 400 fmol biotinylated oligonucleotide as described previously61. To test the specificity of the protein 
complexes to each allele, we added 25-fold excess unlabeled probes, and for supershift assays, we added 6 ug of 
antibody to the binding reactions. We tested antibodies for ATF2, IRF1, IRF2, IRF3, IRF7, FOXA2, P300, SPI1, 
STAT4. Protein-DNA complexes were resolved by gel electrophoresis and transferred and detected by 
chemiluminescence as described previously61. 
Results 
Joint profiling of gene expression and chromatin accessibility in human liver tissue 
We obtained liver tissue from 20 deceased donors from the St. Jude liver bank and profiled gene expression 
using RNA-seq and chromatin accessibility using ATAC-seq32 (Figure 3.1A). We identified 13,782 expressed 
genes. By generating triplicate ATAC-seq libraries, we obtained an average of 204 million high-quality autosomal 
ATAC-seq alignments (HQAA) per sample and used these reads to identify 223,265 consensus accessible chromatin 
regions (peaks) with median peak width of 617 base pairs (Figure 3.1B).  
To predict the regulatory function of ATAC-seq peaks, we assigned peaks to liver tissue chromatin states 
from the Roadmap Epigenomics Project3 and tested for enrichment of transcription factor (TF) binding sites and 
motifs in peaks. Among all 223,265 peaks, 34% were located in enhancers and 10% in promoters, and among the 
50,000 most accessible peaks, 54% were located in enhancers and 38% in promoters (Figure 3.1C). We found 90 
TF motifs enriched in peaks (E-value<1x10-100), including motifs for HNF4G, FOXA family members (HNF3), 
CEBPB62, the multifaceted protein CTCF63, and KLF family members, which regulate numerous processes in 
liver64. Of 17 TFs with ChIP-seq data in liver tissue45, binding sites for all TFs were significantly enriched 
(permutation p<1x10-3) in ATAC peaks, and 11 TFs had over 90% of their binding sites within ATAC peaks, similar 
to previous findings15. Taken together, ATAC peaks marked previously annotated transcriptional regulatory 
elements and TF binding sites in liver tissue. 
We next determined if genes with ATAC peaks at their transcription start site (TSS) were more likely to be 
expressed compared to genes without TSS peaks. A larger proportion of expressed genes had an ATAC peak 
directly overlapping the TSS (74%) compared to non-expressed genes (24%). Similarly, genes with a peak at the 
TSS tended to have higher expression than genes without a peak at the TSS (Figure 3.1D; Kolmogorov-Smirnov 
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test, p<2.2x10-16). Together, the data provide high-quality gene expression and chromatin accessibility profiles in 
human liver tissue. 
Identification of genetic variants associated with liver chromatin accessibility 
We identified chromatin accessibility quantitative trait loci (caQTL) using RASQUAL5 and two distance 
thresholds: variants within 100 kilobases (kb) and within 1 kb of peak centers (Figure 3.2A). Testing variants within 
100 kb of peak centers, we identified a significant caQTL for 1,770 peaks (caPeaks), corresponding to 1,740 unique 
lead caQTL variants (Figure 3.2A). For a substantial portion of caPeaks, the lead caQTL variant was either within 
the caPeak (n=654, 37%) or was within 1 kb of the caPeak center (n=692, 39%). Testing variants within 1 kb of 
peak centers, we identified a significant caQTL for 3,123 peaks (Figure 3.2A). We used this set of 3,123 caQTL for 
all subsequent analyses unless noted otherwise. 
We compared caQTL results from RASQUAL to simple allelic imbalance (AI). 1,912 (81%) caQTL 
exhibited nominal (beta-binomial p<0.05) and 1,112 (47%) exhibited genome-wide AI (FDR<5%), all with the same 
direction of effect as the caQTL. Lead caQTL variants and representative AI variants exhibiting nominal AI showed 
strongly correlated effect sizes (Pearson’s R=0.75, Figure 3.2B). AI effect sizes tended to be larger than caQTL 
effect sizes (Figure 3.2B), possibly because AI was calculated using individual variants whereas caQTL were 
identified using entire peaks.  
To determine the extent of shared genetic effects across different markers of transcriptional regulatory 
elements, we compared the 3,123 caQTL to 921 H3K27ac QTL from a recent report12. Of the 921 H3K27ac QTL 
peaks, 85 (9%) are within 1 kb of a caPeak and have a lead variant in strong LD (r2>0.8) with the caQTL lead. The 
largely distinct results may be due to the small sample sizes, analysis differences, and different genetic effects on the 
two epigenetic marks. 
To predict the regulatory function of caPeaks, we compared caPeaks to liver tissue chromatin states from 
the Roadmap Epigenomics Consortium3. Relative to non-caPeaks (eigenMT-adjusted p>0.5), caPeaks were more 
frequently located in enhancers (48.6% vs. 33.0%) and promoters (11.7% vs. 9.3%) (Figure 3.2C). caQTL variants 
were significantly enriched in enhancers (OR=2.9), promoters (OR=2.0), and transcribed regions (OR=1.8) and 
depleted in polycomb (OR=0.5) and heterochromatin (OR=0.6) states, which are associated with gene repression 
and presumably inaccessible chromatin (Figure 3.2D). Taken together, caQTL showed strong overlap with active 
transcriptional regulatory elements, with particularly strong enrichment in enhancers. 
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Disruption of transcription factor binding motifs by caQTL 
One way genetic variants may alter chromatin accessibility is by disrupting TF binding sites5,6,8. Among 
4,585 variants within a caPeak and in strong LD with the caQTL lead, 3,132 (68%) variants altered the binding 
affinity of a TF motif (Figure 3.3A). Of the 2,793 variant-containing caPeaks, 2,249 (81%) contained at least one 
variant predicted to disrupt a motif, and 602 of these contained 2 or more predicted motif-disrupting variants. Motifs 
for many TFs were disrupted by multiple caQTL variants, and 109 TF motifs were disrupted by 20 or more variants. 
Disruption of motifs for 29 of these 109 TFs was significantly associated with caQTL status (log OR>0, p<4.6x10-4) 
(Figure 3.3B), including TFs from the HNF, FOXA, and CEBP families62, CTCF, and ATF2. FOXA and CEBP 
factors can act as pioneer factors by binding to inaccessible chromatin and initiating the establishment of accessible 
chromatin65 and ATF2 can alter chromatin structure to activate or repress transcription66, suggesting that this 
approach identifies TFs that may influence chromatin accessibility. 
To investigate how often TFs bind the more accessible allele, we compared alleles associated with higher 
chromatin accessibility to the motifs. Among 7,629 motifs for all TFs, the more accessible allele matched the motif 
better for 4,770 motifs (63%, binomial p<4.1x10-107). Similarly, among 3,132 motifs corresponding to the highest 
expressed TF among motifs at each variant, the more accessible allele matched the motif better for 1,953 motifs 
(62%, binomial p<8.0x10-44). When restricting analysis to 993 observations of the 29 TFs for which motif disruption 
is associated with caQTL status, the more accessible allele matched the motif better for 834 motifs (84%, binomial 
p<5.1x10-111). TFs exhibited variation in the percent of motifs that matched better to the more accessible allele 
(Figure 3.3C). For 11 TFs, including HNF4A, ATF4, ERF, and FOXA2, over 90% of stronger motif matches 
corresponded to the more accessible allele, while for SPI1 only 56% of stronger motif matches corresponded to the 
more accessible allele. These results suggest that TFs typically, but not always, bind to the more accessible allele. 
Identifying putative target genes for caPeaks 
Connecting caPeaks to their target genes is challenging, particularly when the caPeaks are distal to 
transcription start sites (TSS’s). Individual approaches for identifying target genes have limitations and may not 
always show a direct regulatory relationship between a caPeak and gene. To address these challenges, we used four 
approaches to connect caPeaks to genes (Figure 3.4A).  
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First, we identified caPeaks proximal (-2 kb/+1 kb) to TSSs of genes expressed in liver. Of 3,123 total 
caPeaks, 114 (4%) were proximal to the TSS of at least 1 gene. Among these 114 caPeaks, 15 were proximal to the 
TSS of two or three genes (Figure 3.4A). This approach identified 131 unique caPeak-gene connections. 
Second, we used liver tissue promoter capture Hi-C2 to identify caPeaks that physically interact with gene 
promoters. We identified 329 distal caPeaks (>15 kb from any promoter as defined in the Hi-C analysis) that interact 
with promoters for 451 genes, including a caPeak that interacts with the promoter of SNX10 (Figure 3.4B). Among 
caPeaks that overlapped the promoter of one gene and interact with the promoter of another gene, we identified an 
additional 104 caPeaks that interact with promoters of 190 genes. Combining promoter-distal and promoter-
promoter interactions, we identified 697 caPeak-gene connections (Figure 3.4A).  
Third, we identified caPeak sizes that either correlated with expression level of nearby genes or with the 
size of ATAC peaks at promoters. More caPeaks were correlated with promoter ATAC peaks than with gene 
expression level; 120 caPeaks were significantly correlated (FDR<5%) with promoter ATAC peaks while only 2 
caPeaks were correlated with gene expression (FDR<5%), resulting in 121 unique caPeaks because gene RP11-
101E14.2 had both types of correlations (Figure 3.4A). When using the same p-value threshold for both analyses 
(p<2.9x10-4), 5 additional caPeaks were correlated with gene expression. As an example at a regulatory element 
previously shown to regulate SORT167, caPeak9372 is positively correlated with a peak proximal to a SORT1 TSS 
(peak9400, Spearman rho=0.76, p<1.6x10-4; Figures 3.4C-4D) and nominally correlated with SORT1 expression 
(Spearman rho=0.69, p<1.2x10-3). The vast majority of peak-peak correlations (167 of 173, 97%) are positive, 
suggesting that higher caPeak accessibility is usually associated with higher accessibility of connected promoter 
peaks. Using either caPeak-promoter peak or caPeak-gene correlations, we identified 196 caPeak-gene connections 
(Figure 3.4A). 
Finally, we identified caQTL for which the lead variant exhibited high LD (r2>0.8) with an eQTL lead 
variant for 15,418 autosomal genes from a liver tissue eQTL meta-analysis of 1,183 individuals11. Of 3,119 unique 
caQTL lead variants, 414 (13%) were in strong LD with at least 1 eQTL lead variant, which is similar to the 
percentage reported in a previous caQTL study6. Among caQTL lead variants, 71 were in strong LD with more than 
one eQTL lead variant, suggesting some caPeaks may affect expression of multiple genes. In total, we identified 463 
target genes for 415 caPeaks, representing 506 unique caPeak-gene connections (Figure 3.4A). For example, we 
identified a caQTL signal with the same variants as an eQTL signal for SORT1 (Figures 3.4E-4F). At connected 
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loci, the allele associated with higher chromatin accessibility was usually associated with higher gene expression 
(390 of 506 loci, 77%; Figure 3.4G), suggesting caPeaks frequently act as promoters or enhancers to gene 
expression. We obtained a similar result when restricting to caQTL variants associated with only one peak and 
colocalized with eQTL variants associated with only one gene (273 of 337 loci, 81%). 
Together the four methods identified a total of 1,461 caPeak-gene connections, although the approaches 
showed low overlap.  Only 69 caPeak-gene connections were predicted by two methods, and no connections by 
three methods, likely due to the low power of many of the approaches (Figure 3.4H). These 69 caPeak-gene 
associations consist of 67 unique caPeaks and 67 unique genes; two caPeaks had two target genes. The methods that 
showed the most overlap were eQTL and TSS proximity (32 connections) and eQTL and HiC chromatin contacts 
(22 connections) (Figure 3.4H). This integrated approach predicted a target gene for 861 of 3,123 caPeaks (28%), 
suggesting caPeaks frequently interact with genes. 
Prediction of regulatory mechanisms at GWAS loci 
To identify genetic variants that may influence disease by altering chromatin accessibility, we identified 
caQTL and GWAS signals that may be shared, based on strong LD (r2>0.8) between lead caQTL and lead GWAS 
variants. Using GWAS variants for 19 traits relevant to liver function and cardiometabolic traits from the NHGRI-
EBI GWAS catalog58, we identified 110 potentially shared caQTL and GWAS signals, corresponding to 111 
caPeaks, because one caQTL signal was associated with two caPeaks. We identified at least one colocalized caQTL 
for 15 of the 19 traits, and liver enzymes showed the highest percentage of potentially shared caQTL and GWAS 
signals (15 signals, 19%) (Table 3.1). For traits with at least 5 GWAS-caQTL shared signals, we identified a high 
percentage of shared signals (>5%) for C-reactive protein, total cholesterol, and LDL cholesterol, consistent with the 
involvement of liver in inflammation and lipid metabolism10. 
To identify plausible regulatory mechanisms at GWAS loci, we integrated our GWAS-colocalized caQTL 
with TF motif-disrupting variants and predicted caPeak target genes. Of the 111 caPeaks at potentially shared 
caQTL-GWAS signals, 85 harbored a TF motif-disrupting variant, 56 had a predicted target gene, and 45 had both 
types of data. The gene with a TSS closest to the GWAS lead variant was predicted to be a target gene for 25 of 56 
caPeaks (45%).  
We identified seven GWAS-caQTL shared signals with strong evidence of regulatory mechanisms. At 
these GWAS loci, the caPeak had a target gene identified by two approaches and harbored TF motif-disrupting 
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variants (Table 3.2). We identified shared caQTL, eQTL, and GWAS signals and a correlated caPeak-promoter 
peak pair (Table 2; Figures 3.4C-4F) at the SORT1 locus associated with LDL cholesterol for which the alternate 
allele (rs12740374-T) has been shown to create a CEBP binding site and increase hepatic SORT1 expression67. At a 
less well characterized locus, the caQTL signal with lead variant rs13395911 associated with caPeak119621 is 
colocalized with GWAS signals for plasma liver enzyme levels in European68 and Asian69 individuals and an eQTL 
for EFHD111 (Figures 3.5A-5C). Increased accessibility corresponds to higher EFHD1 expression level and higher 
liver enzyme levels. caPeak119621 physically interacts with the promoter of EFHD1 in liver tissue promoter capture 
Hi-C data2 (Figure 3.5D), further suggesting that caPeak119621 may affect EFHD1 expression. The peak overlaps 
ChIP-seq peaks for 12 TFs in liver (Figure 3.5E), and rs13395911 disrupts motifs for eight TFs expressed in liver. 
The motif with the largest difference between rs13395911 alleles is for FOXA2, and the allele with higher chromatin 
accessibility matches the motif better (Figure 3.5F). These and other connections provide potential regulatory 
mechanisms linking variants to regulatory element, transcription factors and genes that may influence the GWAS 
traits.   
Identification of a putative functional variant at the LITAF locus 
Near the LITAF gene, which encodes lipopolysaccharide (LPS) induced TNF factor, we identified a caQTL 
signal for caPeak75869 and tested variants for allelic differences in transcriptional activity and protein binding. This 
caQTL signal is potentially shared with a GWAS signal for LDL cholesterol70 and an eQTL signal for LITAF11 
(Figures 3.6A-6B). caPeak75869 loops to the promoter of LITAF in liver tissue promoter capture Hi-C2 (Figure 
3.6C). caPeak75869 contains the lead caQTL variant rs57792815 (caQTL p<5.0x10-17) and two additional variants 
in strong LD with the caQTL lead, rs3784924 (r2=0.95) and rs11644920 (r2=0.98). The haplotype associated with 
higher accessibility consists of the rs57792815-T, rs3784924-A, and rs11644920-A alleles. We tested a 666-bp 
DNA construct spanning the three variants for haplotype differences in transcriptional activity using luciferase 
reporter assays, testing the construct in two orientations relative to a minimal promoter. Given that LITAF is 
involved in lipopolysaccharide (LPS)-stimulated immune response71, we tested transcriptional activity in four cell 
types: HepG2 hepatocytes, THP-1 monocytes, THP-1 differentiated macrophages, and LPS-stimulated THP-1 
macrophages. In all four cell types, the forward orientation construct containing the alleles associated with higher 
accessibility showed significantly higher transcriptional activity than the construct containing the other alleles, with 
the strongest differences observed in hepatocytes (fold change=2.49, p=2x10-4) and LPS-stimulated macrophages 
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(fold change=1.39, p=7x10-4; Figure 3.6D). The same haplotype showed significantly higher transcriptional activity 
in the reverse orientation for hepatocytes (p=1x10-4) and unstimulated macrophages (p=0.02) and a trend toward 
higher transcriptional activity in the other cell types. We next tested each of the three haplotype variants for allelic 
differences in protein binding using nuclear extract from HepG2 cells. Only rs11644920 showed allele-specific 
binding, with the T allele showing increased binding (Figure 3.6E). Although caPeak75869 contained motifs and 
liver ChIP-seq binding sites for numerous TFs (Figure 3.6F), we were unable to identify the protein that showed 
allelic differences in binding to rs11644920 through supershift assays. Together, these results suggest that altered 
transcription factor binding at rs11644920 and increased chromatin accessibility of the regulatory element marked 
by caPeak75869 may lead to increased transcriptional activity and higher LITAF expression. 
Discussion 
We profiled chromatin accessibility in 20 individuals and identified caQTL in human liver tissue. caQTL 
variants frequently disrupt TF binding motifs, and alleles that better match a motif more often have higher chromatin 
accessibility, consistent with TFs stabilizing chromatin in an accessible state. We identified 1,461 putative caPeak-
gene links using four approaches, suggesting that caPeaks frequently regulate gene expression. We identified 110 
caQTL at GWAS signals, including 56 with a predicted caPeak target gene, identifying regulatory mechanisms that 
may be responsible for trait variation. Among variants at a caQTL, eQTL, and LDL cholesterol GWAS signal near 
the LITAF gene, one variant showed allelic differences in transcriptional activity and in vitro TF binding. This study 
contributes to the epigenomic characterization of human liver tissue and will aid in functional characterization of 
GWAS loci that act in liver. 
Combining caQTL, caPeak-gene links, and disrupted TF motifs helps identify mechanisms at GWAS loci. 
At the well-characterized SORT1 GWAS locus for lipid and cardiovascular traits67, we showed that the previously 
described functional variant rs12740374 is associated with chromatin accessibility and that the caPeak containing 
this variant is correlated with a peak at the SORT1 promoter. We also identified plausible regulatory mechanisms at 
less well-characterized loci. At a GWAS signal for BMI72 and LDL cholesterol70, we identified a caQTL potentially 
shared with a PRMT6 eQTL signal and observed that the caPeak overlapped the PRMT6 TSS. PRMT6 has been 
shown to regulate hepatic glucose metabolism in mice73. Our data suggest that a variant at this locus may increase 
chromatin accessibility and alter TF binding at the PRMT6 TSS, leading to higher PRMT6 expression and decreased 
LDL cholesterol. At a GWAS locus for plasma liver enzyme levels6869, we predicted EFHD1 as a target gene based 
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on both caQTL-eQTL colocalization and a promoter capture Hi-C link. While EFHD1 is expressed in liver tissue, 
the GTEx portal shows that expression is much higher in other tissues1, and the gene’s roles in liver have not been 
characterized74. Our data suggest that EFHD1 may be a target gene at this locus and act through one of the many cell 
types in liver tissue. These and other results highlight the utility of caQTL to identify mechanisms at GWAS loci. 
At the LITAF locus, we provided direct evidence that variant rs11644920 can alter transcriptional 
regulation. Here, the caQTL, liver eQTL, and LDL cholesterol GWAS signals are shared, and the variant, 
mechanism and cell type responsible for these associations were unknown. LITAF encodes a transcription factor that 
can mediate effects on inflammation71, suggesting a potential role in hepatocytes and/or macrophages in an 
inflammatory environment. We showed that variants in the caPeak alter transcriptional reporter activity in 
hepatocytes, monocytes, macrophages and lipopolysaccharide-stimulated macrophages. In all cell types, the caPeak 
showed a similar magnitude of enhancer activity and alleles showed differences in transcriptional activity, 
suggesting that the variant may act in any or all of these cell types. We further provided evidence that rs11644920 
alters protein binding, at least in vitro, although we failed to experimentally validate the specific TFs that 
discriminate between alleles. Further study is needed to provide direct evidence that these variants alter transcription 
of the LITAF gene and how altered levels of LITAF may affect cholesterol levels. 
The maximum distance threshold between peaks and tested variants had a substantial impact on caQTL 
detection. Analyzing variants within a narrow region around a peak reduced the multiple testing burden for nearby 
variants, whereas testing variants in a broader region allowed identification of variants within one peak that may 
also influence another peak. A wide range of distance thresholds have been applied to caQTL discovery, including 
variants within 1 kb and 20 kb of peak centers6, 50 kb from peak ends4, and 1 Mb from peak ends8. We found many 
more significant results when using variants within 1 kb of peak centers compared to variants within 100 kb of peak 
centers, potentially due to reduced multiple testing burden and low power to detect long-range caQTL effects due to 
small sample size. 
We used four approaches to provide suggestive evidence that a caPeak may regulate a specific gene. TSS 
proximity is useful to detect variation in promoter accessibility, although our results showed only 4% of caPeaks are 
TSS-proximal. Promoter capture Hi-C data2 identifies distal regions that physically interact with promoters, 
indicating potential regulatory relationships. However, Hi-C data mapped in only one sample may miss chromatin 
contacts that differ by genotype or environmental exposure. The identification of caPeaks correlated with promoter 
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peaks is based on the concept that co-regulated regions should show similar chromatin accessibility patterns. The 
same concept motivates correlating caPeak accessibility with gene expression, although gene expression is affected 
by many other factors, which may be why we identified more correlated caPeak-promoter peak pairs than caPeak-
gene pairs, and both correlation approaches are limited by sample size. The LD-based method we used to predict 
shared caQTL and eQTL signals helps identify peaks and genes with a shared genetic basis, although this method is 
influenced by limited fine-mapping of the lead caQTL variant, use of an LD threshold, and choice of LD reference 
panel, and would be more comprehensive if we could analyze conditionally distinct eQTL signals1. While each of 
these approaches was useful to predict links between caPeaks and genes, additional experiments are needed to 
identify causal relationships. 
The caQTL presented here are a resource for studying liver regulatory elements and will help identify 
mechanisms at GWAS loci for multiple traits that act through liver. The 56 caQTL at GWAS loci with predicted 
target genes are strong candidates for future functional studies. While caQTL can pinpoint functional regulatory 
variants, the modest sample size and analyses restricted to common variants limit fine-mapping potential and 
highlight the importance of considering LD proxies. The promising regulatory mechanisms identified here motivate 
identification of liver caQTL in larger sample sizes.  
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Figure 3.1. Joint profiling of gene expression and chromatin accessibility in human liver tissue. (A) RNA-seq 
and ATAC-seq was performed in liver samples from 20 donors. (B) Distribution of consensus ATAC peak widths in 
base pairs. (C) Percent of consensus ATAC peaks by chromatin state in liver tissue from the Roadmap Epigenomics 
Project. All peaks, gray; 50,000 most accessible consensus peaks, black; quiescent represents unannotated regions. 
(D) Comparison of the distribution of expression between genes with and without an ATAC peak overlapping the 





Figure 3.2. Identification and characterization of caQTL. (A) caQTL identified using variants within 100 kb or 1 
kb of peak centers. (B) Comparison of effect sizes between caQTL and simple allelic imbalance (Pearson’s R=0.75). 
(C) Comparison of the number of caPeaks and non-caPeaks assigned to each chromatin state in liver tissue from the 
Roadmap Epigenomics Project. caPeaks, purple; non-caPeaks, gray; quiescent represents unannotated regions. (D) 
Enrichment of caQTL variants in liver chromatin states. Error bars represent 95% confidence intervals. * indicates 





Figure 3.3. Disruption of TF binding motifs by caQTL variants. (A) Allele affinities for TF binding and 
chromatin accessibility for variants within caPeaks and in strong LD with the caQTL lead variant (r2>0.8). (B) 
Association of caQTL status with motif disruption status. Only TFs with at least 20 motifs disrupted by caQTL 
variants were included, and only significant associations (p<4.6x10-4) are shown. (C) Percent of disrupted motifs for 
which the allele with higher chromatin accessibility matched the motif better. Percents are shown for the 29 TFs that 
had at least 20 motifs disrupted by caQTL variants. Black line, percent for all disrupted motifs across all tested TFs; 






Figure 3.4. Prediction of target genes for caPeaks using four approaches. (A) Illustrations of four approaches to 
predict caPeak target genes. (B) Hi-C chromatin contact shown as an arc between caPeak191932 and the SNX10 
promoter. Selected ATAC-seq signal tracks are shown for each caQTL genotype of rs12534816. More accessible 
homozygotes, purple; heterozygotes, black. (C) Genome browser image showing the correlation across rs12740374 
genotypes of caPeak9372 and a peak at a SORT1 promoter. (D) The same peak correlation with points representing 
normalized peak counts of individual samples colored by rs12740374 genotype. (E) SORT1 eQTL associations at 
the signal shared with the caQTL for caPeak9372 and (F) caQTL associations with caPeak9372. In both plots, the 
caQTL lead variant within 1 kb of the peak center is indicated by a purple diamond and LD is based on 1000G phase 
3 Europeans. (G) Comparison of directions of effect among all shared caQTL and eQTL signals. The A allele 
represents the more accessible allele than C, and more red marks indicate higher gene expression. (H) UpSet plot 







Figure 3.5. A plausible regulatory mechanism at the EFHD1 locus for plasma liver enzyme levels. (A) Variant 
association with plasma levels of the liver enzyme alanine transaminase in Japanese individuals, (B) eQTL 
association for EFHD1, and (C) caQTL associations for caPeak119621. For all three plots, the caQTL lead variant 
within 1 kb of the peak center is indicated by a purple diamond and LD is based on 1000G phase 3 East Asians (A) 
or Europeans (B and C). (D) Hi-C chromatin contact shown as an arc between caPeak119621 and the EFHD1 
promoter. Selected ATAC-seq signal tracks are shown for each rs13395911 genotype. More accessible 
homozygotes, purple; heterozygotes, black; less accessible homozygote, gray. (E) Transcription factor ChIP-seq 
peaks in liver tissue from ENCODE that overlap caPeak119621. (F) Sequence logo plot for the FOXA2 motif s 
disrupted by caQTL variant rs13395911 (arrow). The motif match is shown on the negative strand, and variant 







Figure 3.6. Identification of a putative functional variant at the LITAF locus for LDL cholesterol. (A) eQTL 
association for LITAF and (B) caQTL associations for caPeak75869 at an LDL cholesterol GWAS signal. In both 
plots, the caQTL lead variant within 1 kb of the peak center is indicated by a purple diamond, and LD is based on 
1000G phase 3 Europeans. (C) Hi-C chromatin contact between caPeak75869 and the LITAF promoter. Selected 
ATAC signal tracks are shown for each rs57792815 genotype. More accessible homozygotes, purple; heterozygotes, 
black; less accessible homozygotes, gray. (D) Transcriptional activity of a 666-bp DNA element spanning 
caPeak75869 and containing rs3784924, rs11644920, and rs57792815 in HepG2 hepatocytes, THP-1 monocytes, 
THP-1 differentiated macrophages, and LPS-stimulated THP-1 macrophages. The DNA element was tested in the 
forward orientation relative to the genome. V, empty vector; H1, haplotype 1 of more accessible alleles; H2, 
haplotype 2 of less accessible alleles. (E) EMSA using HepG2 nuclear extract shows allelic differences in protein 
binding for rs11644920. Green arrow, band represents T-allele-specific binding; black arrows, T-allele-preferential 
binding; white arrow, non-specific binding. Competition probes were unlabeled and in 25-fold excess.  (F) TF ChIP-




Trait Number of GWAS 
signals a 
Number of shared caQTL-
GWAS signals b 
Percent of shared 
caQTL-GWAS signals c 
Liver enzymes 77 15 19.5 
C-reactive protein 81 5 6.2 
Total cholesterol 292 18 6.2 
LDL cholesterol 240 14 5.8 
Glucose 54 3 5.6 
Insulin 18 1 5.6 
Bilirubin 20 1 5.0 
HDL cholesterol 314 14 4.5 
Triglycerides 279 11 3.9 
Cardiovascular disease 454 13 2.9 
Body mass index 986 24 2.4 
Blood pressure 1,540 37 2.4 
WHRadjBMI 209 4 1.9 
Type 2 diabetes 268 5 1.9 
HbA1c 66 1 1.5 
Glycated albumin 2 0 0.0 
Liver injury 17 0 0.0 
NAFLD 9 0 0.0 
Serum albumin 15 0 0.0 
Table 3.1. Shared GWAS-caQTL signals by trait. aCounted as lead GWAS variants not in high LD (r2<0.8) with 
another. bShared if the caQTL lead variant was in strong LD (r2>0.8) with the GWAS lead. cPercent of all GWAS 
signals that are shared with a caQTL. LDL, low-density lipoprotein; HDL, high-density lipoprotein; WHRadjBMI, 


























































Table 3.2. Selected caQTL at GWAS loci. Loci are shown for shared caQTL-GWAS signals if the caPeak was 
linked to a target gene by two methods and if the caPeak harbored motif-disrupting variants. LD r2 between the 
caQTL and GWAS lead variants. b Methods that linked the caPeak to a gene. Corr, correlation between caPeak and 
promoter peak accessibility. c Direction of chromatin accessibility and gene expression relative to the allele 
associated with an increase in the GWAS trait, where “I” indicates increased and “D” indicates decreased 
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CHAPTER 4: CHROMATIN ACCESSIBILITY DIFFERENCES DURING ADIPOGENESIS IDENTIFY 
CONTEXT-DEPENDENT REGULATORY VARIANTS 
 
Introduction 
Identifying functional variants, molecular mechanisms, and relevant tissue/cell types for genome-wide 
association study (GWAS) loci remains challenging, especially at signals without coding variants. Regulatory 
variants and mechanisms have been detected based on variant location in transcriptional regulatory elements of trait-
relevant tissues1–3, including variants located in regulatory elements present only in certain cellular contexts4. 
GWAS loci are colocalized with gene expression quantitative trait loci (eQTL) in trait-relevant tissues5–10. Some 
GWAS loci are colocalized with context-dependent eQTL, such as those in stimulated, but not naïve, immune 
cells11.  Mapping transcriptional regulatory elements and gene expression in additional contexts may help 
characterize molecular mechanisms of additional GWAS loci. 
Adipose tissue influences insulin sensitivity, blood cholesterol levels, inflammation, and related 
cardiometabolic traits through its roles in lipid storage and hormone secretion12,13. Hundreds of GWAS loci for 
cardiometabolic traits are shared, or colocalized, with gene expression quantitative trait loci (eQTL) in adipose 
tissue5–7. At a subset of colocalized GWAS-eQTL signals, statistical analyses suggest that adipose tissue gene 
expression mediates the effect of the genetic variant on the GWAS trait7. Variants at cardiometabolic GWAS loci 
are also overrepresented in transcriptional regulatory elements in adipose tissue1–3. However, adipose tissue contains 
multiple cell types, including adipocytes and their precursors (preadipocytes)14. Mapping genetic effects on gene 
regulation in preadipocytes and adipocytes at various stages of differentiation may uncover additional roles for 
GWAS variants. 
Multiple approaches exist to study gene regulation in specific cell types within adipose tissue. Gene 
expression has been profiled using microarrays in adipocyte, preadipocyte, and immune cells isolated from whole 
adipose tissue using flow cytometry sorting15. Chromatin accessibility differences have been identified between 
primary preadipocytes and in vitro differentiated adipocytes16. The Simpson Golabi-Behmel Syndrome (SGBS) 
human preadipocyte cell strain is a well-characterized adipocyte cell model17 that has been used to study differences 
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in gene expression, chromatin accessibility, histone modifications, and transcription factor (TF) binding during 
adipocyte differentiation and other differences in cell environment18,19.  
In this study, we identified differences in chromatin accessibility and gene expression between adipocyte 
differentiation states in SGBS cells. We identified variants at GWAS loci that resided in regulatory elements more 
accessible in preadipocytes or adipocytes and predicted genes likely regulated by these elements. Finally, we 




SGBS cells20 were generously provided by Dr. Martin Wabitsch (University of Ulm) and cultured as 
previously described21. Briefly, we cultured SGBS preadipocytes in serum-containing medium until confluent, then 
rinsed in phosphate-buffered-saline (PBS) and differentiated for four days in basal medium (DMEM:F12 + 3.3mM 
biotin + 1.7mM panthotenate) supplemented with 0.01 mg/mL transferrin, 20 nM insulin, 200 nM cortisol, 0.4 nM 
triiodothyronine, 50 nM dexamethasone, 500 uM IBMX, and 2 uM rosiglitazone. After four days, we maintained 
differentiated SGBS cells in basal medium supplemented with 0.01 mg/mL transferrin, 20 nM insulin, 200 nM 
cortisol, 0.4 nM triiodothyronine.  
ATAC-seq library preparation 
We profiled chromatin accessibility in SGBS cells at days 0, 2, 4, and 14 of adipocyte differentiation 
following the Omni-ATAC protocol22,23 using unique, dual-barcoded indices. We isolated nuclei and used a cell 
countess to aliquot 50,000 nuclei per library. After initial optimization of Tn5:nuclei ratios, we proceeded with 5uL 
of Tn5 per library, although some early libraries were prepared with 2.5uL of Tn5 (Table 4.2). We cleaned the 
transposase reaction and final library with Zymo DNA Clean and Concentrator. We visualized and quantified 
libraries using a TapeStation. Paired-end sequencing was performed using 150-bp reads on an Illumina Novaseq at 
Novogene (Beijing, China) or with 50-bp reads on an Illumina HiSeq 4000 at the University of North Carolina 
sequencing core (Chapel Hill, North Carolina; Table 4.2). 
ATAC-seq read alignment and peak calling 
We trimmed sequencing adapters and low quality base calls from the 3’ ends of reads using cutadapt24 with 
parameters -q 20 –minimum-length 36. We aligned trimmed reads to the hg19 human genome25 using bowtie226 
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with parameters –minins 36 –maxins 1000 –no-mixed –no-discordant –no-unal and selected nuclear chromosomal 
alignments with mapq>20 using samtools27. We removed alignments overlapping blacklisted regions28 using 
BEDTools pairToBed29 with the parameter -type notospan. We removed duplicate alignments using Picard 
MarkDuplicates (https://github.com/broadinstitute/picard) and generated ATAC-seq quality metrics using ataqv30. 
Prior to peak calling, we trimmed alignments so their 5’ ends corresponded to the Tn5 binding site (+4 for + strand 
alignments and -5 for – strand alignments)22 and smoothed signal by extending alignments 100 bp on either side of 
the Tn5 binding sites using BEDTools slop29. We called peaks (FDR<5%) with MACS231 with parameters -q 0.05 –
nomodel –bdg and generated ATAC signal bigwig files from MACS2 bedGraph files using the bedGraphToBigWig 
tool from ucsctools32.  
For each analyzed day of SGBS differentiation, we generated a set of representative ATAC peaks using the 
following method. First, we merged peak genomic coordinates across replicates for a given day using BEDTools 
merge29. Second, we defined representative peaks as merged peaks that overlapped individual replicate peaks in 
greater than 50% of replicates (at least 3 out of 5 replicates for day 14 and 6 out of 10 replicates for days 0 and 4).  
Identification of differentially accessible peaks  
We generated a set of consensus peaks to test for differential chromatin accessibility by merging the top 
100,000 representative peaks in each day (ranked by median MACS2 p-value across replicates). We quantified the 
accessibility of these consensus peaks in each library using featureCounts33. We computed the GC percent of each 
peak using BEDTools nuc29 and generated within-library GC bias normalization factors using full quantile 
normalization with EDASeq34 and used DESeq235 size factors to control for differences in sequencing depth 
between libraries. Adjusting peak counts for batch effects (defined as library preparation date) did not improve 
clustering of replicates within each differentiation day, so we did not adjust for batch in the differential chromatin 
accessibility analysis. We tested for differential chromatin accessibility using DESeq235 and classified peaks with 
FDR<5% and log fold change (LFC)>1 as significantly differential.  
Enrichment of transcription factor motifs in differential peaks 
We tested for enrichment of 319 transcription factor (TF) motifs in adipocyte or preadipocyte-dependent 
peaks using the findMotifsGenome tool from HOMER36 with the -size 200 option. We used peaks that were not 
differential in any pairwise day comparison (FDR>50%, absolute value of log2 fold change < 1) as background in 
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the enrichment analyses. We classified motifs with a p-value less than the Bonferroni-corrected threshold of 1.6x10-4 
(0.05 / 319 motifs) as significant. 
Gene ontology enrichment of genes near differential peaks 
We tested if genes near adipocyte and preadipocyte-dependent peaks were enriched for specific biological 
processes using the Genomic Regions Enrichment of Annotations Tool (GREAT) web tool 
(http://great.stanford.edu/public/html/)37 with the GO Biological Process ontology38,39. We ran GREAT with the 
default parameters of basal plus extension, proximal 5 kb upstream to 1 kb downstream, distal 1000 kb (1 Mb), and 
a whole genome background. We classified ontology terms with Minimum Region-based Fold Enrichment>=2 and 
FDR<5% as significantly enriched. 
RNA-seq library preparation, read alignment, and identification of differentially expressed genes 
We isolated total RNA from SGBS cells at days 0, 2, 4, and 14 of differentiation using the Total RNA 
Purification Kit (product #17200) from Norgen Biotek (Ontario, Canada). Novogene (Beijing, China) generated 
poly-A RNA libraries and performed paired-end RNA sequencing (RNA-seq, read length = 150 base pairs (bp)) 
using a NovaSeq 6000 (Illumina, California, USA). We trimmed sequencing adapters and low quality base calls 
from the 3’ ends of RNA-seq reads using cutadapt24 with parameters -q 20 –minimum-length 36. We aligned reads 
to the hg19 human genome25 using STAR40 with parameters --sjdbOverhang 149 --twopassMode Basic --quantMode 
TranscriptomeSAM --outFilterMultimapNmax 20 --alignSJoverhangMin  8 --alignSJDBoverhangMin 1 --
outFilterMismatchNmax 999 --outFilterMismatchNoverReadLmax 0.04 --alignIntronMin  20 --alignIntronMax 
1000000 --alignMatesGapMax 1000000. We quantified expression of genes from GENCODE v29 lift3741 and 
corrected for GC bias using salmon42 with parameters –seqBias –gcBias –gencode. We generated RNA-seq quality 
metrics using the CollectRnaSeqMetrics tool from Picard (https://github.com/broadinstitute/picard). 
To identify differentially expressed genes, we imported salmon transcript quantifications and collapsed to 
the gene level using tximport (https://github.com/mikelove/tximport). We retained 18,299 genes with median 
DESeq2-normalized count >= 1 across all libraries. Adjusting gene counts for batch effects (defined as RNA 
extraction date) improved the clustering of samples by differentiation day, so we included batch as a covariate in the 
differential gene expression analysis. We tested for differential gene expression using DESeq235 and classified genes 
with FDR<5% and log fold change (LFC)>1 as significantly differential. 
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Gene ontology enrichment of differential genes 
We tested if differentially expressed genes were enriched for specific biological processes using the 
PANTHER statistical overrepresentation test43 with the GO-Slim Biological Process ontology38,39. We ran 
PANTHER using the fisher exact test for calculating enrichment and used all 18,299 genes examined in the 
differential expression analysis as background for the enrichment tests. We classified ontology terms with fold 
enrichment>=2 and FDR<5% as significantly enriched. 
GWAS loci colocalized with adipose tissue eQTL and overlap with differential peaks 
We obtained a published set of 231 cardiometabolic trait GWAS loci colocalized with adipose tissue eQTL 
(eQTL n=434)7. A GWAS locus was considered colocalized with an eQTL if the GWAS and eQTL lead variants 
were in strong LD (r2>=0.8) and if the eQTL lead variant was no longer significantly associated with gene 
expression (p>9.6x10-6) when conditioning on the GWAS lead7. We restricted to 228 loci where the GWAS lead 
variant was biallelic and present in the 1000 Genomes phase 3 reference panel. We identified LD proxies of the 
GWAS lead variants (r2>0.8) using PLINK v1.944 and identified loci that had a proxy variant within a preadipocyte-
dependent or adipocyte-dependent peak using BEDTools intersect29.  
Transcriptional activity reporter assays 
SGBS preadipocytes and adipocytes were maintained and transcriptional reporter luciferase assays were 
performed as previously described3,21. Primers were designed to amplify the entire chromatin accessibility region 
containing variants of interest. Amplified regions containing the reference and alternate allele for variants of interest 
were inserted in pGL4.23 firefly luciferase reporter vectors (Promega) in a ‘forward’ and ‘reverse’ orientation (with 
respect to the genome) upstream of a minimal promoter and luciferase gene. Three to five independent clones were 
cotransfected with Renilla luciferase vector in triplicate using Lipofectamine 3000 (Life Technologies) into SGBS 
cells at differentiation day 0 (preadipocyte) and day 2 (adipocyte). Luciferase activity of experimental clones was 
normalized to Renilla luciferase to control for differences in transfection efficiency. All transcriptional reporter 
assays were repeated on different days. Data are reported as fold change in activity relative to an empty pGL4.23 




Identification of differential chromatin accessibility during adipocyte differentiation 
We collected SGBS cells at days 0, 2, 4, and 14 of adipocyte differentiation and profiled chromatin 
accessibility using Omni-ATAC-seq22,23 and gene expression using RNA-seq (Table 4.1). For ATAC-seq, we 
identified an average of 76 million high-quality nuclear alignments across all libraries (Table 4.2) and identified 
147,587 consensus peaks. Using principal component analysis (PCA) of ATAC-seq read counts in consensus peaks, 
we identified that the ATAC-seq libraries clustered into three distinct groups: libraries from day 0, libraries from 
days 2 and 4, and libraries from day 14 (Figure 4.1). We identified 58,784 peaks that showed differential chromatin 
accessibility between any two days of differentiation (FDR<5%, absolute value log2 fold change (LFC)>1). We 
found that the chromatin accessibility profiles of days 2 and 4 were essentially identical (no differential peaks, 
Figure 4.2), so we removed day 2 from further analyses because it had fewer replicates than day 4. We found many 
more differential peaks between days 0 and 4 (52,653) than between days 4 and 14 (1,118, Figure 4.2). In addition, 
86% of the differential peaks between days 0 and 14 were differential between days 0 and 4 with the same direction 
of effect (34,163 of 39,721). Given the similarity between days 4 and 14, and to reduce the number of chromatin 
profiles to compare, we defined ‘adipocyte-dependent’ peaks as the intersection of peaks more accessible on days 4 
or 14 relative to day 0 (n=15,919) and ‘preadipocyte-dependent’ peaks as the intersection of peaks more accessible 
on day 0 relative to days 4 or 14 (n=18,244). 
We tested if adipocyte and preadipocyte-dependent peaks were found near genes involved in cell state-
relevant biological processes and contained binding motifs for cell state-relevant transcription factors (TFs). 
Adipocyte-dependent peaks were found near genes enriched in 24 biological processes, including insulin signaling, 
white fat cell differentiation, glucose metabolism, and fat metabolism (Table 4.3). Preadipocyte-dependent peaks 
were found near genes enriched in 3 biological processes, which were all involved in cell adhesion (Table 4.4). 
Motifs for TFs that promote adipogenesis, such as PPAR and CEBP factors45, were enriched in adipocyte-dependent 
peaks but not preadipocyte-dependent peaks (Table 4.5). Motifs for TFs that inhibit adipogenesis, such as GATA 
factors and PU.145,46, were enriched in preadipocyte-dependent peaks but not adipocyte-dependent peaks (Table 
4.6). Taken together, adipocyte and preadipocyte-dependent peaks are found near cell state-relevant genes and 
contain cell state-relevant TF motifs. 
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Identification of differential gene expression during adipocyte differentiation 
We profiled gene expression across adipocyte differentiation (Table 4.1) and identified an average of 46 
million transcriptomic alignments across all libraries (Table 4.7). Similar to ATAC-seq libraries, we found that 
RNA-seq libraries clustered into three distinct groups using PCA of gene counts (days 0, 2-4, and 14; Figure 4.3) 
and the profiles of days 2 and 4 were essentially identical (only 3 differential genes; Figure 4.4). We identified a 
similar number of differentially expressed genes (FDR<5%, absolute value LFC>1) between days 0 and 4 (n=2,171) 
and days 0 and 14 (n=2,107) (Figure 4.4). In contrast to differential chromatin accessibility, for which 86% of 
changes between days 0 and 14 were observed by day 4, only 1,282 of 2,107 (61%) of differential genes between 
days 0 and 14 were identified by day 4. These results suggest that gene expression changes continue after most 
accessible chromatin sites have stabilized. As with chromatin accessibility, we defined ‘adipocyte-dependent’ genes 
as the intersection of genes more expressed on days 4 or 14 relative to day 0 (n=734) and ‘preadipocyte-dependent’ 
genes as the intersection of genes more expressed on day 0 relative to days 4 or 14 (n=548). 
We next determined whether adipocyte and preadipocyte-dependent gene sets contained genes with roles 
relevant to their respective cell states. We identified adipocyte-dependent genes including PPARG and CEBPA, 
which promote adipocyte differentiation45, and ADIPOQ and LEP, which encode the adiponectin and leptin 
hormones12. Preadipocyte-dependent genes included WNT2 and GATA2, which have been shown to be down-
regulated during adipocyte differentiation45,47. Adipocyte-dependent genes were enriched for 38 biological process 
ontology terms, including terms for lipid metabolism, hormone response, and glucose homeostasis (Table 4.8). 
Preadipocyte-dependent genes were enriched for 163 biological process terms, many of which are involved in cell 
cycle and cell division (Table 4.9). These results indicate that we identified differentially expressed genes with 
functions relevant to the corresponding cell states. 
Context-dependent peaks overlap variants at GWAS loci colocalized with adipose tissue eQTL 
To link regulatory elements to adipose tissue gene expression and cardiometabolic traits, we tested if 
context-dependent peaks overlapped proxy variants at a published set of cardiometabolic GWAS loci that 
colocalized with adipose tissue eQTL signals7. Of 228 tested GWAS loci, 59 (26%) harbored a proxy variant within 
either an adipocyte-dependent or preadipocyte-dependent peak (Table 4.10). Of these 59 loci, 26 had a proxy in an 
adipocyte-dependent peak but not a preadipocyte-dependent peak, 23 had a proxy in a preadipocyte-dependent peak 
but not an adipocyte-dependent peak, and 10 had a proxy in both types of peaks. Among the cardiometabolic traits, 
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body mass index (BMI) had the most loci harboring context-dependent peaks (15 loci had an adipocyte-dependent 
peak and 21 loci had a preadipocyte-dependent peak; Table 4.11), likely in part because BMI had the largest 
number of initial GWAS-colocalized eQTL. At 4 loci, we identified 5 eQTL genes that were also adipocyte-
dependent genes: SCD, FADS1, SYPL2, AL139819.1, and SLC22A3. The context-dependent peaks at these 59 
GWAS-colocalized eQTL may have context-dependent roles on adipose tissue gene regulation and are candidates 
for further functional analysis. 
GWAS variants show context and allele-dependent effects in transcriptional reporter activity 
We tested regulatory elements at two GWAS-colocalized eQTL loci for context-dependent effects on 
transcriptional reporter activity. At the first locus, a GWAS locus for metabolic traits and plasma phospholipid 
levels is colocalized with an eQTL for the adipocyte-dependent gene SCD (Table 4.10). SCD encodes the stearoyl-
CoA desaturase enzyme, which is involved in fatty acid synthesis48. Variant rs603424 is the only proxy variant at 
this locus based on LD and is found within an adipocyte-dependent peak (peak19405; Figure 4.5 left). We tested 
both alleles of a 592-bp region that encompassed the majority of the peak for differences in transcriptional activity 
between adipocytes and preadipocytes (Figure 4.5 right). When combining across alleles, we observed higher 
transcriptional activity in adipocytes compared to preadipocytes in both the forward orientation (adipocyte fold 
change (FC) relative to empty vector=4.74, preadipocyte FC=0.22, difference between conditions p=1.36x10 -8) and 
reverse orientation (adipocyte FC=10.14, preadipocyte FC=0.84, p=6.83x10-5). In adipocytes we observed 
significantly higher transcriptional activity for the G allele compared to the A allele in both the forward orientation 
(G allele FC=5.82, A allele FC=3.66, difference between alleles p=0.003) and the reverse orientation (G allele 
FC=15.89, A allele FC=4.38, p=0.0001; Figure 4.5 right). The G allele is associated with higher SCD expression in 
the eQTL data. These results suggest that the regulatory element marked by peak19405 may have both context-
dependent and allele-dependent effects on transcription. 
At the second locus, a GWAS locus for type 2 diabetes (T2D) and triglycerides (TG) is colocalized with an 
eQTL for the EYA2 gene (Table 4.10). EYA2 encodes the eyes absent transcriptional coactivator and phosphatase 2 
transcription factor, which is involved in numerous processes including muscle development, hypertrophy, and 
cancer49–51. A proxy variant at this locus (rs55966194) is found within an adipocyte peak in the first intron of EYA2 
(peak81750; Figure 4.6 left), and none of the 12 other proxy variants at this locus overlap context-dependent peaks.  
We tested both alleles of a 419-bp region that encompassed the majority of the peak for differences in transcriptional 
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activity between adipocytes and preadipocytes (Figure 4.6 right). When combining across alleles, we observed 
significantly higher transcriptional activity in adipocytes compared to preadipocytes in both the forward orientation 
(adipocyte FC=38.23, preadipocyte FC=0.18, p=1.23x10-13) and reverse orientation (adipocyte FC=6.68, 
preadipocyte FC=0.17, p=2.20x10-16). We observed significantly higher transcriptional activity for the C allele 
compared to the G allele in the reverse orientation, but not the forward orientation, for both adipocytes (C allele 
FC=7.72, G allele FC=5.64, p=0.0001) and preadipocytes (C allele FC=0.21, G allele FC=0.13, p=0.002; Figure 4.6 
right). We observed much lower transcriptional activity in adipocytes in the reverse orientation compared to the 
forward orientation, so the allelic differences in the reverse orientation should be interpreted with caution. The C 
allele is associated with higher EYA2 expression in the eQTL data. These results suggest that the regulatory element 
marked by peak81750 may impact transcription in a context-dependent, and possibly allele-dependent, manner. At 
both loci, we observed higher transcriptional activity in the context for which the peak had higher chromatin 
accessibility, suggesting that context-dependent peaks can identify regulatory elements with context-dependent 
function. 
Discussion 
Here we identified differences in chromatin accessibility and gene expression during adipocyte 
differentiation. Among 147,587 total accessible regions, we defined 15,919 adipocyte-dependent peaks and 18,244 
preadipocyte-dependent peaks. We identified variants within these context-dependent accessible chromatin regions 
at 59 GWAS-adipose tissue eQTL loci, suggesting context-dependent roles for these variants on gene regulation and 
cardiometabolic traits. Variants at two of these loci showed context-dependent effects on transcriptional reporter 
activity, suggesting that context-dependent accessible chromatin regions can predict context-dependent regulatory 
effects. Our results are consistent with previous reports of context-dependent effects of GWAS variants on gene 
regulation4,11. The data presented here help uncover the regulatory elements altered by GWAS variants and in which 
cellular states these alterations occur. 
Context-dependent chromatin accessibility helped prioritize GWAS variants with potential context-
dependent effects on gene regulation. We identified a variant, rs603424, at a GWAS-colocalized eQTL for SCD that 
showed higher transcriptional reporter activity in adipocytes compared to preadipocytes. Variant rs603424 was a 
particularly strong candidate for context-dependent regulatory activity because it overlapped a peak more accessible 
in adipocytes, it was the only proxy variant at the GWAS locus, and it was an eQTL for the SCD gene, which was 
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more expressed in adipocytes. The role of SCD in fatty acid synthesis48 also suggests a role in adipocytes. However, 
other loci are more complicated. The T2D GWAS locus colocalized with an eQTL for EYA2 contains 13 proxy 
variants, only one of which, rs55966194, overlapped a context-dependent accessible chromatin region. While the 
regulatory element containing rs55966194 showed higher transcriptional activity in adipocytes, there may be other 
candidate causal variants at this locus. The context-dependent transcriptional activity of these two regulatory 
elements are promising and motivate testing of the other 57 loci we predict to have context-dependent effects. 
We were able to predict context-dependent effects on gene regulation by mapping chromatin accessibility 
in only one individual and one change in cellular context. Given that chromatin accessibility can vary by 
genotype11,52, mapping chromatin accessibility in additional individuals across adipocyte differentiation may identify 
additional context-dependent regions targeted by GWAS variants. Chromatin accessibility in adipocytes also 
changes in response to inflammation18, so mapping chromatin accessibility in additional contexts may also uncover 
new context-dependent genetic regulatory mechanisms. Identifying which GWAS variants are causal and in which 
cellular contexts they act will help guide therapeutic strategies. 
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Figure 4.1. Comparison of ATAC-seq libraries using principal component analysis. Principal component 
analysis (PCA) of ATAC read counts in 147,587 consensus peaks. Peak counts were normalized by the DESeq2 rlog 





More accessible in the later day 
 
More accessible in the earlier day 
 
Figure 4.2. Comparison of differentially accessible peaks between pairwise day comparisons. UpSet plots 
indicating the number of differentially accessible peaks (FDR<5%, absolute value LFC>1) shared between each 
pairwise day comparison. The top plot shows peaks more accessible in the later day of a pairwise comparison (day 4 
> day 0 for example) and the bottom plot shows peaks more accessible in the earlier day (day 0 > day 4 for 
example). The horizontal bars on the right side of the plots show the number of total differential peaks in each 
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Figure 4.3. Comparison of RNA-seq libraries using principal component analysis. Principal component analysis 
(PCA) of RNA read counts in 18,299 genes with median DESeq2-normalized count>=1. Gene counts were 
normalized by the DESeq2 rlog function and adjusted for batch effects (RNA extraction day) using the Limma 
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Figure 4.4. Comparison of differentially expressed genes between pairwise day comparisons. UpSet plots 
indicating the number of differentially expressed genes (FDR<5%, absolute value LFC>1) shared between each 
pairwise day comparison. The top plot shows genes more expressed in the later day of a pairwise comparison (day 4 
> day 0 for example) and the bottom plot shows genes more expressed in the earlier day (day 0 > day 4 for 
example). The horizontal bars on the right side of the plots show the number of total differential genes in each 
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Figure 4.5. A variant near the SCD gene is found within a peak more accessible in adipocytes and shows 
context-dependent transcriptional reporter activity. (left) Genome browser shot of the GWAS locus for 
metabolic traits and plasma phospholipid levels that is colocalized with an adipose tissue eQTL for SCD. Selected 
ATAC signal tracks for each day of differentiation are shown. (right) Transcriptional activity of a 592-bp DNA 
element spanning peak19405 and containing rs603424 in SGBS cells at day 0 (preadipocyte) and day 2 (adipocyte) 
of differentiation. The DNA element was tested in the forward and reverse orientations relative to the genome. V: 






Figure 4.6. A variant near the EYA2 gene is found within a peak more accessible in adipocytes and shows 
context-dependent transcriptional reporter activity. (left) Genome browser shot of the GWAS locus for type 2 
diabetes (T2D) and triglycerides (TG) that is colocalized with an adipose tissue eQTL for EYA2. Selected ATAC 
signal tracks for each day of differentiation are shown. (right) Transcriptional activity of a 419-bp DNA element 
spanning peak81750 and containing rs55966194 in SGBS cells at day 0 (preadipocyte) and day 2 (adipocyte) of 
differentiation. The DNA element was tested in the forward and reverse orientations relative to the genome. V: 





Differentiation day Number ATAC-seq replicates Number RNA-seq replicates 
0 10 6 
2 2 2 
4 10 6 
14 5 4 
 




Sample Day Date Total reads Aligned reads #peaks %reads in peaks TSS enrichment 
S00b1r1 0 Oct10_2017 97.3 57.5 147,944 64 5.9 
S00b1r2 0 Oct10_2017 75.1 45.3 133,522 52 5.9 
S00b2r1 0 July2_2018 98.3 77.3 157,596 58 5.9 
S00b2r2 0 July2_2018 71.2 51.0 132,142 48 6.5 
S00b2r3 0 July2_2018 129.2 97.5 150,754 49 5.9 
S00b2r4 0 July2_2018 65.5 43.4 116,318 38 5.8 
S00b2r5 0 July2_2018 43.5 33.6 155,237 56 9.6 
S00b2r6 0 July2_2018 60.7 40.9 118,621 43 6.2 
S00b4r1 0 dec19_2018 189.6 97.2 191,773 49 7.2 
S00b4r2 0 dec19_2018 201.2 102.1 162,246 48 5.4 
S02b3r1 2 dec17_2018 146.1 77.9 164,274 52 6.3 
S02b3r2 2 dec17_2018 92.0 47.2 113,441 26 5.5 
S04b2r1 4 July2_2018 99.6 79.7 165,682 52 6.4 
S04b2r2 4 July2_2018 101.6 67.9 141,195 45 7.1 
S04b2r3 4 July2_2018 91.3 67.6 154,912 50 6.3 
S04b2r4 4 July2_2018 86.1 62.3 144,845 48 6.8 
S04b2r5 4 July2_2018 45.9 37.7 156,758 52 11.3 
S04b2r6 4 July2_2018 147.1 106.9 164,104 49 7.4 
S04b3r1 4 dec17_2018 157.4 80.8 163,193 50 6.7 
S04b3r2 4 dec17_2018 117.0 72.4 154,669 49 5.8 
S04b4r1 4 dec19_2018 159.1 112.9 172,115 53 5.9 
S04b4r2 4 dec19_2018 47.5 34.3 124,029 49 5.9 
S14b1r1 14 Oct10_2017 382.6 152.1 170,636 48 6.8 
S14b1r2 14 Oct10_2017 245.1 137.9 167,758 45 8.5 
S14b1r3 14 Oct10_2017 253.7 156.5 171,050 52 8.4 
S14b3r1 14 dec17_2018 99.1 62.6 144,757 43 6.2 
S14b3r2 14 dec17_2018 90.8 45.7 106,454 23 5.1 
 
Table 4.2. ATAC-seq library quality metrics. Sample names use the following naming scheme: ‘S’ for SGBS, 
‘##’ representing day of differentiation (‘00’ for day 0, ‘02’ for day 2, etc), ‘b#’ indicates batch number, and ‘r#’ 
indicates the replicate within a given batch. ‘Date’ is the date the ATAC-seq library was prepared. Reads are 
reported in millions of reads. ‘Aligned reads’ is the number of blacklist-filtered and non-duplicated reads aligning to 
nuclear chromosomes (mapq>20). a: These samples were prepared using 2.5uL of Tn5 and sequenced with 50-bp 
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cellular response to insulin stimulus 81 7.E-57 1.E-54 2.3 482 3.E-02 
response to insulin 82 1.E-56 2.E-54 2.0 598 4.E-02 
insulin receptor signaling pathway 206 2.E-34 1.E-32 2.3 288 2.E-02 
cellular response to hydrogen peroxide 400 4.E-21 1.E-19 2.1 194 1.E-02 
white fat cell differentiation 495 6.E-18 2.E-16 2.8 95 6.E-03 
positive regulation of glucose metabolic 
process 549 1.E-16 3.E-15 2.1 147 9.E-03 
response to fluid shear stress 583 5.E-16 1.E-14 2.0 160 1.E-02 
regulation of cardiac muscle 
hypertrophy in response to stress 608 1.E-15 3.E-14 2.9 75 5.E-03 
regulation of fatty acid oxidation 611 2.E-15 4.E-14 2.3 121 8.E-03 
semaphorin-plexin signaling pathway 618 3.E-15 6.E-14 2.1 144 9.E-03 
branching in salivary gland 
morphogenesis 642 8.E-15 2.E-13 2.1 137 9.E-03 
positive regulation of gluconeogenesis 709 1.E-13 2.E-12 2.9 68 4.E-03 
cellular response to fluid shear stress 744 6.E-13 1.E-11 2.3 99 6.E-03 
dichotomous subdivision of an epithelial 
terminal unit 899 1.E-10 1.E-09 2.2 83 5.E-03 
clathrin coat assembly 916 1.E-10 2.E-09 2.4 68 4.E-03 
intracellular lipid transport 941 2.E-10 3.E-09 2.3 74 5.E-03 
response to laminar fluid shear stress 955 3.E-10 3.E-09 2.3 73 5.E-03 
positive regulation of fatty acid 
oxidation 969 3.E-10 4.E-09 2.2 83 5.E-03 
commissural neuron axon guidance 1013 9.E-10 1.E-08 2.4 64 4.E-03 
negative regulation of vascular 
permeability 1463 5.E-07 4.E-06 2.0 63 4.E-03 
substrate-dependent cell migration, cell 
extension 1646 2.E-06 2.E-05 2.0 53 3.E-03 
intracellular cholesterol transport 1742 5.E-06 4.E-05 2.3 36 2.E-03 
glycogen catabolic process 1916 2.E-05 1.E-04 2.0 45 3.E-03 
regulation of glial cell migration 2960 2.E-03 8.E-03 2.0 22 1.E-03 
 
Table 4.3. Gene ontology enrichment for genes near adipocyte-dependent peaks. Gene ontology enrichment 
was performed using the Genomic Regions Enrichment of Annotations Tool (GREAT) with the GO Biological 
Process ontology. We ran GREAT with the default parameters of basal plus extension, proximal 5 kb upstream to 1 
kb downstream, distal 1000 kb (1 Mb), and a whole genome background. We classified ontology terms with 


























cell adhesion mediated by integrin 635 6.E-13 1.E-11 2.5 82 4.E-03 
positive regulation of focal adhesion 
assembly 704 1.E-11 2.E-10 2.1 108 6.E-03 
positive regulation of adherens junction 
organization 756 4.E-11 6.E-10 2.0 109 6.E-03 
 
Table 4.4. Gene ontology enrichment for genes near preadipocyte-dependent peaks. Gene ontology enrichment 
was performed using the Genomic Regions Enrichment of Annotations Tool (GREAT) with the GO Biological 
Process ontology. We ran GREAT with the default parameters of basal plus extension, proximal 5 kb upstream to 1 
kb downstream, distal 1000 kb (1 Mb), and a whole genome background. We classified ontology terms with 




Motif Consensus P-value 
CEBP ATTGCGCAAC 1e-631 
CEBP:AP1 DRTGTTGCAA 1.E-222 
GRE VAGRACAKWCTGTYC 1.E-199 
GRE NRGVACABNVTGTYCY 1.E-166 
ARE RGRACASNSTGTYCYB 1.E-163 
PGR AAGAACATWHTGTTC 1.E-148 
Olig2 RCCATMTGTT 1.E-100 
Atf4 MTGATGCAAT 1.E-95 
Tcf21 NAACAGCTGG 1.E-90 
Atoh1 VNRVCAGCTGGY 1.E-80 
ZBTB18 AACATCTGGA 1.E-74 
PR VAGRACAKNCTGTBC 1.E-63 
NF1-halfsite YTGCCAAG 1.E-53 
PPARE TGACCTTTGCCCCA 1.E-52 
Ap4 NAHCAGCTGD 1.E-50 
AR-halfsite CCAGGAACAG 1.E-49 
Chop ATTGCATCAT 1.E-44 
Ptf1a ACAGCTGTTN 1.E-42 
RXR TAGGGCAAAGGTCA 1.E-39 
NeuroD1 GCCATCTGTT 1.E-39 
HEB VCAGCTGBNN 1.E-29 
Ascl1 NNVVCAGCTGBN 1.E-28 
EBF1 GTCCCCWGGGGA 1.E-27 
BMAL1 GNCACGTG 1.E-27 
MyoG AACAGCTG 1.E-26 
Myf5 BAACAGCTGT 1.E-22 
HNF4a CARRGKBCAAAGTYCA 1.E-20 
Tcf12 VCAGCTGYTG 1.E-20 
EBF DGTCCCYRGGGA 1.E-19 
Max RCCACGTGGYYN 1.E-17 
MyoD RRCAGCTGYTSY 1.E-16 
NPAS2 KCCACGTGAC 1.E-16 
SCL AVCAGCTG 1.E-16 
E2A DNRCAGCTGY 1.E-11 
n-Myc VRCCACGTGG 1.E-10 
CEBP:CEBP NTNATGCAAYMNNHTGMAAY 1.E-10 
ZNF711 AGGCCTAG 1.E-09 
Hoxc9 GGCCATAAATCA 1.E-09 
Usf2 GTCACGTGGT 1.E-09 
USF1 SGTCACGTGR 1.E-08 
Esrrb KTGACCTTGA 1.E-08 
c-Myc VVCCACGTGG 1.E-07 
THRa GGTCANYTGAGGWCA 1.E-06 
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TR4 GAGGTCAAAGGTCA 1.E-06 
ZFX AGGCCTRG 1.E-06 
Nur77 TGACCTTTNCNT 1.E-05 
CLOCK GHCACGTG 1.E-05 
Nr5a2 BTCAAGGTCA 1.E-05 
HOXA9 GGCCATAAATCA 1.E-05 
Foxa2 CYTGTTTACWYW 1.E-05 
ZNF189 TGGAACAGMA 1.E-05 
ZBTB12 NGNTCTAGAACCNGV 1.E-05 
NF1 CYTGGCABNSTGCCAR 1.E-04 
RBPJ:Ebox GGGRAARRGRMCAGMTG 1.E-04 
 
Table 4.5. Motif enrichment in adipocyte-dependent peaks using Homer.  




Motif Consensus P-value 
Atf3 DATGASTCATHN 1E-1327 
AP-1 VTGACTCATC 1E-1260 
BATF DATGASTCAT 1E-1250 
Fra1 NNATGASTCATH 1E-1204 
Fosl2 NATGASTCABNN 1E-640 
Jun-AP1 GATGASTCATCN 1E-426 
Bach2 TGCTGAGTCA 1E-142 
TEAD YCWGGAATGY 1E-91 
Gata4 NBWGATAAGR 1E-88 
Gata2 BBCTTATCTS 1E-86 
Gata1 SAGATAAGRV 1E-85 
GATA3 AGATAASR 1E-82 
ETS1 ACAGGAAGTG 1E-77 
TEAD4 CCWGGAATGY 1E-70 
ERG ACAGGAAGTG 1E-63 
RUNX1 AAACCACARM 1E-62 
Fli1 NRYTTCCGGH 1E-58 
RUNX2 NWAACCACADNN 1E-57 
TEAD2 CCWGGAATGY 1E-54 
RUNX SAAACCACAG 1E-50 
Etv2 NNAYTTCCTGHN 1E-49 
ETV1 AACCGGAAGT 1E-48 
RUNX-AML GCTGTGGTTW 1E-47 
MafK GCTGASTCAGCA 1E-42 
EWS:ERG-fusion ATTTCCTGTN 1E-42 
Ets1-distal MACAGGAAGT 1E-39 
GABPA RACCGGAAGT 1E-37 
EHF AVCAGGAAGT 1E-33 
KLF5 DGGGYGKGGC 1E-32 
EWS:FLI1-fusion VACAGGAAAT 1E-32 
MafA TGCTGACTCA 1E-28 
Pdx1 YCATYAATCA 1E-28 
Elk1 HACTTCCGGY 1E-21 
SPDEF ASWTCCTGBT 1E-21 
ETS:RUNX RCAGGATGTGGT 1E-19 
PU.1 AGAGGAAGTG 1E-17 
Klf4 GCCACACCCA 1E-17 
Elk4 NRYTTCCGGY 1E-17 
NFAT:AP1 SARTGGAAAAWRTGAGTCAB 1E-13 
ETS AACCGGAAGT 1E-13 
EKLF NWGGGTGTGGCY 1E-11 
Sox10 CCWTTGTYYB 1E-11 
ELF1 AVCCGGAAGT 1E-11 
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Reverb GTRGGTCASTGGGTCA 1E-11 
PAX5 GTCACGCTCSCTGM 1E-10 
Tcf4 ASATCAAAGGVA 1E-10 
PAX3:FKHR-fusion ACCRTGACTAATTNN 1E-10 
ELF5 ACVAGGAAGT 1E-09 
FOXA1 WAAGTAAACA 1E-09 
SpiB AAAGRGGAAGTG 1E-08 
FOXM1 TRTTTACTTW 1E-08 
Mef2c DCYAAAAATAGM 1E-07 
Egr2 NGCGTGGGCGGR 1E-07 
Mef2b GCTATTTTTGGM 1E-06 
CRX GCTAATCC 1E-06 
GSC RGGATTAR 1E-06 
FOXA1 WAAGTAAACA 1E-05 
Hoxb4 TGATTRATGGCY 1E-05 
ZFP3 GGGTTTTGAAGGATGARTAGGAGTT 1E-05 
Pax8 GTCATGCHTGRCTGS 1E-05 
Mef2a CYAAAAATAG 1E-04 
Bapx1 TTRAGTGSYK 1E-04 
Srebp1a RTCACSCCAY 1E-04 
Sox6 CCATTGTTNY 1E-04 
Brn2 ATGAATATTC 1E-04 
Mef2d GCTATTTTTAGC 1E-04 
NF-E2 GATGACTCAGCA 1E-04 
 
Table 4.6. Motif enrichment in preadipocyte-dependent peaks using Homer.  




Sample Day Date Total reads Transcript reads Fraction mRNA bases 
S00b1r1 0 dec17_2018 66.0 52.5 0.88 
S00b1r2 0 dec17_2018 69.1 55.6 0.89 
S00b2r1 0 dec19_2018 58.9 46.3 0.86 
S00b2r2 0 dec19_2018 60.1 49.0 0.90 
S00b3r1 0 June11_2019 50.2 44.2 0.96 
S00b3r2 0 June11_2019 57.5 50.3 0.96 
S02b1r1 2 dec17_2018 50.4 36.4 0.79 
S02b1r2 2 dec17_2018 60.7 46.2 0.84 
S04b1r1 4 dec17_2018 53.2 42.2 0.87 
S04b1r2 4 dec17_2018 58.6 45.9 0.87 
S04b2r1 4 dec19_2018 61.4 47.9 0.86 
S04b2r2 4 dec19_2018 65.5 50.5 0.85 
S04b3r1 4 June11_2019 58.1 49.9 0.95 
S04b3r2 4 June11_2019 49.5 41.5 0.95 
S14b1r1 14 dec17_2018 51.2 41.2 0.90 
S14b1r2 14 dec17_2018 52.6 42.1 0.89 
S14b3r1 14 June11_2019 56.6 48.0 0.94 
S14b3r2 14 June11_2019 54.0 45.4 0.94 
 
Table 4.7. RNA-seq library quality metrics. Sample names use the following naming scheme: ‘S’ for SGBS, ‘##’ 
representing day of differentiation (‘00’ for day 0, ‘02’ for day 2, etc), ‘b#’ indicates batch number, and ‘r#’ 
indicates the replicate within a given batch. ‘Date’ is the date RNA was extracted. Reads are reported in millions of 
reads. ‘Transcriptome reads’ is the number of reads aligning to the transcriptome using salmon. ‘Fraction mRNA 
bases’ is the fraction of bases across aligned reads that fall within mRNA regions (exons and untranslated regions) 

















lipid metabolic process (GO:0006629) 260 36 11.7 + 3.1 2.E-08 4.E-05 
monocarboxylic acid metabolic process 
(GO:0032787) 110 20 5.0 + 4.0 7.E-07 7.E-04 
response to oxygen-containing 
compound (GO:1901700) 125 19 5.6 + 3.4 1.E-05 3.E-03 
negative regulation of molecular 
function (GO:0044092) 113 17 5.1 + 3.3 4.E-05 6.E-03 
fatty acid metabolic process 
(GO:0006631) 71 13 3.2 + 4.1 6.E-05 6.E-03 
lipid biosynthetic process 
(GO:0008610) 117 17 5.3 + 3.2 6.E-05 6.E-03 
negative regulation of catalytic activity 
(GO:0043086) 90 15 4.1 + 3.7 4.E-05 6.E-03 
carboxylic acid metabolic process 
(GO:0019752) 244 26 11.0 + 2.4 1.E-04 1.E-02 
oxoacid metabolic process 
(GO:0043436) 254 27 11.4 + 2.4 1.E-04 1.E-02 
organic acid metabolic process 
(GO:0006082) 257 27 11.6 + 2.3 1.E-04 1.E-02 
triglyceride metabolic process 
(GO:0006641) 15 6 0.7 + 8.9 2.E-04 1.E-02 
cellular lipid metabolic process 
(GO:0044255) 223 24 10.1 + 2.4 2.E-04 1.E-02 
lipid catabolic process (GO:0016042) 55 10 2.5 + 4.0 4.E-04 2.E-02 
steroid metabolic process 
(GO:0008202) 26 7 1.2 + 6.0 4.E-04 2.E-02 
transmembrane receptor protein 
tyrosine kinase signaling pathway 
(GO:0007169) 101 14 4.6 + 3.1 4.E-04 2.E-02 
response to hormone (GO:0009725) 90 13 4.1 + 3.2 5.E-04 2.E-02 
small molecule catabolic process 
(GO:0044282) 92 13 4.1 + 3.1 6.E-04 3.E-02 
response to lipid (GO:0033993) 57 10 2.6 + 3.9 6.E-04 3.E-02 
regulation of hormone levels 
(GO:0010817) 19 6 0.9 + 7.0 5.E-04 3.E-02 
organic acid catabolic process 
(GO:0016054) 58 10 2.6 + 3.8 6.E-04 3.E-02 
carboxylic acid catabolic process 
(GO:0046395) 58 10 2.6 + 3.8 6.E-04 3.E-02 
response to endogenous stimulus 
(GO:0009719) 172 19 7.8 + 2.5 8.E-04 3.E-02 
negative regulation of peptidase 
activity (GO:0010466) 30 7 1.4 + 5.2 9.E-04 3.E-02 
negative regulation of endopeptidase 
activity (GO:0010951) 30 7 1.4 + 5.2 9.E-04 3.E-02 
hormone metabolic process 
(GO:0042445) 14 5 0.6 + 7.9 1.E-03 3.E-02 
negative regulation of proteolysis 
(GO:0045861) 31 7 1.4 + 5.0 1.E-03 3.E-02 
negative regulation of cellular protein 
metabolic process (GO:0032269) 100 13 4.5 + 2.9 1.E-03 3.E-02 
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response to peptide (GO:1901652) 42 8 1.9 + 4.2 1.E-03 3.E-02 
cellular response to hormone stimulus 
(GO:0032870) 76 11 3.4 + 3.2 1.E-03 3.E-02 
response to peptide hormone 
(GO:0043434) 42 8 1.9 + 4.2 1.E-03 3.E-02 
negative regulation of hydrolase 
activity (GO:0051346) 42 8 1.9 + 4.2 1.E-03 3.E-02 
negative regulation of protein 
metabolic process (GO:0051248) 103 13 4.6 + 2.8 1.E-03 4.E-02 
neutral lipid metabolic process 
(GO:0006638) 24 6 1.1 + 5.6 2.E-03 4.E-02 
acylglycerol metabolic process 
(GO:0006639) 24 6 1.1 + 5.6 2.E-03 4.E-02 
enzyme linked receptor protein 
signaling pathway (GO:0007167) 153 17 6.9 + 2.5 2.E-03 4.E-02 
glucose homeostasis (GO:0042593) 16 5 0.7 + 6.9 2.E-03 4.E-02 
cellular response to endogenous 
stimulus (GO:0071495) 157 17 7.1 + 2.4 2.E-03 4.E-02 
ammonium ion metabolic process 
(GO:0097164) 25 6 1.1 + 5.3 2.E-03 4.E-02 
 
Table 4.8. Gene ontology term enrichment for adipocyte-dependent genes using the Panther 


















organelle fission (GO:0048285) 285 54 10.2 + 5.3 2.E-21 2.E-18 
nuclear division (GO:0000280) 267 53 9.6 + 5.5 9.E-22 2.E-18 
cell cycle (GO:0007049) 393 63 14.1 + 4.5 2.E-21 2.E-18 
mitotic nuclear division 
(GO:0140014) 240 48 8.6 + 5.6 7.E-20 2.E-17 
mitotic cell cycle process 
(GO:1903047) 240 48 8.6 + 5.6 7.E-20 3.E-17 
cell cycle process (GO:0022402) 350 57 12.6 + 4.5 1.E-19 3.E-17 
mitotic cell cycle (GO:0000278) 240 48 8.6 + 5.6 7.E-20 3.E-17 
regulation of cell cycle (GO:0051726) 200 33 7.2 + 4.6 5.E-12 1.E-09 
chromosome segregation 
(GO:0007059) 94 23 3.4 + 6.8 1.E-11 3.E-09 
sister chromatid segregation 
(GO:0000819) 61 19 2.2 + 8.7 2.E-11 4.E-09 
mitotic sister chromatid segregation 
(GO:0000070) 49 17 1.8 + 9.7 6.E-11 1.E-08 
nuclear chromosome segregation 
(GO:0098813) 77 19 2.8 + 6.9 6.E-10 1.E-07 
regulation of cell cycle process 
(GO:0010564) 84 19 3.0 + 6.3 2.E-09 3.E-07 
negative regulation of cell cycle 
process (GO:0010948) 28 11 1.0 + 10.9 5.E-08 7.E-06 
negative regulation of cell cycle 
(GO:0045786) 74 16 2.7 + 6.0 7.E-08 9.E-06 
meiotic cell cycle (GO:0051321) 58 14 2.1 + 6.7 1.E-07 2.E-05 
meiotic nuclear division 
(GO:0140013) 58 14 2.1 + 6.7 1.E-07 2.E-05 
regulation of mitotic cell cycle 
(GO:0007346) 102 18 3.7 + 4.9 2.E-07 2.E-05 
meiotic cell cycle process 
(GO:1903046) 58 14 2.1 + 6.7 1.E-07 2.E-05 
negative regulation of nuclear division 
(GO:0051784) 13 8 0.5 + 17.1 3.E-07 2.E-05 
multicellular organismal process 
(GO:0032501) 697 54 25.0 + 2.2 3.E-07 3.E-05 
anatomical structure development 
(GO:0048856) 677 53 24.3 + 2.2 4.E-07 3.E-05 
regulation of nuclear division 
(GO:0051783) 30 10 1.1 + 9.3 8.E-07 6.E-05 
cytoskeleton organization 
(GO:0007010) 490 41 17.6 + 2.3 1.E-06 1.E-04 
multicellular organism development 
(GO:0007275) 544 44 19.5 + 2.3 1.E-06 1.E-04 
mitotic cell cycle phase transition 
(GO:0044772) 73 14 2.6 + 5.3 2.E-06 1.E-04 
developmental process (GO:0032502) 760 55 27.3 + 2.0 2.E-06 2.E-04 
cell cycle phase transition 
(GO:0044770) 78 14 2.8 + 5.0 3.E-06 2.E-04 
regulation of mitotic cell cycle phase 
transition (GO:1901990) 46 11 1.7 + 6.7 3.E-06 2.E-04 
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cell cycle checkpoint (GO:0000075) 47 11 1.7 + 6.5 4.E-06 2.E-04 
regulation of mitotic nuclear division 
(GO:0007088) 29 9 1.0 + 8.6 4.E-06 2.E-04 
nervous system development 
(GO:0007399) 302 29 10.9 + 2.7 5.E-06 2.E-04 
system development (GO:0048731) 473 39 17.0 + 2.3 6.E-06 3.E-04 
reproduction (GO:0000003) 84 14 3.0 + 4.6 7.E-06 3.E-04 
reproductive process (GO:0022414) 84 14 3.0 + 4.6 7.E-06 3.E-04 
negative regulation of mitotic cell 
cycle (GO:0045930) 50 11 1.8 + 6.1 7.E-06 3.E-04 
regulation of cell cycle phase 
transition (GO:1901987) 51 11 1.8 + 6.0 8.E-06 3.E-04 
cellular developmental process 
(GO:0048869) 525 41 18.9 + 2.2 9.E-06 4.E-04 
mitotic cell cycle checkpoint 
(GO:0007093) 35 9 1.3 + 7.2 2.E-05 6.E-04 
antimicrobial humoral immune 
response mediated by antimicrobial 
peptide (GO:0061844) 7 5 0.3 + 19.9 3.E-05 1.E-03 
cell differentiation (GO:0030154) 476 37 17.1 + 2.2 3.E-05 1.E-03 
cellular response to 
lipopolysaccharide (GO:0071222) 21 7 0.8 + 9.3 4.E-05 1.E-03 
regulation of organelle organization 
(GO:0033043) 238 23 8.6 + 2.7 4.E-05 1.E-03 
supramolecular fiber organization 
(GO:0097435) 206 21 7.4 + 2.8 4.E-05 2.E-03 
cellular response to molecule of 
bacterial origin (GO:0071219) 22 7 0.8 + 8.9 5.E-05 2.E-03 
regulation of chromosome segregation 
(GO:0051983) 23 7 0.8 + 8.5 6.E-05 2.E-03 
regulation of sister chromatid 
segregation (GO:0033045) 23 7 0.8 + 8.5 6.E-05 2.E-03 
microtubule cytoskeleton organization 
involved in mitosis (GO:1902850) 42 9 1.5 + 6.0 6.E-05 2.E-03 
cellular response to biotic stimulus 
(GO:0071216) 23 7 0.8 + 8.5 6.E-05 2.E-03 
negative regulation of cell cycle phase 
transition (GO:1901988) 24 7 0.9 + 8.1 7.E-05 2.E-03 
negative regulation of mitotic cell 
cycle phase transition (GO:1901991) 24 7 0.9 + 8.1 7.E-05 2.E-03 
actin filament-based process 
(GO:0030029) 216 21 7.8 + 2.7 8.E-05 2.E-03 
myeloid leukocyte migration 
(GO:0097529) 25 7 0.9 + 7.8 9.E-05 3.E-03 
negative regulation of mitotic nuclear 
division (GO:0045839) 10 5 0.4 + 13.9 1.E-04 3.E-03 
defense response (GO:0006952) 110 14 4.0 + 3.5 1.E-04 3.E-03 
negative regulation of chromosome 
segregation (GO:0051985) 10 5 0.4 + 13.9 1.E-04 3.E-03 
negative regulation of mitotic sister 
chromatid separation (GO:2000816) 10 5 0.4 + 13.9 1.E-04 3.E-03 
negative regulation of sister chromatid 
segregation (GO:0033046) 10 5 0.4 + 13.9 1.E-04 3.E-03 
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negative regulation of mitotic sister 
chromatid segregation (GO:0033048) 10 5 0.4 + 13.9 1.E-04 3.E-03 
negative regulation of chromosome 
separation (GO:1905819) 10 5 0.4 + 13.9 1.E-04 3.E-03 
anatomical structure morphogenesis 
(GO:0009653) 343 28 12.3 + 2.3 1.E-04 3.E-03 
actin cytoskeleton organization 
(GO:0030036) 207 20 7.4 + 2.7 1.E-04 3.E-03 
regulation of chromosome separation 
(GO:1905818) 18 6 0.7 + 9.3 1.E-04 3.E-03 
regulation of mitotic sister chromatid 
separation (GO:0010965) 18 6 0.7 + 9.3 1.E-04 3.E-03 
neuron differentiation (GO:0030182) 193 19 6.9 + 2.7 2.E-04 4.E-03 
mitotic sister chromatid separation 
(GO:0051306) 19 6 0.7 + 8.8 2.E-04 4.E-03 
response to lipopolysaccharide 
(GO:0032496) 29 7 1.0 + 6.7 2.E-04 5.E-03 
humoral immune response 
(GO:0006959) 12 5 0.4 + 11.6 2.E-04 5.E-03 
establishment of chromosome 
localization (GO:0051303) 12 5 0.4 + 11.6 2.E-04 5.E-03 
chromosome localization 
(GO:0050000) 12 5 0.4 + 11.6 2.E-04 5.E-03 
regulation of mitotic sister chromatid 
segregation (GO:0033047) 20 6 0.7 + 8.4 2.E-04 5.E-03 
response to molecule of bacterial 
origin (GO:0002237) 30 7 1.1 + 6.5 2.E-04 5.E-03 
meiotic chromosome segregation 
(GO:0045132) 21 6 0.8 + 8.0 3.E-04 6.E-03 
chemokine-mediated signaling 
pathway (GO:0070098) 13 5 0.5 + 10.7 3.E-04 6.E-03 
leukocyte migration (GO:0050900) 31 7 1.1 + 6.3 3.E-04 6.E-03 
neurogenesis (GO:0022008) 221 20 7.9 + 2.5 3.E-04 6.E-03 
cell morphogenesis (GO:0000902) 205 19 7.4 + 2.6 3.E-04 6.E-03 
generation of neurons (GO:0048699) 207 19 7.4 + 2.6 3.E-04 7.E-03 
meiosis I cell cycle process 
(GO:0061982) 32 7 1.2 + 6.1 3.E-04 7.E-03 
leukocyte chemotaxis (GO:0030595) 22 6 0.8 + 7.6 3.E-04 7.E-03 
mitotic spindle organization 
(GO:0007052) 32 7 1.2 + 6.1 3.E-04 7.E-03 
positive regulation of cell population 
proliferation (GO:0008284) 43 8 1.5 + 5.2 3.E-04 7.E-03 
response to chemokine (GO:1990868) 14 5 0.5 + 9.9 4.E-04 7.E-03 
cellular response to chemokine 
(GO:1990869) 14 5 0.5 + 9.9 4.E-04 7.E-03 
chromosome separation 
(GO:0051304) 33 7 1.2 + 5.9 4.E-04 7.E-03 
inflammatory response (GO:0006954) 57 9 2.1 + 4.4 4.E-04 8.E-03 
chemotaxis (GO:0006935) 114 13 4.1 + 3.2 5.E-04 8.E-03 
taxis (GO:0042330) 114 13 4.1 + 3.2 5.E-04 8.E-03 
cellular component morphogenesis 




(GO:0071621) 15 5 0.5 + 9.3 5.E-04 9.E-03 
cell division (GO:0051301) 46 8 1.7 + 4.8 5.E-04 9.E-03 
mitotic metaphase plate congression 
(GO:0007080) 8 4 0.3 + 13.9 6.E-04 1.E-02 
cellular response to lipid 
(GO:0071396) 36 7 1.3 + 5.4 6.E-04 1.E-02 
response to other organism 
(GO:0051707) 88 11 3.2 + 3.5 6.E-04 1.E-02 
response to external biotic stimulus 
(GO:0043207) 88 11 3.2 + 3.5 6.E-04 1.E-02 
meiosis I (GO:0007127) 26 6 0.9 + 6.4 7.E-04 1.E-02 
meiotic telophase I (GO:0007134) 26 6 0.9 + 6.4 7.E-04 1.E-02 
response to biotic stimulus 
(GO:0009607) 89 11 3.2 + 3.4 7.E-04 1.E-02 
telophase (GO:0051326) 26 6 0.9 + 6.4 7.E-04 1.E-02 
response to bacterium (GO:0009617) 37 7 1.3 + 5.3 7.E-04 1.E-02 
meiotic cell cycle phase 
(GO:0098762) 26 6 0.9 + 6.4 7.E-04 1.E-02 
meiosis I cell cycle phase 
(GO:0098764) 26 6 0.9 + 6.4 7.E-04 1.E-02 
M phase (GO:0000279) 26 6 0.9 + 6.4 7.E-04 1.E-02 
mitotic spindle assembly checkpoint 
(GO:0007094) 9 4 0.3 + 12.4 8.E-04 1.E-02 
DNA replication initiation 
(GO:0006270) 17 5 0.6 + 8.2 8.E-04 1.E-02 
metaphase/anaphase transition of cell 
cycle (GO:0044784) 17 5 0.6 + 8.2 8.E-04 1.E-02 
metaphase/anaphase transition of 
mitotic cell cycle (GO:0007091) 17 5 0.6 + 8.2 8.E-04 1.E-02 
biological phase (GO:0044848) 27 6 1.0 + 6.2 8.E-04 1.E-02 
cell cycle phase (GO:0022403) 27 6 1.0 + 6.2 8.E-04 1.E-02 
actin filament organization 
(GO:0007015) 139 14 5.0 + 2.8 9.E-04 1.E-02 
DNA biosynthetic process 
(GO:0071897) 93 11 3.3 + 3.3 1.E-03 1.E-02 
regulation of cellular component 
organization (GO:0051128) 357 26 12.8 + 2.0 1.E-03 1.E-02 
regulation of actin filament-based 
process (GO:0032970) 94 11 3.4 + 3.3 1.E-03 1.E-02 
DNA metabolic process 
(GO:0006259) 278 22 10.0 + 2.2 1.E-03 2.E-02 
cytokinesis (GO:0000910) 40 7 1.4 + 4.9 1.E-03 2.E-02 
metaphase plate congression 
(GO:0051310) 10 4 0.4 + 11.1 1.E-03 2.E-02 
membrane fission (GO:0090148) 40 7 1.4 + 4.9 1.E-03 2.E-02 
negative regulation of organelle 
organization (GO:0010639) 54 8 1.9 + 4.1 1.E-03 2.E-02 
negative regulation of molecular 
function (GO:0044092) 113 12 4.1 + 3.0 1.E-03 2.E-02 
cell chemotaxis (GO:0060326) 30 6 1.1 + 5.6 1.E-03 2.E-02 
actin polymerization or 
depolymerization (GO:0008154) 70 9 2.5 + 3.6 2.E-03 2.E-02 
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extracellular matrix organization 
(GO:0030198) 44 7 1.6 + 4.4 2.E-03 2.E-02 
multi-organism process (GO:0051704) 118 12 4.2 + 2.8 2.E-03 2.E-02 
DNA replication (GO:0006260) 72 9 2.6 + 3.5 2.E-03 2.E-02 
negative regulation of cell death 
(GO:0060548) 45 7 1.6 + 4.3 2.E-03 3.E-02 
peripheral nervous system 
development (GO:0007422) 5 3 0.2 + 16.7 2.E-03 3.E-02 
positive regulation of supramolecular 
fiber organization (GO:1902905) 45 7 1.6 + 4.3 2.E-03 3.E-02 
response to external stimulus 
(GO:0009605) 253 20 9.1 + 2.2 2.E-03 3.E-02 
locomotion (GO:0040011) 254 20 9.1 + 2.2 2.E-03 3.E-02 
positive regulation of cytoskeleton 
organization (GO:0051495) 46 7 1.7 + 4.2 2.E-03 3.E-02 
spindle organization (GO:0007051) 60 8 2.2 + 3.7 2.E-03 3.E-02 
plasma membrane bounded cell 
projection morphogenesis 
(GO:0120039) 123 12 4.4 + 2.7 3.E-03 3.E-02 
neuron projection morphogenesis 
(GO:0048812) 123 12 4.4 + 2.7 3.E-03 3.E-02 
cell projection morphogenesis 
(GO:0048858) 123 12 4.4 + 2.7 3.E-03 3.E-02 
negative regulation of cellular 
component organization 
(GO:0051129) 76 9 2.7 + 3.3 3.E-03 3.E-02 
cell part morphogenesis 
(GO:0032990) 124 12 4.5 + 2.7 3.E-03 3.E-02 
extracellular structure organization 
(GO:0043062) 48 7 1.7 + 4.1 3.E-03 3.E-02 
DNA-dependent DNA replication 
(GO:0006261) 62 8 2.2 + 3.6 3.E-03 3.E-02 
negative regulation of chromosome 
organization (GO:2001251) 24 5 0.9 + 5.8 3.E-03 3.E-02 
cell-cell adhesion (GO:0098609) 93 10 3.3 + 3.0 3.E-03 3.E-02 
system process (GO:0003008) 93 10 3.3 + 3.0 3.E-03 3.E-02 
regulation of actin cytoskeleton 
organization (GO:0032956) 93 10 3.3 + 3.0 3.E-03 3.E-02 
cellular response to cytokine stimulus 
(GO:0071345) 65 8 2.3 + 3.4 4.E-03 4.E-02 
regulation of actin polymerization or 
depolymerization (GO:0008064) 65 8 2.3 + 3.4 4.E-03 4.E-02 
regulation of G2/M transition of 
mitotic cell cycle (GO:0010389) 15 4 0.5 + 7.4 4.E-03 4.E-02 
regulation of actin filament length 
(GO:0030832) 65 8 2.3 + 3.4 4.E-03 4.E-02 
cell development (GO:0048468) 255 19 9.2 + 2.1 4.E-03 4.E-02 
microtubule cytoskeleton organization 
(GO:0000226) 255 19 9.2 + 2.1 4.E-03 4.E-02 
cellular response to organic substance 
(GO:0071310) 290 21 10.4 + 2.0 4.E-03 4.E-02 
regulation of neuron death 
(GO:1901214) 7 3 0.3 + 11.9 4.E-03 4.E-02 
cell motility (GO:0048870) 201 16 7.2 + 2.2 4.E-03 4.E-02 
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mitotic DNA replication checkpoint 
(GO:0033314) 7 3 0.3 + 11.9 4.E-03 4.E-02 
localization of cell (GO:0051674) 201 16 7.2 + 2.2 4.E-03 4.E-02 
neuron apoptotic process 
(GO:0051402) 7 3 0.3 + 11.9 4.E-03 4.E-02 
chromosome condensation 
(GO:0030261) 16 4 0.6 + 7.0 4.E-03 5.E-02 
regulation of cytoskeleton 
organization (GO:0051493) 132 12 4.7 + 2.5 4.E-03 5.E-02 
regulation of cytokinesis 
(GO:0032465) 16 4 0.6 + 7.0 4.E-03 5.E-02 
immune system process 
(GO:0002376) 182 15 6.5 + 2.3 5.E-03 5.E-02 
regulation of cell cycle G2/M phase 
transition (GO:1902749) 16 4 0.6 + 7.0 4.E-03 5.E-02 
regulation of cell death (GO:0010941) 99 10 3.6 + 2.8 5.E-03 5.E-02 
regulation of cell division 
(GO:0051302) 16 4 0.6 + 7.0 4.E-03 5.E-02 
cellular response to growth factor 
stimulus (GO:0071363) 68 8 2.4 + 3.3 5.E-03 5.E-02 
response to growth factor 
(GO:0070848) 69 8 2.5 + 3.2 5.E-03 5.E-02 
 
Table 4.9. Gene ontology term enrichment for preadipocyte-dependent genes using the Panther 













Phospholipid levels  
rs603424 SCD* peak19405 adipocyte rs603424 1.00 
Metabolic traits, 
Phospholipid levels 
rs603424 AL139819.1* peak19405 adipocyte rs603424 1.00 
Coronary heart 
disease 










rs174547 FADS1* peak24179 adipocyte rs174541 0.91 
eGFRcrea rs1933182 SYPL2* peak6999 adipocyte rs3768495 0.86 
eGFRcrea rs1933182 SYPL2* peak6999 adipocyte rs3768493 0.86 
eGFRcrea rs1933182 SYPL2* peak6999 adipocyte rs10858091 0.86 
eGFRcrea rs1933182 SYPL2* peak6999 adipocyte rs3768494 0.85 
eGFRcrea rs1933182 SYPL2* peak6999 adipocyte rs2140924 0.85 
eGFRcrea rs1933182 SYPL2* peak6989 adipocyte rs370088 0.85 
Coronary heart 
disease 
rs2048327 SLC22A3* peak122422 adipocyte rs2661839 0.82 
HDL, LDL, TG rs12748152 RP5-
968P14.2 
peak2035 preadipocyte rs57217461 1.00 
HDL, LDL, TG rs12748152 PIGV peak2035 preadipocyte rs57217461 1.00 
HDL, LDL, TG rs12748152 RP5-
968P14.2 
peak2042 preadipocyte rs58421016 1.00 
HDL, LDL, TG rs12748152 PIGV peak2042 preadipocyte rs58421016 1.00 
HDL, LDL, TG rs12748152 RP5-
968P14.2 
peak2045 preadipocyte rs34618114 1.00 
HDL, LDL, TG rs12748152 PIGV peak2045 preadipocyte rs34618114 1.00 
BMI rs2275426 MAST2 peak3612 preadipocyte rs7540325 1.00 
BMI rs2275426 MAST2 peak3618 preadipocyte rs4134386 1.00 
Glycated hemoglobin  rs6684514 C1orf85 peak8580 adipocyte rs2277871 1.00 
Glycated hemoglobin  rs6684514 CCT3 peak8580 adipocyte rs2277871 1.00 
Glycated hemoglobin  rs6684514 C1orf85 peak8580 adipocyte rs2277870 1.00 
Glycated hemoglobin  rs6684514 CCT3 peak8580 adipocyte rs2277870 1.00 
Glycated hemoglobin  rs6684514 C1orf85 peak8587 preadipocyte rs111850227 1.00 
Glycated hemoglobin  rs6684514 CCT3 peak8587 preadipocyte rs111850227 1.00 
BMI rs912768 PRDX6 peak9673 adipocyte rs1886638 1.00 
BMI rs912768 PRDX6 peak9673 adipocyte rs912768 1.00 
WHRadjBMI, WHR rs17326656 LHCGR peak69622 adipocyte rs17326656 1.00 
blood urea nitrogen rs11123170 PAX8 peak72540 adipocyte rs10175462 1.00 
WHR rs1789882 ADH1A peak101238 adipocyte rs1693458 1.00 
WHR rs1789882 ADH1A peak101238 adipocyte rs3133155 1.00 
WHRadjBMI rs1544474 LAMB1 peak128118 adipocyte rs1544474 1.00 
Metabolic traits rs2066938 UNC119B peak35333 adipocyte rs2066938 1.00 
WHRadjBMI, WHR, 
HDL, TG, BMI, T2D 
rs7307277 RP11-
380L11.4 
peak35619 adipocyte rs7978610 1.00 
BMI rs912768 PRDX6 peak9679 adipocyte rs1461025 1.00 
WHRadjBMI rs11917361 CCDC12 peak89520 preadipocyte rs4018905 1.00 
WHRadjBMI rs11917361 SETD2 peak89520 preadipocyte rs4018905 1.00 
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WHRadjBMI rs11917361 ELP6 peak89520 preadipocyte rs4018905 1.00 
WHRadjBMI rs11917361 CCDC12 peak89520 preadipocyte rs9311403 1.00 
WHRadjBMI rs11917361 SETD2 peak89520 preadipocyte rs9311403 1.00 
WHRadjBMI rs11917361 ELP6 peak89520 preadipocyte rs9311403 1.00 
T2D, TG rs6063048 EYA2 peak81750 adipocyte rs55966194 0.99 
BMI rs1020548 BEND6 peak117576 preadipocyte rs17685277 0.99 
eGFRcrea rs2928148 INO80 peak45130 adipocyte rs11856848 0.99 
BMI rs9846123 WDR6 peak89666 preadipocyte rs9311433 0.99 
BMI rs9846123 ARIH2 peak89666 preadipocyte rs9311433 0.99 
BMI rs9846123 NCKIPSD peak89666 preadipocyte rs9311433 0.99 
BMI rs9846123 CCDC36 peak89666 preadipocyte rs9311433 0.99 
BMI rs9846123 RP11-3B7.1 peak89666 preadipocyte rs9311433 0.99 
WHRadjBMI, WHR, 
HDL, TG, BMI, T2D 
rs7307277 RP11-
380L11.4 
peak35626 adipocyte rs11057413 0.99 
BMI rs886444 CDK5RAP3 peak56838 preadipocyte rs4794333 0.99 
BMI rs2814992 UHRF1BP1 peak116157 preadipocyte rs2814969 0.99 
BMI rs2814992 SPC peak116157 preadipocyte rs2814969 0.99 
BMI rs2814992 UHRF1BP1 peak116157 preadipocyte rs2814970 0.99 
BMI rs2814992 SPC peak116157 preadipocyte rs2814970 0.99 
BMI rs2814992 UHRF1BP1 peak116159 preadipocyte rs9469863 0.99 
BMI rs2814992 SPC peak116159 preadipocyte rs9469863 0.99 
BMI rs2820311 LMOD1 peak11035 adipocyte rs2820316 0.99 
BMI rs2820311 IPO9 peak11035 adipocyte rs2820316 0.99 
BMI rs6494481 TRIP4 peak46646 adipocyte rs2470895 0.99 
TC rs2854322 EVI2A peak55460 preadipocyte rs2905872 0.99 
BMI rs498240 NELFE peak115932 adipocyte rs623529 0.98 
BMI rs498240 NELFE peak115932 adipocyte rs621701 0.98 
HDL, LDL, TG rs12748152 RP5-
968P14.2 
peak2055 adipocyte rs12760759 0.98 
HDL, LDL, TG rs12748152 PIGV peak2055 adipocyte rs12760759 0.98 
WHRadjBMI, WHR rs7798002 AC003090.1 peak124070 preadipocyte rs10260677 0.98 
WHRadjBMI, WHR, 
HDL, TG, BMI, T2D 
rs7307277 RP11-
380L11.4 
peak35626 adipocyte rs11057412 0.98 
BMI rs2814992 UHRF1BP1 peak116142 adipocyte rs2814972 0.98 
BMI rs2814992 SPC peak116142 adipocyte rs2814972 0.98 
BMI rs2814992 UHRF1BP1 peak116157 preadipocyte rs2764207 0.98 
BMI rs2814992 SPC peak116157 preadipocyte rs2764207 0.98 
BMI rs2814992 UHRF1BP1 peak116157 preadipocyte rs2814968 0.98 
BMI rs2814992 SPC peak116157 preadipocyte rs2814968 0.98 
BMI rs2814992 UHRF1BP1 peak116159 preadipocyte rs9462015 0.98 
BMI rs2814992 SPC peak116159 preadipocyte rs9462015 0.98 
BMI rs2275426 MAST2 peak3625 adipocyte rs785481 0.98 
BMI rs2275426 MAST2 peak3626 adipocyte rs6675726 0.98 
Metabolic traits rs2066938 UNC119B peak35335 adipocyte rs34673751 0.98 
WHRadjBMI, WHR rs7798002 AC003090.1 peak124071 preadipocyte rs4722530 0.98 
WHRadjBMI rs17154889 PPIP5K2 peak109353 preadipocyte rs35100629 0.97 
T2D rs4932265 C15orf38-
AP3S2 
peak48620 adipocyte rs12594774 0.97 
T2D rs4932265 AP3S2 peak48620 adipocyte rs12594774 0.97 
WHRadjBMI, WHR rs7798002 AC003090.1 peak124071 preadipocyte rs10262483 0.97 
Glycated hemoglobin  rs6684514 C1orf85 peak8578 preadipocyte rs2273832 0.97 
Glycated hemoglobin  rs6684514 CCT3 peak8578 preadipocyte rs2273832 0.97 
Glycated hemoglobin  rs6684514 C1orf85 peak8578 preadipocyte rs2273833 0.97 
Glycated hemoglobin  rs6684514 CCT3 peak8578 preadipocyte rs2273833 0.97 
WHRadjBMI rs17154889 PPIP5K2 peak109353 preadipocyte rs17154825 0.97 
BMI rs6738445 AC068039.4 peak74899 preadipocyte rs10200608 0.96 
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WHR rs9988 MRPS7 peak58722 adipocyte rs1005714 0.96 
HDL, BMI, TC rs7941030 UBASH3B peak27761 preadipocyte rs7118212 0.96 
HDL, BMI, TC rs7941030 UBASH3B peak27761 preadipocyte rs7101940 0.96 
WHR rs9988 MRPS7 peak58722 adipocyte rs1005713 0.96 
WHRadjBMI rs1544474 LAMB1 peak128118 adipocyte rs41281051 0.96 
BMI rs4886506 SCAPER peak47745 preadipocyte rs11629727 0.96 
BMI rs12574668 C11orf49 peak23743 adipocyte rs7125907 0.96 
HDL, BMI, TC rs7941030 UBASH3B peak27756 preadipocyte rs10790517 0.95 
WHRadjBMI, WHR rs672356 CCDC144B peak54881 adipocyte rs4924750 0.95 
WHRadjBMI, WHR rs672356 RP1-
178F10.3 
peak54881 adipocyte rs4924750 0.95 
T2D rs4932265 C15orf38-
AP3S2 
peak48620 adipocyte rs2165069 0.95 
T2D rs4932265 AP3S2 peak48620 adipocyte rs2165069 0.95 
WHRadjBMI, WHR rs672356 CCDC144B peak54881 adipocyte rs7211382 0.94 
WHRadjBMI, WHR rs672356 RP1-
178F10.3 
peak54881 adipocyte rs7211382 0.94 
HDL, BMI, TC rs7941030 UBASH3B peak27761 preadipocyte rs10790519 0.94 
HDL, BMI rs2013208 RBM6 peak89770 preadipocyte rs2252833 0.94 
BMI rs6738445 AC068039.4 peak74904 preadipocyte rs6758704 0.94 
BMI, HDL rs9931407 CTC-
277H1.7 
peak51879 preadipocyte rs115328599 0.94 
BMI, HDL rs9931407 FHOD1 peak51879 preadipocyte rs115328599 0.94 
BMI rs10497807 PLCL1 peak76404 preadipocyte rs10192466 0.93 
WHRadjBMI rs17764730 CTC-
228N24.3 
peak110427 preadipocyte rs1560637 0.93 
WHRadjBMI rs17154889 PPIP5K2 peak109359 preadipocyte rs62362544 0.93 
BMI rs10497807 PLCL1 peak76405 adipocyte rs9288281 0.93 
WHRadjBMI rs17154889 PPIP5K2 peak109353 preadipocyte rs6862616 0.92 
Metabolic traits, 
eGFRcrea 
rs13391552 ALMS1P peak70992 adipocyte rs7604682 0.92 
BMI rs10268050 NUDCD3 peak125300 adipocyte rs10246459 0.92 
BMI rs10268050 NUDCD3 peak125300 adipocyte rs10231203 0.92 
BMI rs10268050 NUDCD3 peak125300 adipocyte rs10249846 0.92 
BMI rs10268050 NUDCD3 peak125301 preadipocyte rs10229330 0.92 
HDL, BMI, TC rs7941030 UBASH3B peak27761 preadipocyte rs10892873 0.92 
WHRadjBMI rs11917361 CCDC12 peak89520 preadipocyte rs13098228 0.92 
WHRadjBMI rs11917361 SETD2 peak89520 preadipocyte rs13098228 0.92 
WHRadjBMI rs11917361 ELP6 peak89520 preadipocyte rs13098228 0.92 
WHRadjBMI rs11917361 CCDC12 peak89520 preadipocyte rs13061071 0.92 
WHRadjBMI rs11917361 SETD2 peak89520 preadipocyte rs13061071 0.92 
WHRadjBMI rs11917361 ELP6 peak89520 preadipocyte rs13061071 0.92 
T2D rs12681990 ZNF703 peak132216 adipocyte rs10955009 0.92 
LDL, TC, Phytosterol 
levels 
rs72875462 ABCG5 peak69153 preadipocyte rs114938914 0.91 
HDL, BMI, TC rs7941030 UBASH3B peak27761 preadipocyte rs61679561 0.91 
WHRadjBMI rs7479183 PIDD peak21210 adipocyte rs11246319 0.91 
WHRadjBMI rs7479183 AP006621.6 peak21210 adipocyte rs11246319 0.91 
eGFRcrea rs2928148 INO80 peak45118 adipocyte rs4923890 0.91 
BMI rs12964689 NPC1 peak60585 preadipocyte rs1788783 0.91 
BMI rs12964689 C18orf8 peak60585 preadipocyte rs1788783 0.91 
BMI, WHR rs998732 YJEFN3 peak64504 adipocyte rs2905433 0.91 
BMI, WHR rs998732 YJEFN3 peak64504 adipocyte rs2905433 0.91 
BMI, WHR rs998732 YJEFN3 peak64521 adipocyte rs76095338 0.91 
BMI, WHR rs998732 YJEFN3 peak64521 adipocyte rs76095338 0.91 
Metabolic traits rs6499165 PLA2G15 peak52001 adipocyte rs3961283 0.91 
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BMI, HDL rs9931407 CTC-
277H1.7 
peak51851 adipocyte rs114556591 0.90 
BMI, HDL rs9931407 FHOD1 peak51851 adipocyte rs114556591 0.90 
BMI, HDL rs9931407 CTC-
277H1.7 
peak51856 preadipocyte rs115992891 0.90 
BMI, HDL rs9931407 FHOD1 peak51856 preadipocyte rs115992891 0.90 
Metabolic traits, 
eGFRcrea 
rs13391552 ALMS1P peak70992 adipocyte rs7580750 0.90 
WHRadjBMI, WHR, 
HDL, TG, BMI, T2D 
rs7307277 RP11-
380L11.4 
peak35616 preadipocyte rs34854841 0.90 
BMI rs2230590 MST1R peak89770 preadipocyte rs2252833 0.90 
BMI rs9838283 RP11-
804H8.6 
peak89841 preadipocyte rs34889917 0.89 
BMI rs9838283 HEMK1 peak89841 preadipocyte rs34889917 0.89 
BMI rs62034325 SULT1A2 peak50669 adipocyte rs12446550 0.89 




rs17145738 BCL7B peak126180 adipocyte rs13231516 0.88 
T2D rs1061810 HSD17B12 peak23483 preadipocyte rs10838175 0.88 
T2D, HDL, TG, 
BMI, WC, Adiposity, 
WHR, Adiponectin, 
FIns 
rs2972144 IRS1 peak78188 preadipocyte rs2943656 0.87 
BMI rs919433 AC013264.2 peak76364 preadipocyte rs7574271 0.87 
WHR, BMI, TG chr10:65318766 BF2 peak17144 adipocyte rs10761756 0.87 
BMI rs1075901 ZSWIM7 peak54626 preadipocyte rs1065822 0.87 
BMI rs1075901 ADORA2B peak54626 preadipocyte rs1065822 0.87 
Metabolic traits, 
eGFRcrea 
rs13391552 ALMS1P peak70995 adipocyte rs13538 0.87 
Glycated hemoglobin 
levels 
rs6980507 SMIM19 peak132658 adipocyte rs2923447 0.86 
BMI rs6494481 TRIP4 peak46654 preadipocyte rs28635082 0.86 
Metabolic traits, 
eGFRcrea 
rs13391552 ALMS1P peak70995 adipocyte rs4547554 0.86 
LDL rs9438900 TMEM50A peak1902 preadipocyte rs6699113 0.85 
BMI rs2814992 UHRF1BP1 peak116159 preadipocyte rs9394248 0.85 
BMI rs2814992 SPC peak116159 preadipocyte rs9394248 0.85 
Cardiac hypertrophy rs1320448 OBFC1 peak19765 preadipocyte rs73329737 0.84 
BMI, WHR rs524281 PACS1 peak24632 preadipocyte rs7942894 0.81 
BMI, WHR rs524281 RP11-
755F10.1 
peak24632 preadipocyte rs7942894 0.81 
WHRadjBMI rs11917361 CCDC12 peak89532 preadipocyte rs11710322 0.80 
WHRadjBMI rs11917361 SETD2 peak89532 preadipocyte rs11710322 0.80 
WHRadjBMI rs11917361 ELP6 peak89532 preadipocyte rs11710322 0.80 
 
Table 4.10. Proxy variants found within context-dependent peaks at cardiometabolic GWAS loci colocalized 
with adipose tissue eQTL signals. GWAS loci colocalized with adipose tissue eQTL signals were obtained from 
Raulerson et al7. ‘r2 with lead’ is the linkage disequilibrium (LD) r2 between the GWAS lead variant and the proxy 
variant found within the peak. The table is first sorted by whether the eQTL gene is adipocyte context-dependent 
(indicated by asterisks), and then by LD ‘r2 with lead) in decreasing order. BMI: body mass index, WC: waist 
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circumference, WHR: waist-hip ratio, WHRadjBMI: waist-hip ratio adjusted for body mass index, HDL: high 
density lipoprotein cholesterol, LDL: low density lipoprotein cholesterol, TC: total cholesterol, TG: triglycerides, 
T2D: type 2 diabetes, FGlu: fasting glucose, Fins: fasting insulin, CRP: C-reactive protein, eGFRcrea: estimated 















BMI 84 15 17.9 21 25 
WHRadjBMI 47 5 10.6 5 10.6 
WHR 39 7 17.9 4 10.3 
T2D 28 4 14.3 3 10.7 
HDL 25 5 20 6 24 
TG 18 6 33.3 3 16.7 
LDL 15 2 13.3 3 20 
Metabolic traits 12 5 41.7 0 0 
TC 8 1 12.5 3 37.5 
eGFRcrea 5 3 60 0 0 
 
Table 4.11. Number of GWAS-colocalized eQTL signals with a proxy variant in a context-dependent peak 
divided by GWAS trait. Only traits with at least 5 GWAS-colocalized eQTL signals are shown. The table is sorted 
by the total number of loci per trait in decreasing order. BMI: body mass index, WHRadjBMI: waist-hip ratio 
adjusted for body mass index, WHR, waist-hip ratio, T2D: type 2 diabetes, HDL: high density lipoprotein 
cholesterol, TG: triglycerides, LDL: low density lipoprotein cholesterol, TC: total cholesterol, eGFRcrea: estimated 
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CHAPTER 5: DISCUSSION 
 
GWAS have identified thousands of loci associated with cardiometabolic traits1–5, but GWAS do not 
identify which variants at these loci are functional or the molecular mechanisms of functional variants6. It is well 
established that GWAS variants are overrepresented in transcriptional regulatory elements, which are typically 
marked by chromatin accessibility, in trait-relevant tissues and cell types7–9 and that regulatory elements are useful 
in predicting functional variants that alter transcription10,11. Integrating chromatin accessibility with other genomic 
data types, such as gene expression, chromatin contacts, and TF binding sites, provides further mechanistic insights 
at GWAS loci. However, the chromatin accessibility profiles of many primary tissues are under-annotated. 
Chromatin accessibility profiles across multiple individuals and environmental contexts are needed to fully 
characterize genetic effects on transcription and disease. In this dissertation, I presented chromatin accessibility 
profiles in 3 subcutaneous adipose tissue samples, 20 liver tissue samples, and replicates of preadipocyte and 
adipocyte cells from the SGBS adipocyte cell model. I identified accessible chromatin regions that differ by 
genotype in liver tissue and that differ across states of adipocyte differentiation. In all cell and tissue types, I 
identified candidate functional variants found within accessible chromatin at cardiometabolic GWAS loci. I 
integrated chromatin accessibility data with additional genomic datasets to identify target genes and disrupted TF 
motifs at GWAS loci. The work in this dissertation contributes to the regulatory characterization of cardiometabolic-
relevant tissues and identifies potential molecular mechanisms at GWAS loci. 
Whole adipose tissue and SGBS cells both have benefits and drawbacks for studying adipose chromatin 
accessibility. ATAC peaks in adipose tissue may better reflect in vivo chromatin structure and thus may sometimes 
be more useful in identifying disease-relevant regulatory elements compared to ATAC peaks from cell models. For 
example, GWAS variants for insulin traits were enriched in adipose tissue peaks but not SGBS adipocyte or 
preadipocyte peaks. While GWAS variants for waist-hip ratio were significantly enriched in both adipose tissue and 
SGBS peaks, they were much more strongly enriched in tissue peaks. However, we found that generating consistent, 
high-quality ATAC data in SGBS cells is easier than in tissue. We identified more ATAC peaks and generally 
higher signal-to-noise in SGBS cells, likely due to the homogenous cell content and controlled environment of cell 
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models compared to tissue. ATAC peaks in SGBS cells also originate from a single cell state: either preadipocytes 
or adipocytes depending on differentiation state. However, some peaks in SGBS may reflect the effects of cells 
growing in a dish and may not be relevant to in vivo conditions. ATAC peaks in adipose tissue could originate from 
one or more cell types within heterogeneous adipose tissue. Identifying ATAC peaks present in both adipose tissue 
and SGBS cells overcomes some of the drawbacks of the two approaches and may identify regulatory elements 
present in adipocytes or preadipocytes within tissue. 
Through working with wet-lab biologists during my graduate research, I learned how difficult it is to 
generate chromatin accessibility profiles in frozen adipose tissue. We hoped to use ATAC-seq to map chromatin 
accessibility in 400 individuals. However, we could not reliably generate high-quality data. Wet-lab biologists in the 
lab optimized multiple assay parameters and tracked various experimental indicators. I processed the resulting 
sequencing data and assessed data quality. However, we were unable to identify any experimental metrics that 
would predict data quality prior to sequencing. We suspect that the high lipid content of adipocytes and/or the tissue 
freezing protocol may disrupt chromatin structure or interfere with the ATAC protocol. Future improvements to the 
ATAC protocol, new chromatin accessibility assays, or the use of fresh, rather than frozen, tissue may help 
generation of more consistent, high quality chromatin accessibility profiles in adipose tissue.  
We were more successful in profiling chromatin accessibility using frozen liver tissue compared to adipose 
tissue. We identified more ATAC peaks and observed higher signal-to-noise in liver compared to adipose. ATAC-
seq may work better in liver because liver typically has a lower lipid content than adipose tissue. Comparison of 
ATAC-seq data between liver samples with high vs. low lipid content would help determine if lipid content 
negatively impacts the ATAC protocol. Differences in tissue extraction, handling, and storage could also contribute 
to differences in ATAC-seq quality. Importantly, the increased success of ATAC-seq in liver tissue allowed us to 
generate chromatin profiles in enough individuals to test for genetic differences in chromatin accessibility. 
The caQTL I presented in CHAPTER 3 provided mechanistic insight at GWAS loci, similar to findings in 
previous studies12–16. Compared to simple location of GWAS proxy variants within accessible chromatin regions, 
colocalization of GWAS and caQTL signals provides stronger evidence that GWAS variants may alter regulatory 
element activity. Colocalization of caQTL, GWAS, and eQTL signals provides even more insight by identifying the 
putative gene/s targeted by the altered regulatory element. caQTL are just associations however, and additional 
experiments are needed to prove that caQTL variants alter chromatin accessibility in vivo. Additionally, 
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colocalization is just a measure of sharing between two association signals and it does not indicate whether a variant 
mediates its effect on one of the traits through the other trait. Statistical mediation tests can help infer causal 
directions at colocalized loci, such as a variant mediating effect on gene expression through chromatin accessibility 
changes, but wet-lab experiments are truly needed to demonstrate causality. For example, CRISPR-Cas9 could be 
used to inactivate a regulatory element and the gene expression of the linked gene could be measured to determine if 
the regulatory element regulates the gene17. Mapping caQTL followed by functional experiments is a promising 
approach for identifying variants that may influence gene expression and disease by altering chromatin accessibility.  
We identified 3,123 significant liver caQTL despite a modest sample size of 20 individuals. The reasonable 
number of caQTL is partly due to the high sequencing depth and signal-to-noise of the liver ATAC libraries. 
Compared to mapping QTL using simple linear regression on transformed counts, the RASQUAL model has 
increased detection power through including allelic imbalance and through modeling count data directly13,18,19. 
Whether more caQTL can be detected compared to eQTL at a similar sample size remains to be determined. We did 
not investigate this in our study given our modest sample size. A recent study from Alasoo et al.14 mapped caQTL 
and eQTL in multiple immune cell contexts and consistently identified more caQTL (~11,000-20,000 across cell 
types) compared to eQTL (~2,500-3,000 across cell types) despite smaller caQTL sample sizes. Alasoo et al. used 
the same statistical model and multiple testing correction method for caQTL and eQTL, but they tested for 
association of variants within a smaller window for caQTL (within 50kb of peak edges) compared to eQTL (within 
500kb of gene bodies). We found that decreasing the window size for tested variants from 100kb to 1kb increased 
the number of identified caQTL, likely due to a reduced multiple testing burden. Therefore, the smaller window size 
for caQTL compared to eQTL in Alasoo et al. could partly explain the increased number of caQTL. Another 
technical explanation for this is that many more peaks (n=296,220) than genes (n=15,797) were used for QTL 
mapping; a higher percent of tested genes had an eQTL compared to the percent of peaks with a caQTL. Another 
explanation for this is that caQTL may have higher effect sizes than eQTL. However, Keele et al.20 mapped caQTL 
and eQTL in three mouse tissues and found that caQTL effect sizes were generally lower than eQTL effect sizes. In 
contrast to Alasoo et al.14, Keele et al.20 identified a smaller number of caQTL relative to eQTL using the same 
sample size for both analyses and a more similar number of tested peaks (~11,000-24,000 across tissues) and genes 
(~8,000-11,000 across tissues) compared to Alasoo et al. Keele et al. used the same statistical model, multiple 
testing correction procedure, and variant window sizes for caQTL and eQTL, which makes the comparison of 
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caQTL and eQTL number more straightforward than in Alasoo et al. However, the sample sizes in both studies were 
not particularly large (eQTL n=84 and maximum caQTL n=42 for Alasoo et al. and eQTL n=47 and caQTL n=47 
for Keele et al.). Larger studies that jointly map eQTL and caQTL in the same samples will help determine if the 
effect sizes of caQTL and eQTL differ from each other. 
Although caQTL can be mapped in small sample sizes, mapping caQTL with more samples has numerous 
benefits. The power to detect low frequency variants will increase with sample size. We found that some peaks, such 
as peak9372 at the SORT1 locus, vary dramatically by genotype, with the less accessible homozygote not exhibiting 
a peak. Therefore, larger sample sizes may allow identification of peaks that vary strongly by genotype that are 
absent in the 20 samples we analyzed. Inclusion of diverse samples may allow identification of caQTL that have 
different effects based on sex, genetic ancestry, age, or other characteristics. 
We suspect that the ATAC peak calling strategy impacts caQTL discovery. Unlike genomic locations of 
genes, chromatin accessibility regions are not well-defined and must be inferred from peak calling algorithms. 
Consequently, the sizes and boundaries of chromatin accessibility regions are hard to determine and multiple nearby 
regions can be called as one large peak. Through manual inspection on the UCSC genome browser, we identified 
peaks that appeared to vary by genotype in part, but not all, of the peak. Some of these peaks were not classified as 
caQTL, potentially because the change in one part of the peak was masked by the static region. If peak sizes are 
made too small however, then there may not be enough ATAC-seq counts in the region to detect caQTL. We also 
identified large peaks that showed strong differences by genotype across the entire peak. Consequently, refining 
peak calling is not as simple as breaking peaks into smaller regions. Further research is needed to determine the 
optimal peak calling strategy for caQTL discovery. 
In CHAPTER 3, we found that SGBS cells are a particularly useful resource for identifying GWAS 
variants that may have context-dependent roles on gene regulation. In addition to mapping differences in chromatin 
accessibility and gene expression across differentiation state, we used SGBS cells to identify context-dependent and 
allelic effects on transcription using reporter assays. The combined evidence from genomic experiments and reporter 
assays helps prioritize variants that have functional roles in gene regulation, although further experiments are needed 
to prove function. Moving forward, CRISPR-cas917 could be used to inactivate regulatory elements in SGBS cells, 
or another adipocyte model, to test for effects on gene regulation in vivo. We could also use SGBS cells to measure 
changes in disease-relevant cellular phenotypes, such as insulin resistance, in response to altered regulatory element 
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activity. Although we found that SGBS chromatin accessibility does not completely mirror that of adipose tissue in 
CHAPTER 2, SGBS cells are still valuable to study how GWAS variants impact gene regulation and disease-
relevant cellular phenotypes in adipocytes. 
Mapping chromatin accessibility and gene expression in additional disease-relevant contexts and across 
additional individuals may identify additional context-dependent genetic effects. Gene regulation in adipocytes is 
altered by various stimuli relevant to metabolic disease, such as high insulin, inflammation, and hypoxia21,22. 
Context-dependent genetic associations with chromatin accessibility have also been identified using induced 
pluripotent stem cells (iPSCs) derived from multiple donors23. Therefore, iPSCs could be a useful way to study both 
genetic and environmental effects on adipose function. Single nuclei ATAC-seq could also be used to help identify 
GWAS variants that influence cell type-specific regulatory elements in adipose tissue, as has been done in other 
tissues24. All of these strategies will be useful in identifying context-dependent effects of GWAS variation.  
The work I presented in this dissertation contributes to the understanding of how disease-associated genetic 
variants influence gene regulation in cardiometabolic-relevant tissues. I identified candidate functional variants, 
target regulatory elements, and target genes that can be tested for causal relationships in future experiments. 
Identifying genes and regulatory elements that cause disease may lead to therapeutic strategies. Therapies could be 
designed that target individual genes or networks of genes involved in similar biological pathways25. In addition, 
regulatory elements could be targeted for therapy using epigenome editing26. Context-dependent genetic effects can 
be used to identify the precise cell type or cell context in which a therapy may be most effective. Future large-scale 
genetic, epigenomic, transcriptomic, and functional studies in diverse participants will hopefully lead to a detailed 
understanding of the molecular mechanisms underlying cardiometabolic diseases and lead to effective 
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